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ABSTRACT
Malaria is a major global public health problem. One-fifth of the world's population is at 
risk of malaria and drug resistance is spreading. Nearly five times as many cases of 
malaria were reported in 2000 as tuberculosis, AIDS, measles and leprosy cases 
combined. In the time it takes to say the word "malaria," ten children will contract the 
disease and begin fighting for their lives. Since the cinchona alkaloids were introduced as 
a specific treatment for agues 350 years ago, the treatment of severe malaria has changed 
little and therapy remains largely empirical. Quinine and quinidine remain the drugs of 
choice for severe chloroquine-resistant malaria due to Plasmodium falciparum, and with 
the spread of these resistant parasites, the usage of these drugs is increasing. In 1972 
scientists in China discovered the antimalarial properties of a group of sesquiterpene 
lactone peroxides derived from the qinghao plant (Artemisia annua). The principal 
component, qinghaosu (artemisinin), and two derivatives - the water-soluble 
hemisuccinate artesunate and the oil-soluble artemether - are the most rapidly acting and 
potent of all antimalarial drugs. Although much research effort has been invested in 
optimizing antimalarial drug regimes, severe malaria remains a major cause of adult 
mortality in the Asiatic tropics. Despite many clinical trials reducing the mortality from 
severe malaria has proved difficult. Artemether has been shown to be as good as quinine 
but not better. This thesis set out to determine whether Artemether or Artesunate was the 
the better drug, how to manage acute renal failure in severe malaria, to design a severity 
score for malaria and assess whether there had been any change in the parasite clearance
times in Viet Nam over a 18 year period. The results from a series of clinical trials and
research from one hospital in Viet Nam are presented.
This thesis undertook the following studies:
1. A randomised clinical trial of artesunate vs artemether in the treatment of severe 
malaria in adults in Viet Nam.
2. A randomized comparison of pumped venovenous haemofiltration and peritoneal 
dialysis in acute renal failure associated with severe infection.
3. Fluid management in severe malaria.
4. The stage of the development of the falciparum parasites at the time of clinical
presentation with severe malaria is important in predicting outcome.
5. Development of a predictive score of outcome in adults with severe falciparum 
malaria.
6. Assessment of the efficacy of the artemisinin derivatives in the treatment of severe 
falciparum malaria in Viet Nam 1991-2008.
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CHAPTER 1
INTRODUCTION
1.1 Malaria
Malaria is a disease of human beings caused by parasites, more specifically: 
protozoan parasites (Plasmodium parasite). There are four types of malaria parasite, 
which commonly cause malaria in human: Plasmodium falciparum, Plasmodium 
vivax, Plasmodium malariae and Plasmodium ovale. Plasmodium knowlesi is the fifth 
major human malaria parasite that was firstly reported in 1965. Malaria is transmitted 
by Anopheles mosquitoes, and remains a serious infectious disease in tropical areas in 
this 21st century. Malaria transmission is reported from over a 100 countries and to 
cause nearly 300 million cases (5% of global population) each year, with 1 . 2 - 2  
million deaths, mostly from severe and complicated falciparum malaria. Malaria is 
found in all ages, with a particular burden in pregnant women and young children. In 
the hyperendemic areas, 25% of the deaths of children less than 4 years of age are 
associated with severe falciparum malaria, and women particularly in their first 
pregnancy are at particular risk.
In the 1950s, the World Health Organization (WHO) attempted to develop a strategy
for the global eradication programme for malaria. It was however not easily
implemented, only developed countries had much success and the programme failed
in the poor and developing world. Later with the development and spread of drug
resistant strains of Plasmodium falciparum the problem grew and the eradication
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strategy was quietly dropped. During the I960-1990s the slogans were changed and 
people discussed "Malaria Control". Malaria Control Programmes were established 
around the world with the aim of controlling or containing the disease by reducing 
morbidity and mortality. However despite new slogans and many new international 
initiatives malaria has continued to affect adversely public health, economic and 
social development in malaria endemic countries. Malaria and economic development 
are inter-related. High rates of malaria are almost exclusively reported from countries 
with poorly developed economies and social conditions and the relationship between 
malaria and social and economic development has been the subject of much debate in 
recent years. Malaria rarely occurs in developed countries. Climate change, 
insecticide-resistant mosquitoes and the continued emergence of parasites resistant to 
anti-malarial drugs will continue to make the malaria control programmes relevant in 
the future. However with the widespread use of impregnated bed-nets, artemisinin 
combination therapies and economic development in malaria endemic countries offer 
us the best hope in generations to truely roll back (some would argue even eradicate) 
malaria. The development of an effective vaccine would complement these efforts 
but so much could be achieved by implementation of what we already know works.
1.1.1 History of malaria
Malaria is an old disease (Knell, 1991; Poser and Bruyn, 1999). References to malaria
can be found in the ancient Chinese, Egyptian, Roman and Indian writings. One of the
oldest cuneiform script described malaria as Nergal, the Babylonian god of
destruction and pestilence. The Chinese Nei Ching (The Canon of Medicine) edited
4,700 years ago referred to enlarged spleens with repeated fevers. The Egyptian and
19
Sumerian texts, dated 3,500 years ago, referred to fevers and splenomegaly, possibly 
due to malaria. The Indian Vedic (dating from 2,800 to 3,500 years ago) and 
Brahmanic (1,900 to 2,800 years ago) mentioned the autumnal fevers as the “King of 
disease”. The ancient Hindus were aware of the danger of mosquitos. The Charaka 
Samhita, one of the ancient Indian texts on Aynvedic medicine (written about 300 
BC) and the Susruta Samhita (written about 100 BC) referred to diseases with 
different types of fevers: continuous, remittent, quotidian, tertian and quartan. The 
Susruta Samhita indicated the link between fevers and the bites of the insects. The 
Greeks associated malaria with swamps about 500 BC. Hippocrates, the Father of 
Medicine, also described the malaria fevers by 400 BC. He distinguished the 
intermittent fever of malaria from the continuous fever of other diseases and he 
noticed the fever was related to the season and the areas. He also wrote: “Those who 
drink stagnant water have always large, stiff spleens and hard, thin, hot stomachs, 
while their shoulders, collarbones, and faces are emaciated; the fact is that their flesh 
dissolves to feed the spleen...,” he believed in the connection between fevers and 
marshes. Although he misunderstood the cause of malaria, he was named as the first 
malariologist. Plato (427-347 BC) and Aristotle (384-322 BC) reported malaria when 
it occurred in Attica. Plato differentiated continuous from recurrent fevers. The 
ancient Romans, Varro (116-27 BC) attributed malaria to the swamps.
Galen (130-200 AD), a Greek physician recognized the relation of fevers to season 
and to jaundice. He believed that malaria was the result of disorder of yellow bile of 
the body. Unfortunately, his belief that malaria had an internal cause was accepted for 
the next 1,500 years.
In 1666, Thomas Sydenham still believed the imbalance of the humors as the cause of
malaria but he insisted the Cinchona stopped the fevers in his book Methodus curandi
20
febres. The “Peruvian fever tree”, Cinchona, was found by the Jesuit missionaries in 
the South America when they learned how to treat fever with Cinchona from Inca
, i L
herbalists in the early 17 century. Spanish Cardinal Juan de Lugo brought Cichona, 
Jesuit’s powder, to the Hospital Santo Spirito (Rome) in 1637, and it became widely 
used throughout Europe. The British and Dutch introduced it to India later. By 1677, 
Cortex Penuvianus (an official name of Peruvian bark) appeared in the London 
Pharmacopeia. The discovery of the Cinchona is one of the most important events in 
the history of malaria. Richard Morton, an English physician, firstly described the 
clinical picture of malaria and the treatment of malaria with Cinchona in 1692. 
Francesco Torti, professor of medicine at Modena, accurately described the course of 
the disease that was curable by the Cinchona in 1709.
In 1716, Giovanni Maria Lancisi, personal physician of Popes Innocent XI, Innocent 
XII and Clement XI, first described the black pigment of brain and the spleen of the 
malaria patients. He also thought that mosquitoes might have caused malaria.
In 1796, John Crawford, an American physician, wrote essays on the cause of 
malaria. He thought that “when the mosquitoes bite, they lay some eggs into the 
human body......and those eggs produce malaria...” His theory was echoed by two
other Americans, Josiah Clark Nott and Lewis Daniel Beauperthy in 1850 and 1854. 
While doing an autopsy of a patient in 1847, a German physician named Heirich 
Meckel noticed some round, ovoid structures containing black pigments in the blood 
and the spleen.
In 1879-1880, Edwin Klebs (a German pathologist) and Corrado Tommasi Crudeli
(an Italian bacteriologist) announced that malaria was caused by a microbe isolated
from the soil, which they named Bacillus malariae. But George Sternberg (an
American bacteriologist) confirmed that their findings were wrong in 1881.
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Finally, the first scientist who noticed the malaria parasite in the blood of a patient 
suffering from malaria in 1880 was Charles Louis Alphonse Laveran, a French army 
surgeon. Laveran arrived at Constantine, Algeria in 1878, and worked in a military 
hospital full of malaria patients. He also found the pigmented structures in the brain 
and spleen and black bodies in the blood of the malaria patients. On November 6th, 
1880, Laveran saw a moving object on the slide of fresh blood specimen from malaria
f L
patient and named the parasite Oscillaria malariae. In Italy, on December 24 , 1880 
Laveran announced the findings of pigmented erythrocytic cells, trophozoites and 
gametocytes in malaria patients. Later, he concluded that quinine could cure malaria. 
Laveran wrote a letter of communicating his findings to the Academy of Medicine in 
Paris. Laveran received the Nobel Prize in 1907 for his discovery. In 1882, Albert 
King Freeman Afficanus at the George Washington University, USA, again noticed 
the role of mosquito in malaria transmission. Laveran’s discovery was confirmed by 
Louis Pasteur in 1884 and William Osier in 1886. In 1886, Camillo Golgi, an Italian 
neurophysiologist, was the first to describe the tertian and quartan fevers and asserted 
that those two types of fevers were caused by two different parasites. He also 
observed that fever coincided with the rupture and release of merozoites into the 
blood stream. Giovanni Batista Grassi and Raimondo Filetti, both were Italian, first 
named two human malaria parasites as Plasmodium vivax and Plasmodium malariae 
in 1890. Romanowsky described the methods for staining of malaria parasites in 
1891.
Sir Patrick Manson, a British scientist, thought that the malaria disease was
transmitted by mosquito. But on the 20th August of 1897, his colleague, Surgeon
Major Ronald Ross, was the first to demonstrate that malaria patients could transmit
the malaria parasite to mosquitoes. He described the oocysts existed in the gut of
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Anopheles mosquito and the sporozoites in salivary glands of Anopheles mosquito 
and proved that mosquito was the vector of malaria while he was working in 
Secunderabad, India. His report was published on the British Medical Journal on the
tViDecember 18 , 1897. Thus, the mechanism for malaria transmission was found. Ross 
was awarded the Nobel Prize in 1902. And in 1900, Patrick Manson transmitted 
malaria to volunteers in London from infected mosquitoes brought from Italy. In 
1897 William Welch, an American, named the malignant tertian malaria parasite as 
Plasmodium falciparum. Giovanni Battista Grassi, an Italian physician, reported that 
Anopheles claviger mosquito was one malaria vector. Grassi, Amico Bignami and 
Giuseppe Bastianelli accomplished the observation of the life cycle of P. falciparum, 
P. vivax and P. malariae in 1899. They collected mosquitoes and fed them on malaria 
patients in Rome, Italy, then sent them to London where they infected on two 
volunteers, both of whom developed malaria. In 1922, John William Watson Stephens 
introduced the fourth human malaria parasite, Plasmodium ovale. An Austrian 
neurologist, Julius Wagner-Jauregg was offered the Nobel Prize in 1927 “for his 
discovery of the therapeutic value of malaria inoculation in the treatment of dementia 
paralytica.”
A German investigator, Paul Hermann Muller, discovered the insecticide effect of 
Dichloro-diphenyl-trichloroethane (DDT) in 1948, and DDT was widely used for 
malaria control since 1945. Muller received the Nobel Prize for Medicine in 1948. 
Despite all the achievements of the last 60 years Muller was the last Nobel Prize to be 
awarded for work directly on malaria.
The liver stage of vivax parasite was demonstrated by Henry Edward Shortt and Percy
Cyril Claude Gamham in 1948 at the Ross Institute of the London School of Hygiene
and Tropical Medicine, UK. In 2002, the genome of Anopheles gambiae and P.
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falciparum were sequenced. Over the last 40 years a number of candidate malaria 
vaccines have been developed and tested. Perhaps for the first time at the start of the 
21st Century, there is some degree of realistic optimism that a vaccine might be 
feasible, although probably still many years away.
From the 18th through to the 21st century, we have learnt a great deal; the cause of 
malaria, the transmission of disease, the role of female Anopheles mosquito, the 
discoveries of quinine, choloroquine and qinghaosu, massive investments in genomics 
and development of vaccines, but malaria still kills 1-2 million poor people in the 
world each year. There remains much to be done on this old disease.
1.1.2 Current malaria situation in the world
During 2006 there were an estimated 247 million cases of malaria (range: 189-327
million) in the world with 881,000 deaths. Nearly 91% of these malaria deaths were in
Africa, 85% of deaths were children under 5 years of age, and 4% of deaths were in
Southeast Asia region. Malaria was present in 109 countries (Figure 1.1) (World
Malaria Report, 2008). Those alarming and increasing figures might be due to the
increase of the anti-malarial drugs resistant parasites, the development of resistance to
insecticides of mosquitoes, the weakening of public health systems, the population
movements into malaria endemic areas, migration, continued economic problems in
the world’s poorest countries, armed conflict and climate change.
With the implementation of artemisinin-based combination therapy (ACT), the long-
lasting insecticidal nets, the indoor residual spraying of insecticide and the
intermittent preventive treatment in pregnancy, malaria cases have declined in some
endemic countries. The number of deaths has fallen in Thailand, Laos, Cambodia,
24
Viet Nam, Philippines and Suriname over the last decade (World Malaria Report, 
2008).
However, in 2006, half of the global population remains at risk of malaria. With 40% 
of the global population at risk of malaria residing in the Southeast Asia region, 
malaria is still a major public health concern across Asia. With global climate change 
and continued migration of people an additional 260-320 million people worldwide 
could be living in malaria endemic areas by 2080, thus malaria continues to remain a 
major public health problem worldwide.
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1.1.3 History of malaria in Viet Nam
Long ago the Vietnamese people assumed that malaria originated from the forest as 
they recognized most patients had fever, rigors, chill as a result of their exposure to 
the jungle. The disease was since called “SOT RET RUNG” (Jungle Chilly Fever). At 
that time and maybe even today, some Vietnamese people remain convinced that 
malaria is caused by drinking poisonous water from the forest.
The French colonists invaded Viet Nam in 1858 and occupied the Red River Delta of 
North Viet Nam in 1875. During that time the French physicians noticed that more 
soldiers in the northern highlands got “Jungle Chilly Fever” than elsewhere. In 1940, 
Pierre Gourou, a French scientist, finally explained to the the authorities: “The only 
propagating agent of malaria is mosquito, neither the forest spirits nor the poisoned 
water feared by Vietnamese, has the least responsibility. The sunlit terraced rice fields 
with running water of hill regions are veritable breeding sites for the larvae of 
dangerous Anopheles, in contrast with the stagnant paddies of the plains.” At that 
time the anti-malaria activities of the French focused mainly on their soldiers, 
emigrants and for parts of Vietnamese society working in large economic projects 
designed to develop the plentiful natural resources. They were not dedicated to 
providing support for the health and safety needs of the Vietnamese people. There 
were two typical projects: one building the rail road route linking Hai Phong in Viet 
Nam with Yuanam, China and the other to establish rubber plantations in Viet Nam. 
When the French built the rail road, they realized that up until 1904 the progress of 
the project was very slow because of the high sickness and fatality rate of the
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Vietnamese workers caused by the “jungle malaria.” After 1904 the French changed 
their policies from violent beatings of sick workers to supplying antimalarial 
medications. However, these steps could only limit the morbidity and the number of 
fatalities. In the first decade of 1900, the French colonists discovered that some land 
areas in Indochina, especially in the Central Highlands, Viet Nam, were very suitable 
for the planting of the rubber plant and they developed a great number of the rubber 
plantations. A lot of the Vietnamese plantation workers also contacted and died of the 
dreaded “jungle malaria.” The phrase “jungle malaria” originated from these 
plantations. The number of sick and dying Vietnamese workers in the rubber 
plantation development projects steadily greyed which angered the Vietnamese 
people. This was one of the contributing factors that were believed to have lead to the 
Vietnamese people finally rebelling against the French.
Since 1954, both North and South Viet Nam implemented the malaria eradication 
programme. The South Viet Nam got funds from the USA and the WHO but their 
programme was less successful because the main battlefields in the South were also 
the malaria endemic areas and thus not easily accessible to the malaria control 
programme. Thousands of Vietnamese soldiers from both sides died of malaria. Even 
with the best protective measures available, nearly 40,000 malaria cases were reported 
in US Army troops between 1965 and 1970. With the number of cases increasing the 
effectiveness of the US was compromised and from the early 1960s onwards US 
troops also faced the rise of antimalarial drug resistance. The US Army set up a 
malaria drug research programme and Mefloquine, a new antimalarial drug, was 
developed as a direct result of the Viet Nam war. The North Vietnamese forces 
received the majority of their supplies from the Soviet Union and China. In the
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Northern provinces, the eradication programme was based mainly on house spraying 
with residual insecticides which lead to a remarkable reduction in the number of 
malaria cases. Because malaria was the biggest cause of casualties among the North 
Vietnamese troops, the North Vietnamese asked for help from Chinese scientists to 
defeat malaria, and a secret military project, named “Project 523,” was set up 
following a meeting between Cho En Lai and Ho Chi Minh. Eventually this lead to 
the discovery of a completely new antimalarial compound, Qinghaosu, later called 
Artemisinin. The North Vietnamese troops received artemisinin compounds in the 
final stages of the war (Li, personal communication). The drugs were also used very 
early as combination therapy through a series of mixtures labelled CV1, CV2, with 
the final version CV8 (standing for China-Viet Nam) an early version of what is now 
called Artekin and increasingly used globally.
The Viet Nam War ended in 1975. It was estimated that one half of a total of 65 
million Vietnamese people were at risk of malaria. Malaria became an obstacle to the 
economic development of the highland areas by people sent by the government from 
the lowland areas.
1.1.4 Current malaria situation in Viet Nam
In Viet Nam, malaria remains a public health problem particularly in areas such as 
forested areas in the highlands along the borders with Cambodia and Laos and also on 
the northern border with China. Malaria cases also come from coastal areas. 
Woodcutters and poor farmers suffer the most in these epidemic areas. In remote 
areas with few nearby hospitals, relatives still have to travel far with malaria patients.
29
It is estimated that one fifth of Vietnamese people are at risk of malaria, and 
approximately 15 million people live in low transmission endemic areas.
Parasites
In 2003, the annual incidence rate of confirmed malaria was 0.46/1000 countrywide. 
P. falciparum accounted for 79% of malaria cases and P. vivax for 21%. In different 
provinces, the ratio of P. falciparum to P. vivax cases varied from 1:1 to 1:2 (source: 
NMCP, 2004). P. falciparum causes the majority of malaria infections and is 
responsible for most severe cases and mortality. P. vivax is dominant in the Red River 
delta, and recently, in the Mekong River delta. P. falciparum is highly resistant to 
chloroquine, sulfadoxine -  pyrimethamine, and less sensitive to quinine in Central 
and Southern Viet Nam. The level of chloroquine resistance of P. falciparum is 
variable in Viet Nam. As in China, chloroquine in vitro sensitivity has improved, 
presumably due to the reduction in drug pressure. In 1986, 83% of 496 isolates tested 
in vitro were resistant to chloroquine, with an IC99 of 900nmol/L, as opposed to 11% 
resistance with an IC99 of 359nmol/L in 1998. (WHO, 2005) but the clinical use of 
chloroquine for treatment of falciparum malaria is not recommended. The 
development of resistance to Mefloquine has been documented since 1997 (Le et al., 
1997; Trung et al., 2001). P. vivax is still sensitive to chloroquine. P. malariae and P. 
ovale cases are rarely reported. P. knowlesi has not been noticed.
Vectors
There are three main malaria vectors in Viet Nam. Anopheles (An.) dirus: a species 
complex, breeds in shaded water container, found in the forest and the forest-fringe. 
Its density is related to rainfall, and it is highly anthropophilic, highly exophilic and
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exophagic. Mainly found in the Central and South of Viet Nam. An. minimus: only 
breeds in running water, found only in the mountains, hilly areas and forest-fringe. It 
is partly zoophilic, partly exophilic and exophagic. An. sundaicus: found in brackish 
water regions, such as the Mekong river delta and the southern coastal areas. It is 
mainly endophilic and resistant to DDT.
The other secondary vectors are An. varruna, An. jeyporiensis (Central of Viet Nam), 
An. nimpe (South), An. lesteri and An. subpictus (North), An. vagus (plain areas), An. 
macculatus, An. aconitus, An. hyrcanus var. sinensis, An. indefinitus (unpublished 
data from IMPE of Ho Chi Minh City, Viet Nam).
Epidemiological patterns
Malaria in Viet Nam is associated with specific social and ecological factors. The 
urban areas and the plain areas around Hanoi and Ho Chi Minh City are non-endemic 
areas. Stable malaria affects the indigenous populations living in the forested, 
mountainous regions, and all age groups can be infected. Malaria epidemics occur in 
case of largely uncontrolled migration from plains to endemic areas. Severe malaria 
cases have also been seen in non-immune person who travelled to endemic areas, and 
in some occupational groups (such as plantation workers, mining, road-building, 
hunting, forest workers).
The division of Viet Nam into malaria zones has some validity and facilitates 
planning for the Malaria Programme. On the basis of the entomological, ecological 
and social information, the malaria patterns can be characterized region by region.
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Hills and mountains of the North Viet Nam: The transmission is of low intensity. 
Malaria outbreaks occur occasionally. The main vectors are An. minimus and An. 
dirus. Malaria control programme is inadequate because of the migration of the 
population due to many hydro-electric projects and economic migrants. Malaria risk is 
associated particularly with sleeping in plot huts even though bed nets are widely used 
by different ethnic group. The sleeping patterns of these people (late to bed) and the 
biting times of the mosquito (early evening and morning) may explain why bed nets 
have had a limited impact.
The Red river delta and other plains: Here transmission is very rare. Most of malaria 
cases are imported.
The Central and Southern highlands: The two main vectors are An. minimus and An. 
dirus. The transmission is more intensive with peaks occurring during the rainy 
season. Many ethnic minority groups inhabit these areas of dense, primary forests and 
suffer expose to intense malaria transmission so that the immunity develops in early 
childhood. Infants and pregnant women are more at risk more akin to the situation in 
Sub-Saharan Africa. Because of the new economic activities, malaria risk is high in 
the immigrant groups moving into these regions from lowland areas.
The Mekong delta: Malaria occurs in foci along the riverbanks and estuaries. P. vivax 
persist in the coastal areas with the main vector is An. vagus.
Morbidity and mortality
During the Viet Nam War, in the North of Viet Nam a programme of malaria 
eradication was started in 1958. For the first 5 years, the programme appeared to be 
successful, the smear positive rate (SPR) dropped from 5.6% (in samples of 10% the 
population) to 0.28%. But, because of many difficulties the programme lacked
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investment but the SPR was always kept less than 1% until 1975. In South Viet Nam, 
the malaria eradication campaigns were less successful. Malaria was found most in 
the areas which were also areas of intense and repeated battles and many soldiers 
from both sides and civilians died from malaria.
In 1975, after reunification, the National Malaria Programme was implemented across 
the whole country. From the end of 1975 to 1996, many surveys were done by the 
National Programme for Malaria Eradication, and the results showed the positive slide 
rate was 11.7% in 1976 and 2.9% in 1980. The malaria situation worsened after 
1981. There were many factors associated with the resurgence but major issues 
included the terrible economic situation, the establishment of many newly economic 
zones in the central and southern highlands with migration of people, the diminishing 
resources for peripheral health services and the programme for prevention, the 
emergence of drug-resistant strains of P. falciparum and the return of large number of 
Vietnamese soldiers from the Cambodian war. Malaria had re-emerged in the whole 
country and became the most important public health crisis affecting the nation. 
Malaria peaked in 1991, when the number of reported malaria deaths reached 4,646. 
Many cases remain unreported and this figure is undoubtedly a huge underestimate. 
Malaria was the leading cause of death caused by infectious diseases in the country. 
In 1992, the number of malaria cases increased to 225,928, but by the mid-1990s the 
morbidity and mortality began to decline. Again the reasons for this change are 
complex and multifactorial and it is a shame that we still do not know the relative 
contribution of these various interventions to the rolling back of malaria in Viet Nam. 
The factors that are widely thought to have made a major contribution include the 
implementation of a vertical and vigorous malaria control programme, economic 
development, deforestation, and widespread early deployment (before global
33
organisations gave their blessing) of artemisinin drugs. The new malaria control 
programme provided free antimalarial drugs as well as insecticides for treating bed 
nets and spraying. Access to treatment was improved and the more effective 
artemisinin-based drugs were deployed. By 1994, the Government budget for malaria 
control was US$ 5.2 millions, making it the biggest categorical programme.. The 
World Bank provided US$ 4.6 million per year from 1996 to 2000. External support 
reached US$ 1.8 million per year. The national economy began to improve in 1998. 
The contribution of these factors dramatically reduced malaria morbidity by 60% and 
mortality by 97%. Only 148 deaths from malaria were reported in 2000 (NMCP 
report, 2000). Malaria in Viet Nam is shown in Table 1.1, and malaria report in 2006 
(World Malaria Report, 2008) is shown in Table 1.2.
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Table 1.1 Malaria indicators for Viet Nam 1976-2006
Year Clinical malaria cases Confirmed malaria cases Deaths
1976 615,147 1,513
1977 909,501 3,120
1978 727,984 2,291
1979 807,600 1,125
1980 511,557 ' 1,138
1981 657,064 1,152
1982 . 747,228 1,368
1983 835,606 1,659
1984 880,713 1,256
1985 964,849 1,413
1986 1,424,919 1,838
1987 1,274,034 2,133
1988 1,310,387 2,465
1989 965,999 3,434
1990 902,789 123,796 3,340
1991 1,091,251 187,994 4,646
1992 1,294,426 225,928 2,658
1993 1,111,500 156,069 1,054
1994 858,000 140,120 604
1995 666,200 100,116 348
1996 532,900 76,356 198
1997 445,200 65,859 152
1998 383,300 72,091 183
1999 341,500 75,534 190
2000 293,000 74,316 148
2001 188,122 53,601 91
2002 184,901 46,902 50
2003 164,282 37,416 50
2004 128,382 24,909 34
2005 99,061 19,497 18
2006 91,350 22,637 41
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Table 1.2 Estimated and reported cases and deaths, 2006
Estimated Population 84.155.800
Fever cases 8,753,023
Malaria cases 70,324
Malaria death 167
Reported probable and Outpatient malaria cases 91,350
confirmed
Inpatient malaria cases 285
Malaria attributed deaths 41
Reported laboratory Mic. Slides/RDTs taken 2,972,429
confirmed
Mic. slides/RDTs positive 22,637
P. falciparum 17,911
P. vivax 4,497
Mixed 229
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1.2 Malaria parasite
Plasmodia arise from the Coccidian stem (Table 1.3) and present a sexual phase in the 
vector, a first asexual phase in the tissue of the host, followed by the main asexual phase 
in the blood o f the host. There are four species of the genus Plasmodium that infect 
humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium 
malariae. The characteristics of the four human malaria parasites are shown in Table 1.4. 
Recently the fifth species that can infect human is Plasmodium knowlesi, commonly 
found in Southeast Asia, and usually is misdiagnosed by microscopy mainly as 
Plasmodium malariae. This is an emerging infection that was reported for the first time in 
humans in 1965 (Chin et al., 1965). The morphological resemblance of early trophozoites 
of P. knowlesi to P. falciparum and later erythrocytic stages to P. malariae makes it 
extremely difficult to identify P. knowlesi infections by microscopy alone (Lee et al, 
2009).
Transmission
The main vector of human malaria is female anopheles mosquito. More than 60 species of 
Anopheles (An.) can transmit malaria, but their distributions vary between countries. 
Mosquito bites are the main way transmission occurs. The other ways are rare but include 
blood transfusions, needle sharing (among drug abusers) and congenital malaria, 
especially during the first pregnancy and in non-immune patients. The three main vectors 
in Viet Nam are: Anopheles dirus (forestry), An. minimus (near forest) and An. sundaicus 
(coastal region and Mekong river areas). The others also can be found: An. varruna, An. 
jeuporiensis (Central Viet Nam), An. nimpe (South Viet Nam), An. lestein and An. 
subpictus (North Viet Nam). Malaria transmission does not occur at altitudes higher than
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2000m and at temperature below 16°C or above 33°C because the development in the 
mosquito is not efficient enough.
Host Factors
All humans can get malaria, only a few are partially protected from malaria such as those 
with the Duffy blood group, and those with certain forms of haemoglobinopathy (HbS, 
HbF). There is enormous interest in host factors that may reduce or increase the 
susceptibility to malaria however a detailed review of this topic is beyond the scope of 
this thesis. Non-immune person (children, people who live in non-endemic area but 
travel to endemic areas), pregnant women and people who leave endemic areas and then 
return are more likely to develop severe malaria.
Life cycle of malaria parasite
The life cycle of malaria parasite is complex, but it is similar between the five species of 
human malaria. There is a sexual phase in the mosquito (sporogony) and an asexual phase 
in the human body. In the human, schizogony phase starts in the liver cells (exo or pre- 
erythrocytic schizogony or tissue schizogony) and later develops in the red blood cells 
(erythrocytic schizogony).
The asexual phase includes a pre-erythrocytic schizogony and an erythrocytic 
schizogony. When the female anopheles mosquito bites the human host it inoculates the 
parasite sporozoites into the human blood stream. Most of the sporozoites are destroyed. 
Some of them avoid the immune system and migrate to the liver cells within 30 minutes. 
Why the sporozoites target the liver cells and how they invade the hepatocytes so quickly 
remains unknown. Sporozoites pass through several liver cells before invasion and only 
8-10 sporozoites invade successfully (Mota et al., 2001). There are 2 co-receptors on
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sporozoites that mediate the invasion, the circumsporozoite protein (CSP) and the 
thrombospondin-related protein (TRP). Once inside the liver, each sporozoite can develop 
into thousands of merozoites (pre-erythrocytic schizogony or tissue schizogony). These 
merozoites will be released from liver cells at the end of this initial phase. The complete 
time of this phase is between 8-25 days for P. falciparum, 8-27 days for P. vivax, 9-17 
days for P. ovale, and 15-30 days for P. malariae. Each merozoite released from 
hepatocytes will invade red blood cells. Some of the sporozoites of P. vivax and P. ovale 
transform to hypnozoites, a dormant form, which remain in the liver cells for months or 
years, then can be reactivated and cause relapsing malaria. The mechanism of hibernation 
is also not known yet.
The erythrocytic, schizogony: Thousands of merozoites released from hepatocytes invade 
the RBC and go through a sequence of changes which results in the clinical 
manifestations of malaria. In the RBC, the parasite develops into ring forms (young 
trophozoites), trophozoites, schizonts, and erythrocytic merozoites. This erythrocytic 
cycle takes 24 hours for P. knowlesi, 48 hours for P. falciparum, P. vivax and P. ovale', 72 
hours for P. malariae. Then, these merozoites are released by the rupture of RBC and 
invade the uninfected RBCs. The erythrocytic cycle continues synchronously. Some 
merozoites transform into male and female gametocytes in the RBC. The gametocytes 
will infect the mosquitoes when they bite malaria infected patients.
Sexual phase (Sporogozy): The sporogonic cycle begins when the female and male 
gametocytes enter the female Anopheles mosquitoes during a blood meal. In the mid gut 
of the mosquito, the female gametocyte shed the RBC and becomes a macrogamete. The 
male gametocyte divides into flagellated microgametes, each of which may fertilize a 
macrogamete and form a zygote. A zygote develops slowly into motile ookinete, which 
penetrates the wall of the mid gut and transforms into a non-motile oocyst. The nucleus of
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this oocyst divides into thousands of sporozoites. The sporozoites migrate to the salivary 
gland of the mosquito. When the mosquito bites an individual, those sporozoites will 
inoculate into the blood stream and start another asexual phase.
Table 1.3 Classification of the genus Plasmodium
Sub-kingdom Protozoa
Phylum Apicomplexa
Class Sporozoasida
Sub-class Coccidiasina
Order Eucoccidiorida
Sub-order Haemospororina
Family Plasmodidae
Table 1.4 Characteristics of human malaria parasites
P. falciparum P. vivax P. malariae P,. ovale
Tissue
schizogony 5.5 8 15 9
(days)
Erythrocytic 
phase (days) 2 2 3 2
RBC affected All Reticulocytes Old RBC Reticulocytes
Hypnozoites No Yes No Yes
Merozoites per 8-32 12-24 6-12 4-16
schizont
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1.3 The pathophysiology of malaria
Early hypotheses to explain the pathophysiology of falciparum malaria were based on 
pathological observations in fatal cases of falciparum malaria; the cerebral capillaries 
were observed to contain a high proportion of parasitized red blood cells, even when the 
peripheral parasitaemia was low (Marchiafava and Bignami, 1894). Furthermore, the 
predominant forms in the cerebral capillaries and venules were large “late” trophozoites 
and schizonts forms that were seldom seen in peripheral blood smears. It was suggested 
that these parasitized erythrocytes stuck together and had difficulty passing through the 
capillary bed. Flow was consequently reduced, and finally stopped (Dudgeon and Clarke, 
1918; Gaskell and Millar, 1920). The pathological event was considered to be the results 
of obstructed microcirculatory flow or the local release of unidentified toxic materials 
from the malaria parasites. Normal erythrocytes must undergo considerable deformation 
in order to traverse the capillary, and when erythrocytes are rigid (as a result of being 
infected with the malaria parasites), obstruction may occur. It has been argued that 
erythrocytes containing mature parasites might be retained in capillaries by similar 
mechanisms. But if obstruction were due to cell rigidity only, the site of the obstruction 
would be expected to be the site of minimum cross-sectional area, the mid-capillary. The 
tail of erythrocytes stacked behind the obstructing cell should have a similar proportion of 
parasitized red cells as peripheral blood (White, 1986). Furthermore, such obstruction 
should occur uniformly as capillaries have similar internal diameter whereas pathological 
observations show preferential sequestration in different vascular beds, that post­
capillaries are often packed solely with infected erythrocytes (Pongponratn et al., 1991; 
Sein et al., 1993).
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The pathophysiological processes in malaria result from the destruction of erythrocytes, 
the liberation of parasite and erythrocyte material into the blood circulation, and the host 
reaction. During the intraerythrocytic phase of parasite, P. falciparum- infected red blood 
cells (Pf-IRBCs) disappear from the peripheral blood and localize in deep vascular beds 
of the brain and other organs in a process of receptor-mediated cytoadherence to 
endothelial cells (ECs). In falciparum malaria, the parasitized erythrocytes sequester in 
the capillaries and venules of vital organs, interfering with host tissue metabolism and 
blood flow (White and Ho, 1992).
1.3.1 Parasite multiplication
When schizonts in hepatocytes rupture, approximately 105 to 106 merozoites are liberated 
into the circulation. The liberated merozoites invade passing red blood cells immediately. 
In nonimmune individuals, the multiplication rate of asexual stages of P. falciparum 
usually reaches 20-fold per cycle (Kitchen, 1941 and 1949). On average, microscopy can 
detect parasites in the blood (20-50 parasites/pl of blood) on the 11th day after sporozoite 
inoculation. At this stage the host may still feel well or may complain of vague symptoms 
such as malaise, headache, myalgia or anorexia. The fever usually begins two days later.
n #
At the onset of fever, the adult patient has approximately 10 parasites in the body, which 
corresponds to 20-20,000 parasites/pl of blood. In endemic areas the host with immunity 
may tolerate parasitaemias up to 10,000/pl of blood without feeling ill (Smith et al., 1994; 
Amstrong-Schellenberg et al., 1994). The rise in parasite count is logarithmic initially, 
with a rising sine wave pattern of parasitaemia (Fairley, 1947), with considerable 
amplitude in synchronous P. falciparum infections. In most cases, the parasite 
multiplication terminates abruptly to limit the infection at a parasitaemia of 104-105/pl. 
Only P. falciparum has the capacity for such multiplication, and parasite counts may
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exceed 50% in some cases. Several factors limit the parasite multiplication. The host 
mobilizes non-specific then specific immune defences. High fever can damage the 
parasite schizonts and meronts, and brake parasite expansion (Kwiatkowski, 1990). 
Another limiting factor is the availability of suitable red cells; P. falciparum and P. vivax 
prefer younger red cells and P. malariae prefer older cells. Although natural infections 
often contain two or more genetically different parasite strains, the development of the 
parasite population tends to be synchronous from the onset (White et al., 1992). Further 
synchronization takes place within 1-2 hours in untreated infections in nonimmune 
patients. This is associated with malaria paroxysm (fever and rigors). Although one brood 
predominates, in P. falciparum infection there is usually at least one minor brood or 
subpopulation cycling 24 hours out of phase with the major brood (Li et al., 1982).
1.3.2 Parasite biomass
In the benign malarias, the number of parasites in the body may be estimated simply by 
multiplying the parasitaemia by the estimated blood volume (White, 1997). An 
unresolved question about severe malaria is the relationship between parasitaemia and 
stage of development (biomass), and disease severity. In falciparum malaria there are 
large discrepancies between the number of parasites in the peripheral blood and the 
number of parasites in the body (the total parasite biomass). In synchronous P. falciparum 
infection the parasite numbers in the peripheral blood fall at the time of sequestration, and 
rise at the time of schizogony or merogony (White et al., 1992). The total parasite 
biomass comprises the circulating parasites and the more mature sequestered parasites 
that are responsible for pathology. Some patients who die may have had large numbers of 
sequestered parasites, with very low peripheral parasite count. To estimate the total body
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parasite biomass in acute falciparum malaria, plasma histidine-rich protein 2 (PfHPR2) 
concentrations may be useful (Dondorp et al., 2005).
1.3.3 Toxicity and Cytokines
For many years malariologists considered that malaria parasites contain malaria toxins 
that cause the periodical “paroxysm”, but no toxin has ever been identified. Malaria 
parasites induce release of proinflammatory cytokines (Kwiatkowski et al., 1989). 
Cytokines, and in particular tumour necrosis factor (TNF), may play an important role in 
causing some of the pathological changes that characterise malaria. Tumor necrosis factor 
(TNF-a), interleukin (IL)-l and gamma interferon (y-IFN) are produced and these induce 
the release of a cascade of "proinflammatory'’ cytokines including IL-6, IL-8, IL-12, IL- 
18. These are balanced by production of the "anti-inflammatory" cytokines IL-10 (Kern et 
al., 1989; Ho et al., 1998). The concentration of the cytokines in plasma is elevated in 
both vivax and falciparum malaria (Grau et al., 1989, Karunaweera et al., 1992). One of 
the main toxic serum components appear to be lipid peroxides which are formed by the 
interaction of lipoproteins with reactive oxygen intermediates. Malaria parasites are 
extremely susceptible to free radical damage (Malhotra et al, 1988) and lipid peroxidation 
has the effect of stabilizing the reactive oxygen groups, thus creating a more stable 
cytotoxic molecule. Soluble antigens of P. falciparum released into in vitro culture 
supernatants, and also found in the plasma of patients with acute malaria, are potent 
inducers of TNF release from monocytes or macrophages (Bate et al, 1988; Kwiatkowski 
et al., 1989). Some studies have confirmed a positive association between plasma 
concentrations of TNF and other pro-inflammatory cytokines and mortality in severe 
falciparum malaria (Grau et al., 1989; Kern et al., 1989; Kwiatkowski et al., 1990). In 
most of these studies plasma concentrations of TNF have been correlated with several
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indicators of severity, namely hypoglycaemia, hyperparasitaemia, and anaemia. Plasma 
concentrations of IL-1, IL-6, and IL-8 have also been shown being correlated with disease 
severity. IL-10 inhibits the ability of malaria antigens to induce release TNF (Ho et al.,
1995). A study in the Gambia a genetic polymorphism in the TNF promoter region has 
been shown to confer a seven fold increased risk of either death or neurological deficit 
from severe malaria (McGuire et al., 1994). This strongly suggests a link between TNF 
production and its neutralization by tissue bound and circulating receptors is an important 
determinant of the biological effects. If pro-inflammatory cytokines do play a central role 
in severe malaria, then these pathological events are likely to take place locally and may 
not be reflected in systemic cytokine measurements. Preliminary studies indicate that 
these are antipyretic confirming a central role for TNF in fever. Results of studies of 
anticytokine and anti-inflammatory agents (anti-TNF antibodies, pentoxifylline, and 
dexamethasone) in the treatment of severe malaria have been disappointing (Warrell, 
1999). Acute malaria is associated with high levels of most cytokines, but the balance 
differs in relation to severity. IL-12 and TGF-P 1 (transforming growth factor), which 
may regulate the balance between pro- and anti- inflammatory cytokines, are higher in 
uncomplicated than in severe malaria (Perkins et al., 2000). Cytokines are responsible for 
many of the symptoms and signs of malaria such as fever and malaise. There is no direct 
evidence that systemic release of TNF or other cytokines causes coma in human. In a 
recent study on severe malaria in adults, elevated plasma TNF concentrations were 
associated specifically with acute renal failure and TNF levels were actually lower in 
patients with pure cerebral malaria than those of other complications (Day et al., 1999). 
Cytokines may be involved in placental function, suppression of erythropoiesis and 
inhibition of gluconeogenesis. Cytokines also up-regulate the endothelial expression of 
vascular ligands for P. falciparum infected red blood cells, notably ICAM-1 and may
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promote cytoadherence. But studies have also called into question the asscociation of pro- 
inflammatory cytokines with a poor prognosis (Lyke et al., 2004). The role of inducible 
nitric oxide synthase (iNOS) and nitric oxide (NO) in the pathophysiology of severe 
falciparum was first described in 1991 (Clark et al., 1991), and there was a relation 
between reactive nitrogen intermediates (RNI) levels with disease severity (Yaman et al.,
1996). But other trials found a negative association (Anstey et al., 1996; Taylor et al., 
1998; Boutlis et al., 2004).
1.3.4 Sequestration
A characteristic feature of falciparum malaria is the lack of mature forms of the parasite 
in the peripheral circulation of the patients. The essential pathological feature of severe 
falciparum malaria is the abundance of erythrocytes containing mature forms of the 
parasite in the deep vascular beds of vital organs (Berendt et al., 1994). This phenomenon 
is known as sequestration. Sequestration is not distributed uniformly at a microvascular 
level or amongst the vital organs; it is usually least in the skin and greatest in the brain. 
Quantitives studies of sequestration in different organs from fatal cases confirmed that 
sequestration of parasitized RBC in cerebral malaria (MacPherson et al., 1985; 
Pongponratn et al., 1991 and 2003), which may explain why cerebral malaria is a 
prominent feature of severe falciparum malaria in man. Some vessels are completely 
packed with parasitized red blood cells while adjacent vessels are clear (Silamut et al.,
1999). This may cause more gradually reduction in blood flow perhaps with less hypoxia 
because of preserved flow in adjacent capillaries. The severity of falciparum malaria 
appears to be proportional to the density of the parasite in the internal vessels, and not 
necessarily related to the parasitaemia of the peripheral circulation (Pongponratn et al., 
1991 and 2003). In the human body, the microvessels of the heart, lungs, kidneys, small
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intestine, and liver are the other principal sites of sequestration (Sherman et al., 1992). 
Unfortunately, despite considerable interest in immunopathological mechanisms in rodent 
models of severe malaria (Grau et al., 1990) and also the sequestering parasite P. coatneyi 
in the rhesus monkey (Sein et al., 1993) there is no animal model which satisfactorily 
reproduces the clinical features of cerebral malaria in man (White and Ho, 1992).
1.3.5 Cytoadherence
The binding of mature red blood cells to endothelial cells in post- capillary venules, 
called as cytoadherence, is considered as a virulent factor. Parasitized erythrocytes stick 
to the surface of vascular endothelial cells and this explains the process of sequestration. 
The post-capillary venule is the first site in a red cell’s route from the heart where the 
shear forces at the vessel wall drop markedly in a way that should permit adherence and 
this is the site of preferential sequestration. Uninfected erythrocytes will also bind to the 
surface of erythrocytes containing mature forms of the parasite causing “rosetting” 
(David et al., 1988). Numerous stage-specific changes occur in the infected red cell 
membrane at the transition from non-sequestering ring form to the sequestering 
trophozoite. Electron-dense sub-membranous structures appear and enlarge, resulting in 
called “knobs,” which are the sites of red cell to endothelial cell adhesion (Pongponratn et 
al., 1991; Ho et al., 1992). These knobs are considered essential for cytoadherence by 
facilitating the initial attachment of the infected erythrocytes to the vascular endothelial 
cell, and by concentrating the parasite ligands at a particular site. Cytoadherence is an 
important mechanism for parasite escape from the macrophagic phagocytosis of the first 
mechanism, and the spleen plays a major role in mulating the erythrocyte surface 
alterations responsible for parasite sequestration (David et al, 1983). The families of 
molecules, which mediate cytoadherence, are a series of antigenically variant high
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molecular weight proteins exported by the parasite to the red cell exterior. These are 
called Plasmodium falciparum erythrocyte membrane protein l(PfEMP-l) (Howard and 
Gilladoga, 1989). The molecule is trypsin sensitive and trypsin will inhibit cytoadherence. 
Cytoadherence can be inhibited by strain specific anti-sera. PfEMP-1 is also thought to be 
the major surface antigen determining the population structure of P. falciparum. It has 
been shown to undergo antigenic variation at a rate of approximately 2.4% of per parasite 
life cycle (Roberts et al., 1992).
The interaction between parasitized red blood cells and endothelial cells involves specific 
parasite ligands and host receptors. At least six potential receptors have been identified to 
date. The first to be discovered was CD36. The expression of CD36 on the surface of 
cells correlates with their ability to act as targets for cytoadherence of infected cells. 
Recent studies have shown that nearly all freshly isolated parasites from patients with 
acute falciparum malaria bind strongly to CD36 (Ockenhouse et al., 1991). 
Immunohistochemical studies indicate that parasite sequestration co-localises with CD36 
with vascular expression of CD36 outside the brain, whereas within the brain there is very 
little CD36 expression and other ligands are involved presumably. This suggests that 
CD36 is probably the major cytoadherence ligand outside the brain.
The second candidate molecule to be discovered was thrombospondin, a multi-functional 
glycoprotein which is synthesized by many adherent cell types including endothelium and 
which is released on platelet activation. Thrombospondin may contribute to 
cytoadherence, possibly by stabilizing the PfEMP-1 -  CD36 interaction but it does not 
mediate it alone. Intercellular adhesion molecule 1 (ICAM-1) is also a cytoadherence 
receptor for P. falciparum (Berendt et al., 1989). This is the natural receptor for 
rhinovirus invasion, although most natural isolates bind less avidly to ICAM-1 than to 
CD36 (Ockenhouse et al., 1991), recent immunohistochemical studies indicate highly
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significant co-localisation of parasite sequestration within the brain and vascular 
expression of ICAM-1. This suggests that ICAM-1 is probably the major vascular ligand 
for cytoadherence within the brain (Turner et al., 1994). The interaction between ICAM-1 
and infected red cells is of a “rolling” type in which the cell rolls along the vascular 
endothelium somewhat analogous to the movement of a polymorphonuclear leukocyte 
before it penetrates at sites of inflammation (Cooke et al., 1994). This contrasts the static 
adhesion resulting from binding to CD36. Recently other potential ligands have been 
identified: E selectin, vascular adhesive molecule 1 (V-CAM 1), chondroitin sulphate A 
(CSA), and hyaluronic acid (HA). The role of these adhesions is less clear. P. falciparum 
derived molecules on the RBC surface which mediate adherence include PfEMP-1, 
sequestrin, modified RBC band 3, rosettins, Pf 332 (White, 2003).
Parasites sequester themselves in various organs such as brain, heart, lung, liver, kidney, 
subcutaneous tissue and placenta. Cytoadherence results in sequestration of parasitized 
red blood cells in the deep vasculature of organs, and therefore it localizes parasites in 
sites of low oxygen tension that is ideal for their growth. It also prevents infected 
parasitized red blood cells being destroyed in the spleen and it is thought to be the cause 
of organ dysfunction through microcirculation obstruction, endothelial cell activation and 
damage, cytokine release. Extensive binding of parasitized RBC to placental chondroitin 
sulfate A (CSA) is associated with physiopathology during pregnancy (Pouvelle et al.,
2000). Febrile temterature may induce cytoadherence of parasitized RBC 
(Udomsangpetch et al., 2002).
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1.3.6 Red cell deformability
P. falciparum infected erythrocytes have reduced deformability, which is directly 
proportional to the maturity of the intracellular parasite (Cranston et al., 1984). Several 
factors are likely to account for reduced deformability of parasitized erythrocytes, notably 
changes in the cytoskeleton (Maguire et al., 1991), increased membrane stiffness, 
increased cytoplasmic viscosity resulting from changes in membrane permeability 
(Kutner et al., 1983), reduced surface area to volume ratio (increased sphericity), 
principally the rigidity of the parasite itself (Nash et al., 1989), and the enlarging and 
relatively viscous intra-erythrocytic parasite (Paulitschke and Nash, 1993). The 
parasitized red cells become more spherical and rigid, and the surface is irregular and 
covered in small protrusions. This explains why infected cells are less able to pass 
through micropore filters than uninfected cells (Lee et al., 1982). The uninfected red cells 
also have a reduction in deformability (Dondorp et al., 1997). Reduced deformability 
alone cannot explain sequestration in venules (White and Ho, 1992).
1.3.7 Rosetting
Red blood cells containing mature malaria parasites adhere to unparasitized red cells. 
This event leads to the formation of “rosettes” (David et al., 1988; Handunnetti et al., 
1989). Rosetting starts in venules and reduce flow, which may enhance anaerobic 
glycolysis, reduce pH and facilitate adherence of parasitized red cells to venular 
endothelium. Rosetting is mediated by PfEMP-1 and rosettins, and involves the 
complement receptors, heparin sulphate, blood group A antigen and other red cell surface 
molecules (Rowe et al., 1994 and 1995). Rosetting is inhibited by heparin subfractions 
and calcium chelators. All four Plasmodium species infecting human can induce
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rosetting, but only P. falciparum causes severe malaria. Rosetting in P. falciparum is 
associated with cerebral malaria (Carlson et al., 1990; Ho et al., 1991).
1.3.8 Genetic factors and Immunity
The development of clinical disease is dependent on the interplay of the infecting parasite 
with the immune status and genetic background of the host. Following repeated exposure 
to malaria parasites, individuals residing in endemic areas develop immunity. Naturally 
acquired immunity provides protection against clinical disease, especially severe malaria 
and death from malaria, although sterilizing immunity is never achieved. In non-immune 
individuals, P. falciparum may cause severe and life-threatening disease. The other risk 
groups are children and pregnant women, particularly during their first pregnancies.
The thalassaemias are inherited blood disorders that result from mutations in either the a- 
globin or P-globin genes. Thalassaemia and sickle cell disease are not protective against 
malaria. It is the heterozygote carriers of these genes that are protected. The alpha- and 
beta-thalassaemias and the structural variant haemoglobins S, C and E are believed to 
provide protection against malaria (Clegg and Weatherall, 1999). Both HbC and HbS 
affect the early development of naturally acquired immunity against malaria (Verra et al., 
2007). The protective effect conferred by glucose-6-phosphate dehydrogenase (G6PD) 
deficiency remains controversial, but early phagocytosis of G6PD deficient erythrocytes 
parasitized by P. falciparum may explain this protection (Cappadoro et al., 1998). Human 
leucocyte antigens (HLA), such as class I antigen HLA-BW53 and class II antigen HLA- 
DR Bl*1302, may confer protection against severe malaria (Hill et al., 1991, 1992).
It seems that severe malaria does not result from specific immune-mediated damage. 
Proliferative glomerulonephritis, the classical pathological marker of an immunological 
disease, was reported in falciparum malaria (Hartenbower et al., 1972) but it was very
51
rarely seen. Intravascular accumulations of white blood cells are seen occasionally in 
severe malaria patients who died after many days of treatment (Patnaik et al., 1994) and 
malaria antigens may be found on the endothelial basement membranes (Igarashi et al., 
1987). However, histological evidence of vasculitis is absent in fatal cases of facliparum 
malaria. Although immune complexes and free malarial antigen may be detected, the 
glomerulonephritis is rare (Stone et al., 1972). There are a reduction of T cells and an 
increase of gamma-delta T-cells (Ho et al., 1990) in malaria. Hypergammaglobulinaemia 
was seen in people who live in hyperendemic malaria areas but this antibody is not 
directed against malaria antigens. There is an immune suppression in severe malaria, with 
defects in monocytes and neutrophil chemotaxis, reduced monocytic phagocytic function 
and a tendency to bacterial superinfection. The classical and alternative pathways of the 
complement system are profoundly activated in severe malaria but there is no relation 
between clinical disease severity and complement fragments existed (Wenisch et al., 
1997). Recently, molecular biology study found that matrix metalloproteinases (MMPs) 
and tissue inhibitors of metalloproteinases (TIMPs) may be relevant in the pathogenesis 
of severe falciparum malaria, either as proteolytic enzymes that degrade the extracellular 
matrix or as effectors and regulators of the immune response (Dietmann et al., 2008). 
HIV-infected nonimmune adults are at increased risk of severe malaria. The risk is 
associated with a low CD4+ T cell count (Khasnis and Kamad, 2003; Cohen et al., 2005).
1,3.9 Permeability
Systemic vascular permeability increases slightly in severe malaria (Davis et al., 1992). 
Cerebral oedema is a common finding at autopsy in cerebral malaria (Spitz, 1946; Walker 
et al., 1992; Sengupta and Narqi, 1992). Pathological studies in the 1940s (Rigdon, 1944) 
and experimental studies in the 1960s led to a new hypothesis (Maegraith and Fletcher,
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1972). There was an increase in blood-barrier permeability of 1251-albumin in severely ill 
P. knowlesi infected rhesus monkeys and increased penetration of the brain by water- 
soluble dyes which were reversed rapidly by hydrocortisone, mepacrine, and chloroquine 
(Migasena and Maegraith, 1967). It was suggested that there was an increase in cerebral 
capillary permeability with outward leakage of plasma in cerebral malaria. This was 
considered that the extravasation of plasma into the cerebral interstitium, local 
haemoconcentration and reduced microcirculatory blood flow result in cerebral oedema. 
The factors responsible for this were considered to be kinins (Maegraith and Fletcher, 
1972). This theory became widely adopted and was the basis for the widespread use of 
corticosteroids in cerebral malaria. Clinical and experimental observations in man argue 
the permeability hypothesis. In the absence of spinal block, cerebral oedema leading to 
raise intracranial pressure must raise lumbar cerebrospinal fluid pressure, but opening 
pressures at lumbar puncture are within the normal range. Papilloedema is relatively 
unusual (Looareesuwan et al., 1983). Computerized tomography of the brain rarely shows 
evidence of cerebral oedema (Looareesuwan et al., 1983; Newton et al., 1994). Finally, in 
the studies of blood-CSF barrier permeability in cerebral malaria, no increase in 
permeability was observed with a variety of marker substances that included 1251- 
albumin (Badibanga et al., 1986; Warrell et al., 1986). These observations demonstrate 
that cerebral oedema resulting from “leaky” cerebral capillaries is not a consistent, or 
even a common feature of cerebral malaria, and cannot be the cause of coma in cerebral 
malaria.
1.3.10 Cerebral malaria
The major lethal complication of malaria infection particularly in children is cerebral 
malaria, a diffuse usually reversible encephalopathy. The essential underlying
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pathological process is the sequestration of red blood cells containing mature forms of P. 
falciparum in the cerebral microvasculature. Coma is a characteristic feature of 
falciparum malaria. Death rate in cerebral malaria is above 20% (Warrell, 1992; Hien et 
al., 1996), but over 98% of adult survivors recover without sequelae (WHO, 1990). Many 
hypotheses have been proposed to explain the loss of consciousness in cerebral malaria. 
None are completely satisfactory. Ischaemia alone would not account for the excellent 
neurological recovery. Similar cerebral metabolic findings to those in cerebral malaria 
have been recorded in volunteers breathing low concentrations of oxygen (White and Ho, 
1992). Inflammatory processes are not compatible with the time course or pathology. 
Increased systemic levels of pro-inflammatory cytokines may obtund but do not lead to 
profound coma. Cerebral malaria most closely resembles a metabolic or anaesthetic 
encephalopathy. Ultimately abnormalities of neuro-transmitter synthesis, release or 
binding may be implicated. It was suggested that the ubiquitous messenger nitric oxide 
might be important (Clark et al., 1994). Studies on Kenyan children with cerebral malaria 
have proposed that the imbalances of excitatory mediators may be implicated in the 
initiation and maintenance of seizures and neuronal degeneration and might contribute to 
neurological symptoms in cerebral malaria (Dobbie et al., 2000). Studies of cerebral 
blood flow and metabolism and acid-base status (White et al., 1985; Warrell et al., 1988; 
Taylor et al., 1993) suggested that there is an anaerobic cerebral glycolysis in cerebral 
malaria; and this presumably results from cerebral hypoxia. There is also a significant 
contribution from the parasites’ glycolytic metabolism (White and Ho, 1992). Cerebral 
hypoxia may well result from either “patchy” microcirculatory obstruction with adjacent 
areas of increased perfusion, or alternatively a more diffuse and homogenous process in 
which the adherent erythrocytes interfere with gas and substrate exchange throughout the 
brain but do not increase vascular resistance. The most likely scenario is of vasodilation
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to accomodate the increased intracerebral blood volume (Looareesuwan et al., 1995). 
Magnetic resonance imaging is a more sensitive measure of brain water, but there was no 
evidence of cerebral oedema in cerebral malaria (Looareesuwan et al., 1995). Double­
blind placebo-controlled trials of medium and high dose dexamethasone in cerebral 
malaria showed no effect on mortality (Warrell et al., 1982, Hoffman et al., 1988). In one 
of the trials, coma was prolonged in the steroid-treated patients (Warrell et al., 1982). 
Studies in adults with severe falciparum malaria in which transcapillary escape rates for 
radio-labeled albumin, fluoroscein angiography to demonstrate retinal capillary leakage, 
and urinary micro-albumin excretion were measured did indicate a small but significant 
increase in generalized capillary permeability, but this was small and would be unlikely to 
account for any of the major pathological features of severe malaria. This is consistent 
with the observations in some studies on the structural integrity of the blood-brain barrier 
(BBB) and ultrastructure of the brain in fatal cases of falciparum malaria (Brown et al., 
1999; Medana et al., 2001 and 2002). Thus there is little evidence for a severe and 
generalized increase in capillary permeability in severe falciparum malaria. It is likely 
that the post-mortem observation of cerebral oedema in fatal cases of cerebral malaria 
usually results from agonal events (hypotension, severe acidosis, etc.) which occurred in 
the hours preceding death, but there is no clinical evidence that oedema precipitates 
death. However it is also worth considering that coma may be neuroprotective. Neurones 
stressed by an inadequate supply of oxygen and nutrients, and an unfavourable metabolic 
milieu may preserve themselve by reducing energy demands. Premature reversal of coma 
might increase the risk of neuronal damage.
Immune mechanisms have not been proved to have a role in the pathogenesis of cerebral 
malaria. The neuropathological findings in cerebral malaria had been interpreted as 
resulting from a reaction of the central nervous system to the antigenic challenge of P.
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falciparum infection (Toro and Roman, 1978) but the predicted increase in brain water 
associated with this was not observed on magnetic resonance imaging in vivo 
(Looareesuwan et al., 1995). The proposed mechanism for this was an immune complex 
vasculitis of the cerebral vessels. However, the perivenous demyelination described by 
these authors could have been explained by terminal hypoxia. Furthermore 
histopathological studies, immunohistochemical studies, and ultrastructural studies 
usually show no evidence of an inflammatory cell infiltrate despite abundant evidence of 
endothelial cell activation (MacPherson et al., 1985; Turner et al., 1994). However 
another study reported that mononuclear cell margination along the cerebral 
microvascular walls was prominent in 5 of 23 fatal cases of cerebral malaria and 
speculated that this may have contributed to pathology (Patnaik et al., 1994).
Sequestration results from the adherence of parasitized red cells to vascular endothelium. 
Histopathological observations in fatal falciparum malaria suggest that the red blood cells 
containing more mature parasites are sequestered in the brain and other organs. Post­
mortem studies have given conflicting results on the predominant stage of parasite in the 
brain. A study reported almost exclusively schizonts (Lemercier et al., 1966) whereas 
another study found that both trophozoites and schizonts predominate (MacPherson et al, 
1985). Microvascular sequestration was assessed in the brains of 50 Vietnamese and Thai 
patients who died from severe malaria; the results have shown that within the same brain 
different vessels had discrete but different populations of parasites indicating that the 
adhesion characteristics of cerebrovascular endothelium change asynchronously during 
malaria. Furthermore there were significantly more ring form parasites in the cerebral 
microcirculation than expected. Sequestration probably has a major role in the 
pathophysiology of cerebral malaria, particularly in adults (Silamut et al, 1999), but it is 
less consistently implicated in children (Crawley et al., 2001; Taylor et al., 2004). The
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clinical syndromes and the variation in pathological features in severe malaria have 
caused extensive controversy. The increased cerebral lactate production reflected in 
increased jugular venous and cerebrospinal fluid concentrations of lactate indicates 
significant anoxic metabolism, but it is not clear whether these changes provide sufficient 
explanation for coma (White and Ho, 1992). In a retrospective study of 261 Vietnamese 
adult patients with severe malaria three metabolites, the excitotoxin quinolinic acid (QA); 
the protective receptor antagonist kynurenic acid (KA) and the proinflammatory mediator 
picolinic acid (PA) were measured and related to the incidence of neurological 
complications, CSF lactate level and the disease outcome. The results have indicated that 
there was no difference in the levels of KA between groups; no association between QA 
concentrations in CSF and convulsion or depth of coma, and that the significant elevation 
of QA, PA levels and QA: KA ratio in patients with poor outcome was only a 
consequence of impaired renal function in this group (Medana et al., 2002). A post­
mortem study on 54 Vietnamese patients who died from severe falciparum malaria the 
authors found P-amyloid precursor protein (P-APP), a marker of potentially reversible 
axonal damage, normally transported along the axon. P-APP accumulates at the site of 
axonal injury, that is significantly associated with cerebral malaria in adults and that this 
distinguishes cerebral malaria from non-cerebral malaria. This marker highlights the 
internal capsule and pons as areas of primary involvement in axonal injuries. Unlike other 
pathological correlates such as neuronal stress markers, axonal injury does not seem to 
purely reflect the systemic contribution of severe malaria to the specific neurological 
syndrome of cerebral malaria (Medana et al., 2002). Study of cerebrospinal fluid markers 
of brain parenchymal damage confirmed that axons are the cellular component most 
severely affected (Medana et al., 2005) and axonal damage may play an important role in 
the mechanism of cerebral malaria. Recently, a pathological study reported the evidence
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of perturbation of human BBB integrity by the adherence of Pf-IRBCs to brain 
endothelium through a multifactorial and multistep process (Tripathi et ah, 2007).
1,3.11 Renalfailure
Renal impairment is a common complication and a sensitive prognosis indicator in severe 
falciparum malaria in adults; half of these patients have evidence of renal dysfunction 
(Trang et al., 1992). Renal failure is rarely seen in children (Sowunmi, 1996). The basic 
pathology is acute tubular necrosis (Sitprija et al., 1967; Stone et al., 1972; Day et al.,
1997) and reports of glomerulonephritis are very rare (Hartenbower et al., 1972). Renal 
impairment may be caused by renal hypoperfusion due to dehydration and hypovolaemia. 
Renal failure may be compounded by severe anaemia, haemoglobinuria, intravascular 
haemolysis and clogging of the tubules by the products of haemolysis. The pathological 
processes of acute tubular necrosis in severe malaria have not been clearly known. 
Cytoadherence of parasitized red cells in the glomerular capillaries is occasionally seen 
(MacPherson et al., 1985). Studies of renal cortical blood flow (Sitprija et al., 1977) and 
radiological studies (angiography and contrast urography) (Arthachinta et al., 1974) had 
shown renal cortical vasoconstriction. The oxygen consumption of the kidneys is reduced 
in acute renal failure (Day et al., 1996) and it is not improved by administration of 
dopamine that induces arteriolar vasodilatation, consequently increases the renal blood 
flow and glomerular filtration rate (Day et al., 2000). The role of local cytokine release 
and altered regulation of renal microvascular flow is unclear.
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1.3.12 Hepatic dysfunction
Enlargement of liver occurs in malaria. Hepatic dysfunction and jaundice is more 
common in adults with severe malaria than in children. Jaundice is caused by haemolysis. 
There are elevations of unconjugated bilirubin and aspartate aminotransferase levels; and 
reductions in clotting factor synthesis, albuminaemia, metabolic clearance of drugs, 
biliary excretion. Liver blood flow, measured by indocyanine green clearance, is reduced 
during acute malaria, and is significantly lower in severe malaria than in uncomplicated 
malaria. This event is associated with highly venous lactate (Pukrittayakamee et al., 
1994). There may be sequestration and consequent microcirculatory obstruction in the 
portal and hepatic circulations, or portal venoconstriction. The failure of gluconeogenesis 
contributes to hypoglycaemia and lactic acidosis. Liver biopsy usually reveals the dilation 
of hepatic sinusoids containing hypertrophied Kupffer cells and parasitized red cells, 
mononuclear cell infiltration. Other studies have shown either no structural changes or 
slight hepatocyte swelling (Sherlock, 1975). Small areas of centrilobular necrosis have 
been reported (Joshi et al., 1986). The overall prevalence of Hepatitis B surface antigen 
(HbsAg) among Vietnamese patients with severe falciparum malaria was higher than that 
in general catchment population for the study hospital and patients admitted with cerebral 
malaria had a greater risk of registering positive HbsAg to other manifestations of severe 
malaria (Barcus et al., 2002).
1.3.13 Pulmonary oedema
Acute pulmonary oedema in severe malaria results from a sudden increase in pulmonary 
capillary permeability (James, 1985). It usually develops in severe falciparum malaria, 
particularly in pregnant malaria patients. The left ventricular function is usually normal so 
the cause of pulmonary capillary permeability is not known (Charoenpan et al., 1990).
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Interstitial oedema and hyaline-membrane formation are seen. Pulmonary capillaries and 
venules are packed with inflammatory cells and parasitized red cells. Acute respiratory 
distress syndrome is a major cause of death in adults with severe malaria, and it usually 
develops after the start of antimalarial treatment. Pulmonary vascular occlusion occurs 
from sequestration of both RBC and WBC. There is impaired alveolar-capillary 
membrane in severe malaria patients (Maguire et al., 2005).
1.3.14 Hypoglycaemia
Hypoglycaemia is an important manifestation of falciparum malaria and is associated 
with hyperlactataemia. There are many explanations of hypoglycaemia such as increased 
metabolic demands of febrile illness, increased peripheral requirement for glucose 
consequent on anaerobic glycolysis, the glucose consumption of malaria parasites, the 
failure of hepatic gluconeogenesis and glycogenolysis (White et al., 1983; Davis et al., 
1993)
Quinine/quinidine-induced hyperinsulinaemia: quinine stimulates the pancreatic (3-cells to 
release insulin in healthy individuals and in patients with falciparum malaria, both in 
pregnant women with severe or relatively mild disease, and in adults and children with 
severe disease (Davis et al., 1993; Krishna et al., 1994; Looareesuwan et al., 1985; 
Okitolonda et al., 1987; White et al., 1983). Children with severe malaria have 
considerably increased glucose requirements compared with adults. Hypoglycaemia in 
African children with severe malaria, and in adults who have not received previous 
quinine treatment, is associated with appropriately low plasma concentrations of insulin 
(Taylor etal., 1988).
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1.3.15 Metabolic acidosis.
Acidosis, mainly lactic acidosis, results from a compromised microcirculation caused by 
sequestration of parasitized red blood cells. Lactic acidosis is an important cause of death 
in severe falciparum malaria (White et al., 1983 and 1987; Taylor et al., 1988; Krishna et 
al., 1994; Day et al., 2000) and results from several processes: the tissue anaerobic 
glycolysis due to microvascular obstruction, the failure of lactate clearance due to liver 
dysfunction (Day et al., 2000), acute renal failure, the reduction of oxygen carriage due to 
anaemia and the production of lactate by parasites (Pfaller et al., 1982; Van der Jagt et al., 
1990; White and Ho, 1992) and the adhesive forces between red cells and the decreased 
erythrocyte deformability (Dondorp et al., 2000). The acidosis is caused mainly by lactic 
acid, impaired hydrogen ion excretion because of renal failure (English et al., 1996). The 
high level of lactate concentration in venous or arterial blood, or cerebrospinal fluid is a 
poor prognosis in severe malaria (White et al., 1985; Waller et al., 1995) and prolonged 
hyperlactataemia may be the best overall prognostic indicator of outcome. A recent study 
indicated that unidentified anions are also the most important contributors to metabolic 
acidosis in severe malaria in adults (Dondorp et al., 2004).
1.4 The clinical aspect of malaria infection
The clinical manifestations of malaria depend on many factors: parasites, host immunity, 
and intensity of malaria transmission. Malaria incubation periods in naturally acquired 
infections vary between 1 3 - 2 8  days. All clinical features of malaria are associated with 
the multiplication of blood-stage parasites and especially with the often synchronous, 
bursting of large number of parasitised RBC (Kwiatkowski et al., 1989).
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1.4.1 Asymptomatic infection
In the constantly intense P. falciparum malaria transmission areas many infected semi- 
immune adults are asymptomatic, even infected pregnant individuals have no symptoms 
but the birth weight of babies bom to primagravidae is low. Clinical aspects of malaria 
are different in non-immune and semi-immune patients. The parasitaemia at which fever 
occurs is termed the “pyrogenic density”, and it is widely different between parasites and 
host immunity.
1.4.2 Uncomplicated malaria:
The first symptoms of malaria are non-specific and resemble influenza, and are similar 
for all five species of Plasmodium. Feeling unwell, malaise, loss of appetite, headache, 
fatigue, lethargy, muscle and joint aches, abdominal discomfort often precedes fever. In 
some cases, the patients complain of chest pain, cough, abdominal pain, arthralgia, 
myalgia, diarrhoea, vomiting or nausea. The characteristics of typical features of 
uncomplicated malaria illness included three stages: cold stage, hot stage and sweating 
stage. The classical malaria fever chart, the “paroxysm”, is unusually seen now. The fever 
is irregular at the onset of illness. The non-immune patients and children may have high 
fever. Childhood febrile convulsions may be seen. Anaemia with palpable spleen is 
common in children living in high transmission areas. Mild jaundice and slight 
enlargement of the liver is also commonly seen in adults. Overall the clinical symptoms 
of non-complicated malaria are similar to other infectious diseases. In tropical areas any 
fever should be considered to be malaria until the proof of malaria is excluded.
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1.4.3 Severe and complicated malaria
Falciparum malaria can lead to multiple organ dysfunction syndromes (MODS). The 
outcome of severe malaria depends on many factors such as the number of vital organ 
affected, the degree of vital organ failure, the host immunity and the appropriate 
management. However, outcomes are better than for similar degrees of organ failure in 
bacterial sepsis.
1.4.3.1 Cerebral malaria 
Cerebral malaria is one of the most common non-traumatic encephalopathies. The term 
“cerebral malaria” is used to describe any impairment of consciousness or other 
disturbance o f central nervous system in falciparum malaria, after hypoglycaemia is 
corrected and other meningo-encephalopathies are excluded. Cerebral malaria is the most 
prominent feature of severe falciparum malaria, manifests as a diffuse symmetric 
encephalopathy but focally neurological signs are unusual. Headache may be severe in 
malaria but there is no neck stiffness. Nausea and vomiting are common. The onset of 
coma is sudden or gradual, or may follow a generalized convulsion. The patient develops 
drowsiness, confusion, delirium or agitation, disorientation, followed by unconsciousness 
with divergent gaze and variable tone (Figure 1.2). Despite treatment, coma is associated 
with death rates above 20% (Hien et al., 1996; Warrell, 1992). Pout reflex and bruxism 
are common, but other primitive reflexes are usually absent. The tendon reflexes are 
variable, and the plantar reflexes may be flexor or extensor. Decortication (flexor) or 
decerebration (extensor) posturing is also documented. The corneal reflexes are preserved 
in adult patients but lost in children with deep coma (White, 1996). Approximately 15% 
to 20% of patients have retinal haemorrhages (Looareesuwan et al., 1983; Schemann et 
al., 2002). Pupilloedema and cranial nerve abnormalities are rare. Convulsions, usually
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generalized and often repeated, occur in up to 50% of children with cerebral malaria 
(Asindi et al., 1993) and prolonged seizures are associated with poor outcome. Seizures, 
coma, severe anaemia and metabolic acidosis presenting as respiratory failure are 
common in African children. More covert seizure activity is common, particularly in 
children, and may manifest as repetitive tonic-clonic eye movements (Crawley et al.,
1996). While neurological sequelae is rarely seen in adults (3%), about 10% of children 
surviving after cerebral malaria particularly those with prolonged hypoglycaemia, severe 
anaemia, repeated seizures, and deep coma have some neurological sequelae (Molyneux 
et al., 1989; Brewster et al., 1990 and Bondi, 1992) such as hemiparesis, cerebral palsy, 
cortical blindness, deafness, tremor and impaired cognition and learning. There was no 
clear clinical evidence of raised intracranial pressure, and no evidence of deterioration 
immediately following lumbar puncture. Nevertheless brain swelling, and consequent 
brain-stem compression, may contribute to a fatal outcome in cerebral malaria 
particularly in those children who die from sudden respiratory arrest (Waller et al., 1991). 
Post-malaria neurological syndrome (PMNS) was seen in approximately 3% of adults and 
10% of children following cerebral malaria (Molyneux et al., 1989; Brewster et al., 1990). 
A prospective study in Viet Nam showed that the overall incidence of PMNS was 1-2 per 
1000. The syndrome was self-limiting and was associated with use of mefloquine after 
parenteral treatment (Mai et al., 1996). The overall mortality of cerebral malaria is 20% 
(up to 50% in pregnancy) and depends on the associated vital organ failure and the 
availability of medical intensive care facilities (White, 1996). However, all falciparum 
malaria patients with neurological manifestations of any degree should be treated as 
cerebral malaria. Lumbar puncture may be done to rule out associated meningitis. CSF 
opening pressure is normal to elevated; fluid is clear; WBCs are fewer than 10/pL. CSF
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lactate remains an independent and significant predictor of poor outcome in severe 
malaria (Medana et al., 2002).
Figure 1.2 A cerebral malaria patient (N.H.Phu)
1.4.3.2 Acute Renal Failure 
Renal impairment is a sensitive prognostic indicator, and is common among adults with 
severe falciparum malaria but rarely seen in children (Molyneux, 1990; Sowunmi, 1996; 
Phuong et al., 1997). Renal dysfunction was also recently reported in knowlesi malaria 
(Daneshvar et al., 2009). Recent study on malaria in India reported that renal failure was 
seen in 14% of children (Tripathy et al., 2007). Renal failure in severe falciparum malaria 
is caused by hypoperfusion, sequestration or massive intravascular haemolysis in black 
water fever. Pathologically, this syndrome manifests as acute tubular necrosis (Sitprija et 
al., 1967; Stone et al., 1972; Day et al., 1997). Acute renal failure usually manifests as 
oliguria with urine output of less than 400 ml in 24 hours and serum creatinine of more 
than 264pmol/L, failing to improve after rehydration; however, it may be non-oliguric or 
polyuric in some cases. Renal failure is associated with hepatic dysfunction, metabolic
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acidosis and pulmonary oedema in many fatal cases. Without renal replacement therapy 
the mortality rate may rise up to 70%, this was halved to 35% after the introduction of 
peritoneal dialysis (Trang et al., 1992). Peritoneal dialysis (Jackson et al., 1962; Canfield 
et al., 1968; Trang et al., 1992) or other renal replacement therapy should be considered if 
the patients get hyperkalaemia, fluid overload, metabolic acidosis and clinical signs of 
uraemia syndromes. Dialysis considerably improves patient's survival.
1.4.3.3 Jaundice
Mild jaundice in malaria is caused by haemolysis. There is elevation of unconjugated 
bilirubin levels and AST. Severe jaundice is associated with P. falciparum infections and 
is more common in adults than in children (Figure 1.3). However, in severe cases both 
serum unconjugated and conjugated bilirubin levels are high with marked elevation of 
both AST and ALT, and there is prolongation of prothrombin time. Jaundice was 
associated with cerebral malaria, acute renal failure, and hyperparasitemia, after effective 
malaria treatment, liver profile returned to normal within a few weeks. Jaundiced malaria 
patients had transient liver profile impairment that indicated predominantly haemolysis 
rather than liver damage (Wilairatana et al., 1994). Jaundice and hepatomegaly were 
significantly associated with renal failure, and jaundice may have potentiated the effects 
of hypovolemia (Nacher et al., 2001; Prommano et al., 2005). Hepatic dysfunction 
contributes to hypoglycaemia, lactic acidosis, and impaired drug metabolism. When 
accompanied by acute renal failure and metabolic acidosis, liver dysfunction carries a 
poor prognosis. Jaundice was also recently reported in knowlesi malaria (Daneshvar et 
al., 2009).
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Figure 1.3 A severe malaria patient with jaundice (N.H.Phu)
1.4.3.4 Hypotension
The heart is remarkable resilient and cardiac function appears well preserved even in the 
face of a heavy parasite burden and other vital organ dysfunction (Bethell et al., 1996). 
Hypotension in severe malaria may be due to dehydration, bacterial coinfection, 
pulmonary oedema and metabolic acidosis. This is called “algid malaria” (Gage, 1926) 
but the pathophysiology of algid malaria is not well understood. Orthostatic hypotension 
is associated with impaired reflex cardioacceleration and is worsened by the quinoline 
antimalarial drugs (Supanaranond et al., 1993). Shock in severe falciparum malaria in 
adults is associated with peripheral vasodilation and carries a poor prognosis (Bruneel et 
a l, 1997).
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1.4.3.5 Metabolic Acidosis
Metabolic acidosis, predominantly lactic acidosis, is identified as an important cause of 
death in severe falciparum malaria (White et al., 1983 and 1985; English et al., 1997). In 
adults, it may result from renal impairment (White, 1996). Acidosis also commonly 
coexists with severe hypoglycaemia in patients with malaria (Krishna et al., 1994). Lactic 
acidosis can lead to respiratory distress syndrome and shock. Sustained hyperlactataemia 
is the best prognostic indicator of outcome in severe malaria. The prognosis of lactic 
acidosis is poor. The strong anion gap is also a powerful prognostic indicator in severe 
malaria (Dondorp et al., 2004).
1.4.3.6 Acute pulmonary oedema
Pulmonary oedema in falciparum malaria was first reported in the early years (Watson, 
1905). Adults, particularly pregnant women, with severe falciparum malaria may develop 
non-cardiogenic pulmonary oedema (Von Mach et al., 2003). The mortality rate is >80%. 
It is rarely due to fluid overload as a result of rehydration, and may develop even in 
severe malaria patients at relative low or normal filling pressures, with normal central 
venous pressure and normal pulmonary artery occlusion pressure. The mechanism of 
pulmonary oedema in severe malaria is not clearly understood. It is one form of the adult 
respiratory distress syndrome (Brooks et al., 1968; Gurman et al., 1988; Fein et al., 1978; 
James, 1985; Charoenpan et al., 1990; Asiedu et al., 2000) and may be difficult to 
differentiate with aspiration pneumonia. Chest x-ray shows increased interstitial 
shadowing. Tachypnoea is the first sign. Then patient develops hyperventilation or 
Kussmaul’s breathing, hypoxia and cyanosis. Overall, pulmonary oedema carries a poor 
prognosis (Aursudkij et al., 1998). Respiratory distress was also seen in P. knowlesi 
malaria (Daneshvar et al., 2009).
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1.4.3.7 Hypoglycaemia
Hypoglycaemia in malaria may be asymptomatic and often goes unnoticed. In severe 
cases, it is usually associated with severe anaemia, jaundice, lactic acidosis. The clinical 
diagnosis of hypoglycaemia is difficult and the usual physical signs such as sweating, 
gooseflesh, tachycardia, are absent; and the neurological impairment caused by 
hypoglycaemia cannot be distinguished from that caused by malaria. It occurs in 
approximately 8% of adults and 30% of children with cerebral malaria but responds well 
to glucose (White, 1996). It is also commonly seen in cases treated with quinine as a 
result of drug-induced hyperinsulinaemia. Hypoglycaemia is associated with a poor 
prognosis (White et al., 1983; Migasena, 1983; Krishna et al., 1994) and is particularly in 
children and pregnant women (Looareesuwan et al., 1985; White et al., 1987; Taylor et 
al., 1988). Intravenous dextrose infusion can prevent hypoglycaemia. Hypoglycaemia 
tends to be recurrent so that the regular monitoring of blood glucose is necessary.
1.4.3.8 Black Water Fever
Black water fever results from massive intravascular haemolysis in severe falciparum 
malaria. Renal biopsies from ceases of black water fever had demonstrated haemoglobin 
tubular casts and tubular atrophy (Rosen et al., 1968). It usually associated with severe 
anaemia and acute renal failure (Canfield et al., 1969; Chau et al., 1996). The haemolysis 
occurs rapidly, the release of haemoglobin into the circulation is increased and the urine 
becomes dark or black. Haematocrit and haemoglobin levels drop within a few hours.
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Figure 1.4 A black water fever case (N.H.Phu)
1.4.3.9 Haematological abnormalities
Anaemia is a common manifestation of all types of malaria and poses more problems in 
children and pregnancy. The causes of anaemia include accelerated destruction of red 
blood cells, increased splenic clearance in conjunction with ineffective erythropoiesis and 
gastrointestinal bleeding. In non-immune individuals and in areas with unstable 
transmission, anaemia can develop rapidly and transfusion is often required (Phillips et 
al., 1986; Hien et al., 1996). Red blood cell deformability may also contribute to the 
development of severe anaemia (Dondorp et al., 1999). In Africa children may develop 
severe anaemia as a result of repeated malarial infections (Marsh et al., 1995).
Slight coagulation abnormalities are common in falciparum malaria. The fibrin 
degradation products are elevated (Jaroonvesama et al., 1972; Sucharit et al., 1975).
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Increased coagulation cascade activity with antithrombin III depletion and prolongation 
of the prothrombin time can be seen in severe cases (Pukrittayakamee et al., 1989; 
Clemens et al., 1994). Fewer than 5% of patients with severe malaria have significant 
bleeding with evidence of disseminated intravascular coagulation (Phillips et al., 1986). 
Mild thrombocytopenia is usual but it may be profound in severe cases (Skudowitz et al., 
1973; Kelton et al., 1983; Looareesuwan et al., 1992).
Haematemesis, presumably from stress ulceration (Hien et al., 1996) or corticosteroid 
therapy, may also occur (Warrell et al., 1982; Hoffman et al., 1988). Conjunctival 
haemorrhage may be seen in severe jaundice patients.
A vigorous eosinoplilic response shortly after completing antimalarial therapy predicts a 
good recovery from anaemia in acute malaria (Camacho et al., 1999).
Figure 1.5 Conjunctival haemorrhage in severe falciparum malaria (N.H.Phu)
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1.4.4 Malaria in pregnancy
In malaria areas with intense transmission anaemia and a reduction in birth weight are 
common in infected pregnant women (Brabin, 1983; McGregor, 1983) but infected 
mothers remain asymptomatic despite intense parasitization of the placenta due to 
sequestration of parasitized erythrocytes in the placental microcirculation (Bray et al., 
1979). In unstable malaria areas the non-immune and primi-gravidae are usually the most 
affected, pregnant women often develop severe malaria, particularly in the second and 
third trimesters (White and Ho, 1992). Hypoglycaemia, anaemia, cerebral malaria, acute 
pulmonary oedema and fetal loss are particular complications and consequently there is 
an increase of infant and childhood mortality (Menon, 1972; Brabin, 1983; Gaain et al., 
1985; Looareesuwan et al., 1985; Nosten, et al., 1991). Foetal distress, premature labour 
and stillbirth or low birth weight are commonly seen. The mortality is approximately 50% 
of infected pregnant women. Congenital malaria occurs in fewer than 5% of newborns 
whose mothers are infected and is related to the parasite density in maternal blood and in 
the placenta (Quinn et al., 1982; Hulbert, 1992; Balaka et al., 2000). P. vivax malaria in 
pregnant patients is also associated with mild anaemia and a reduction in birth weight, 
this effect is greater in multigravidae than in primigravidae (Nosten et al., 1999). The 
relation between malaria and pregnancy is poorly understood.
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1.5 Diagnosis of malaria
The diagnosis of malaria is based on epidemiological information, clinical symptoms and 
parasitological methods. The clinical diagnosis has low specificity because the symptoms 
of malaria are nonspecific. The WHO recommendations of clinically malaria diagnosis 
based on fever or history of fever and the transmission settings are still valid (WHO, 
2000). The two principal parasitological methods are light microscopy and rapid diagosis 
tests.
1.5.1 Conventional methods
Peripheral blood smear examination for malaria with light microscopy is the gold 
standard in confirming the diagnosis of malaria. Thick and thin films (Figure 1.6 and 1.7) 
from the peripheral blood should be made on clean, grease-free glass slides. Making good 
thin films requires technical skills. Thick film should be dried thoroughly otherwise it 
may wash away during staning. Thin film should be dried then fixed in pure methanol. A 
number of Romanowsky stains like Giemsa’s at pH 7.2, Field’s, Wright’s can be used. 
Thick films are ideally stained by Giemsa’s stain for screening the parasites. Thick films 
also have the advantages of concentrating the parasites by 20 to 40 folds compared with 
thin film, thus increasing diagnostic sensitivity. Thin films are ideally stained by Field’s 
stain, and are more accurate for detecting the malaria species and parasite counting. The 
test takes about 60 to 90 minutes depending on the skill of the technicians, especially the 
time spent on reading the smear. If there is a high degree of suspicion but the result is 
negative, blood smears must be repeated every 6 to 8 hours. Both thick and thin films 
should me examined on the microscope. Thin films are examined under oil immersion 
and the best area is the tail of the films. The peripheral blood smear provides information 
on the species, the density of parasitaemia and the stage of parasite. The number of
73
infected red cells per 1,000 red cells on the thin film should be counted. The parasitaemia 
is expressed as the number of parasitized erythrocytes among 1,000 red cells, and this 
figure is converted to the number of parasitized erythrocytes per microlitre. At a low 
parasitaemia (<1/1,000 RBC on the thin film) the thick film should be counted; the 
number of parasites per 400 white cells is noted and an average of 8,000 WBC/pl is taken 
as standard. The “plus system” is less precise as variation in the thickness of the film 
results in false variation in parasite count, but this system is still widely used. In severe 
malaria, a poor prognosis is indicated by a predominance of more mature P. falciparum 
parasites (>20% of parasites with visible pigment), by the presence of circulating 
schizonts in the peripheral blood film (Silamut and White, 1993). Pigment-containing 
neutrophils (Figure 1.8) are noticed in severe malaria for the prediction of diseases and 
prognosis (Phu et al., 1995) and are associated with cerebral malaria and with death in 
children with severe malaria (Lyke et al., 2003). The presence of malarial pigment in 
monocytes (Figure 1.9) should also be noted because it may provide a clue to recent 
infection if malarial parasites are not detectable (Day et al., 1996). After the peripheral 
blood smears become negative, malaria pigment is evident in peripheral blood leukocytes, 
bone marrow and intradermal smears for several days. Phagocyte pigments can be used to 
diagnose severe malaria in pretreated, parasite-negative patients (van der Berghe et al., 
1951; Day et al., 1996). The sensitivity and specificity of the microscopic test depend on 
the experience of the microscopist; the quality of the slides, stains, microscopes, and the 
time spent examining the smears.
Alternative microscopic methods:
- Acridine orange is used as a direct staining method (Quantitative Buffy Coat 
system or Kawamoto technique).
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- DNA and RNA of malaria parasites can be stained with fluorescent dyes and 
examined under ultraviolet light microscopy.
1.5.2 Rapid diagnosis tests (RDT)
The immunochromatographic tests for malaria diagnosis have been developed in the 
recent years. The rapid diagnosis tests (Figure 1.10) is based on the capture of parasite 
antigens from the peripheral blood using monoclonal or polyclonal antibodies, and target 
the histidine-rich protein 2 of P. falciparum (Pf HRP2) and the parasite lactate 
dehydrogenase (pLDH) of all 4 human malaria species. Different test kits have been 
produced like dipstick, strip, card, pad and well. A finger-prick blood sample or 
anticoagulant blood or plasma can be used. The comparison of peripheral blood smear 
examination and RDTs for malaria is shown in Table 1.5.
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Table 1.5 Comparison of Peripheral Blood Smear Examination and RDTs for
Malaria
Peripheral Smear Rapid Diagnostic Tests
Material Slides and blood films Test strips and fresh blood
Equipment Microscope Kit only
Training Trained microscopist ‘Anyone with a little training
Test duration 60 minutes or more 30 minutes
Test result Direct visualization of the 
parasites
Color changes on antibody 
coated lines
Capability Detects and differentiates all plasmodia at different stages
Detects malaria antigens 
(PfHRP2/PMA/pLDH) from 
asexual and/or sexual forms of 
the parasite
Detection
threshold 20 parasites/pL of blood
100-500/pL for P. falciparum , 
higher for non-falciparum
Species
differentiation
Possible Cannot differentiate among non­
falciparum species
Quantification Possible Not possible
Differentiation 
between sexual 
and sexual stages
Possible Not possible
Disadvantages
Availability of equipment 
and skilled microscopists, 
particularly at remote areas 
and odd hours
Unpredictable efficiency at low 
and very high parasite; cross 
reactions among plasmodial 
species and with auto­
antibodies; persistence of 
antigens
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Figure 1.6 Peripheral blood smear of P. falciparum (thick film) (N.H.Phu)
. fgl
Figure 1.7 Peripheral blood smear of P. falciparum (thin film) (N.H.Phu)
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Figure 1.8 Pigment-containing neutrophil (N.H.Phu)
Figure 1.9 Pigment-containing monocytes (N.H.Phu)
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Figure 1.10 Rapid diagnosis test for malaria (N.H.Phu)
1.5.3 Other tests for malaria diagnosis
- Polymerase Chain Reaction (PCR): The morphologic characteristics provides valuable 
criteria for determination of malaria parasite species, but they occasionally fail to 
differentiate between species that share morphological characteristics (especially P. vivax 
and P. ovale) or in cases where parasite morphology is altered by drug treatment or 
improper storage of the sample. In such cases, molecular diagnostic tests using PCR 
technique have to be found to be highly sensitive and specific for detecting all 4 species 
of human malaria. It is also reportedly 10- fold more sensitive than microscopy (Snounou 
et al., 1993, Sidhu and Madhubala, 2000).
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- Detection of antimalarial antibodies (Serology): Malarial antibodies can be detected by 
indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). 
These tests are useful in epidemiological surveys, do not detect current infection and may 
be important in assessing the response to malaria vaccines in future.
- Flowcytometry: Flowcytometry and automated haematology analyzers have been found 
to be useful in malaria diagnosis during routine blood count (Hanscheid et al., 2001; 
Kramer et al., 2001).
- Mass spectrometry: This new method can detect (in vitro) 10 parasites/pL of blood and 
measure many samples in a few seconds (Demirev et al., 2002; Mann, 2002)
1.6 Laboratory findings
There is a normochromic, normocytic anaemia in malaria. The white blood cell count is 
usually low to normal, although it may be raised in severe infections or in case of 
superinfection. The platelet count is usually lower than 100,000/pl, and it may be 
profound in severe cases (Skudowitz et al., 1973; Looareesuwan et al., 1992; 
Supanaranond et al., 1992). Prolonged prothrombin and partial thromboplastin times may 
occur in severe malaria (Pukrittayakamee et al., 1989; Clemens et al., 1994).
Metabolic acidosis with low plasma concentrations of glucose, sodium, bicarbonate, 
calcium, phosphate, and albumin are documented in severe malaria. There are the 
elevations in lactate, blood urea nitrogen, creatinine, urate, myoglobin, liver enzymes, 
conjugated and unconjugated bilirubin in severe infections.
In adults and children with cerebral malaria, the mean opening pressure at lumbar 
puncture is 160 mmFhO of cerebrospinal fluid. The CSF is usually normal or has a 
slightly elevated total protein level (<1.0g/L) and cell count (< 10/pL) with all 
lymphocytes. High lactate concentration in CSF indicates a poor outcome.
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1.7 Antimalarial drugs
This section describes the key features of the antimalarial drugs relevant to the work of 
this thesis and does not attempt to provide a comphrehensive overview of all antimalarial 
drugs.
Quinine: Quinine is the main alkaloid of cinchona bark. This bark contains a mixture of 
10 alkaloids, but only 2 of them (quinine and quinidine) have a higher potency against 
human malaria parasites. Quinine has a history of more than 350 years and is still widely 
used for severe chloroquine-resistant falciparum malaria. The French chemists Pierre 
Pelletier and Joseph Caventou isolated the alkaloid quinine from cinchona bark in 1820. 
Quinine acts principally as a blood schizonticide, on the mature trophozoites stage of 
parasites. It has some activity against immature falciparum gametocytes and is an 
effective gametocytocide in vivax, ovale and malariae parasite. It is still the drug of 
choice in the management of severe falciparum malaria in areas with known resistance to 
chloroquine and artemisinin based combination therapy (ACT) is not available. Quinine 
sulphate is well absorbed when given orally in healthy subjects, and in patients with 
malaria (Paintaud et al., 1993: Supanaranond et al., 1991; White, 1987). Peak plasma 
concentrations are achieved within in 1-3 hours after oral dose (Hall et al., 1973) and 
plasma half-life is about 11 hours. Studies of intravenous quinine in severe malaria 
(Looareesuwan et al., 1985) show no evidence of extensively toxic effect. The use of 
intramuscular quinine has been controversial for many years, but recent studies (Hien et 
al., 1996) suggest good bioavailability, safety profile and effectiveness even in very 
young children (<2 years) with severe malaria (van Hensbroek et al., 1996; Waller et al., 
1990; White, 1995). Quinine is predominantly (80%) eliminated by hepatic 
biotransformation (White, 1985) and only 10-20% is excreted unchanged in the urine. 
Total systemic clearance is reduced in uncomplicated malaria, and may be reduced in
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severe malaria (White et al., 1982; White, 1987). Quinine has minor adverse effects and 
the typical syndrome known as "cinchonism" occurs with plasma concentrations over 5 
mg/L (Powell and McNamara, 1966). This consists of tinnitus, headache, vertigo, nausea, 
photophobia, blurred of vision and high tone deafness (Roche et al., 1990). 
Hypoglycaemia is the most important problem. In therapeutic doses quinine is a potent 
stimulus to pancreatic insulin secretion (White et al., 1983) and hyperinsulinaemic 
hypoglycaemia is particularly in severe infection and in pregnant women (Looareesuwan 
et al., 1985). Intravenous injections may cause acute cardiovascular toxicity presumably 
because transiently toxic blood concentrations occur before adequate distribution (Davis 
et al., 1988). Quinine can cause postural hypotension in acute malaria (Supanaranond et 
al., 1993). Many strains of P.falciparum resistant to chloroquine are cross-resistant to 
quinine (WHO, 1981). A multicentre, open-label, randomised comparison of parenteral 
quinine and parenteral artesunate in severe falciparum malaria showed that the mortality 
in the quinine group was 22% (SEAQUAMAT, 2005).
Artemisinin and its derivatives: Artemisinin or Qinghaosu is a sesquiterpene lactone with 
an endoperoxide bridge (C-0-0-C) extracted from the leaves of the herb Artemisia annua. 
It has been used as the treatment of fevers in China for more than 1000 years. The active 
antimalarial constituent of this plant was isolated in 1971. The artemisinin and its 
derivatives are the most rapidly effective of the antimalarial drugs and retain efficacy 
even against multi-drug-resistant parasites. Artemisinin and its derivatives are short- 
acting antimalarial drugs that kill parasites more rapidly than conventional antimalarials, 
and are active against both the sexual and asexual stages of the parasite cycles. Increasing 
evidence demonstrates that their widespread deployment leads to a reduction in 
transmission potential, and their early use may prevent the progression to severe 
falciparum malaria. Dihydroartemisinin, the reduced lactol derivative of artemisinin, is
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the common biologically active metabolite of artesunate and artemether. Artesunate and 
artelinate are the water-soluble derivatives; artemether and arteether are both oil soluble. 
These four drugs are the semi-synthetic derivatives of the parent artemisinin compound. 
The artemisinin and its derivatives are well tolerated and are relatively safe. Rectal 
preparations of artemisinin derivatives appear to have acceptable therapeutic efficacy, 
including in severe malaria (Hien et al., 1992; Nosten et al., 1998; Karunajeewa et al., 
2003 and 2007; Gomes et al., 2008). There has been no documented significant toxicity. 
In volunteer studies, a depression of reticulocyte counts has been noted, but increased 
anaemia has not been observed in clinical studies. It has not been found to have any 
teratogenic effects on the embryo in animal studies. The principal toxicity in animals has 
been an unusual dose related selective pattern of neuronal cell damage affecting certain 
brain stem nuclei. Neurotoxicity related to intramuscular administration of the oil based 
artemether and arteether was noticed in laboratory experiments (Brewer et al., 1994; 
Petras et al., 1997; Genovese et al., 1998).
ARTEMISININ: Artemisinin is the natural substance extracted from the leaf of 
Artemisia annua L. It has been formulated as a crystalline powder and can be 
administered orally as a tablet, or in a capsule, and rectally as a suppository. Initially, in 
China, it was also given intramuscularly as an oil suspension and as a water suspension 
(China Cooperative Research Group on Qinghaosu and Its derivatives as Antimalarials 
Metabolism and pharmacokinetics of Qinghaosu and its derivatives, 1982). Recent 
pharmacokinetic studies of the artemisinin derivatives using high performance liquid 
chromatography with electrochemical detection (HPLC-ECD) and bioassay in healthy 
volunteers and non-complicated malaria patients showed that the pharmacokinetic 
parameters of orally administered artemisinin are similar in both groups: artemisinin is 
rapidly absorbed with the peak concentration recorded at 1-2 hours after administration,
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but the absorption is incomplete (Alin et al., 1996; De Vries and Dien, 1996; De Vries et 
al., 1997; Benakis et al., 1997; Ashton et al., 1998). The elimination half-life of 
artemisinin is of 2 to 5 hours (Alin et al., 1996; De Vries et al., 1997). The metabolites 
and the potential for drug interactions have not been fully characterised. The rectal 
bioavailability is 30% relative to the oral dose although there was large interindividual 
variation. Therapeutic concentrations could be achieved with artemisinin suppositories 
(Koopmans et al., 1998; Sidhu et al., 1998). Early studies in China suggested that an 
optimum treatment was 3g of artemisinin given over 3-5 days (10-20 mg/kg in the 1st day 
at (+0 and +4hrs) then lOmg/kg/day in subsequent days) (Li et al., 1994). However, 
studies using monotherapy regimens with less than a 7-day treatment course (oral or 
rectal), and with a 28-day follow-up period, confirmed that the true recrudescence rate 
was unacceptably high (20-50%) (Hien, 1994). The combination of artemisinin (20 mglkg 
given on one day or 3-day dose) and a long elimination half-life drug such as mefloquine 
would seem to overcome many of the problems of high recrudescence rates seen with 
artemisinin monotherapy. Several clinical trials showed that this is an effective treatment 
of multi-drug resistant P. falciparum malaria (Hien et al., 1994; Bich et al., 1996; Le et 
al., 1997). Artemisinin suppositories remain an effective treatment for P. falciparum 
malaria in remote areas where facilities for parenteral antimalarials maybe limited. In the 
early 1990s artemisinine suppositories were shown to be as effective as parenteral 
antimalarial drugs in clinical trials for the treatment of severe malaria (Hien et al., 1992; 
Phuong et al., 1997; Vinh et al., 1997). There is no evidence of neurotoxicity in patients 
who received multiple treatment courses of artemisinin (Kissinger et al., 2000).
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ARTESUNATE: Artesunate, the water-soluble hemisuccinate derivative of
dihydroartemisinin, was developed as a drug for an intravenous use in the treatment of 
severe malaria. It is unstable in neutral solutions and therefore only available in powder 
form as artesunic acid. This powder requires reconstruction with 5% sodium bicarbonate 
solution immediately before use. At neutral pH hydrolysis to DHA is rapid. Artesunate is 
the artemisinin derivative most widely used. It is administered orally, intravenously, 
intramuscularly or rectally. Artesunate is hydrolysed very rapidly after intravenous 
injection to DHA in 2 minutes (Yang et al., 1985). After oral administration artesunate is 
also hydrolysed to DHA and unchanged artesunate is detectable in plasma (Batty et al.,
1998). The mean absolute oral bioavailability of the drug in patients with acute malaria 
was 61%; the absorption and elimination of oral artesunate was rapid with mean 
elimination half-life of 43 minutes (Newton et al., 2000). The oral antimalarial 
bioavailability following artesunate was significantly higher than that after artemether 
(Suputtamongkol et al., 2001). After repeated oral administration of artesunate a time- 
dependent decline of artesunate and DHA concentrations in plasma occurs, the 
mechanism of this decrease of concentration is unclear (Khanh et al., 1999). Despite rapid 
clearance of artesunate and DHA in patients with uncomplicated falciparum malaria 
prompt parasite and fever clearance are achieved and once-daily administration has been 
shown to be highly effective with similar parasite and fever clearance times to those 
treated with a twice-daily regimen (Nosten et al., 1994). Several clinical trials in South 
East Asia have shown that artesunate, given as single oral dose (2-4mg/kg) or for 3 days 
(4mg/kg for the 1 st day then 2mg/kg for 2nd and 3rd day) in combination with 
mefloquine (15 mg/kg as single dose) was an effective and safe treatment for 
uncomplicated falciparum malaria (Nosten et al., 1994; Vinh et al., 1997; Price et al.,
1997). Many randomized controlled studies in Thailand, Viet Nam, and African countries
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indicate that one dose of artesunate (4mg/kg) given daily for 3 days in combination with 
mefloquine (25mg/kg), chloroquine, sulfadoxine/pyrimethamine or amodiaquine is better 
than either a single dose of artesunate with these drugs or the other antimalarials given as 
mono-therapies in terms of recrudescence rates. These studies assessed efficacy for more 
than 28 days and were supported by PCR genotyping; in addition, treatment with 
artesunate results in lower gametocyte rates and may reduce transmission rates (Price et 
al., 1997; Doherty et a l, 1999; von Seidlein et al., 2000). On the basis of pharmacologial 
study parenteral artesunate has considerable pharmacokinetic advantages over artemether 
in the treatment of severe falciparum malaria, particularly in patients who are most 
seriously ill (Hien et al., 2004). Studies in Viet Nam, in patients with uncomplicated 
falciparum malaria treated with a single rectal dose of 2mg/kg of artesunate (produced in 
China) confirmed that fever and parasite clearance times obtained were similar to those 
seen with 20mg/kg artemisinine (Hien, unpublished data). A clinical trial in children with 
uncomplicated falciparum malaria in Gabon using single dose of 50 mg (equivalent to 
0.8-2 mg/kg) of a new pharmaceutical form of this drug (PlasmotrimB Rectocaps, 
MEPHA) obtained similar results (Halpaap et al., 1998). A trial in Thailand using higher 
rectal doses of artesunate (15mg/kg/day for 3 days) was compared with oral artesunate 
(6mg/kg/day) both in combination with mefloquine (25m/kg). The fever clearance time, 
parasite clearance time and cure rates were similar in both groups (Looareesuwan et al., 
1997; Sabchareon et al., 1998). Pharmacokinetic and pharmacodynamic study found that 
repeated administration of artesunate thermostable suppositories in treating 
uncomplicated falciparum malaria could extend the duration of therapeutic plasma levels 
of the drug (Benakis et al., 2006). Artesunate suppositories have been used for the 
treatment of severe malaria in children (Karunajeewa et al., 2003 and 2006).
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ARTEMETHER: Artemether is an oil soluble derivative of artemisinin. It is the methyl 
ether of dihydroartemisinin and has been used widely in China. It is more stable than 
artesunate. In healthy volunteers, artemether was absorbed rapidly after oral 
administration and underwent extensive first-pass metabolism to DHA with the 
concentration of this metabolite higher than that of the other compound. The mean blood 
concentrations were reached at 1.2-2.2 hours and the mean elimination half-life was 2.0-
2.6 hours (Teja-Isavadharm et al., 1996; Mordi et al., 1997). There was no difference in 
pharmacokinetics between healthy volunteers and patients with uncomplicated malaria 
(Bangchang et al., 1994). Plasma antimalarial activity following oral administration is 
significantly greater than following intramuscular administration (Teja-Isavadharm et al., 
1996) because the first-pass biotransformation is inhibited. Some studies demonstrated 
that grape juice significantly increased the oral bioavailability of artemether and acute 
renal failure significantly modified the pharmacokinetics of intramuscular artemether 
with better absorption and bioavailability and a reduction of systemic clearance 
(Karbwang et al., 1998). Artemether oral antimalarial bioavailability is reduced in acute 
malaria (Suputtamongkol et al., 2001). Bioavailability of intramuscular artemether was 
also shown to be highly variable and may be associated with an inadequate response in 
children with severe malaria especially in the presence of respiratory distress (Murphy et 
al., 1997). Monotherapy with oral or intramuscular artemether (1-4 m/kg/day for 3-5 
days) resulted in rapid fever and parasite clearance but the recrudescence rate was high 
(25-40%). Artemether given in combination with other antimalarial drugs with long half- 
lives such as mefloquine have demonstrated cure rates of 95-98% (Price et al., 1995). 
Since 1992, 2042 patients had been recruited to a series of trials using a new combination 
of artemether and lumefantrine (benflumetol). Four tablets of artemether and lumefantrine 
(1 tablet = 20 mg of artemisinin + 120 mg of lumefantrine) given at 0, 8, 24, 48 hours, had
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shown to be very well tolerated by all age groups with a cure rate of 81% (White et al., 
1999). A double-blind trial in Thailand in which patients with uncomplicated multi-drug 
resistant falcipanun malaria were treated with 6 doses of 4 tablets given at 0, 8, 24, 36, 48, 
60 (or 72, 96) hours indicated that the 28 days cure rates were 96.9 - 99.1% (Vugt et al.,
1999). A meta-analysis of nine randomised clinical trials comparing artemether and 
quinine for treatment of severe malaria concluded that these two drugs were equally 
efficacious in terms of reduction in mortality rate (Artemether-Quinine Meta-Analysis 
Group, 2001). No evidence of significant toxicity was found in clinical trials in Viet Nam 
and Thailand (Hien et al., 1996; van Hensbroek et al., 1996; Newton et al., 1999; Hien et 
al., 2003).
The following artemisinin based combination therapy (ACT) regimens are currently 
recommended by the WHO in the treatment of uncomplicated malaria (WHO, 2006):
- artemether + lumefantrine,
- artesunate + amodiaquine,
- artesunate + mefloquine,
- artesunate + sulfadoxine-pyrimethamine.
For the parenteral treatment of severe malaria two drugs are recommended by the WHO 
(WHO, 2006):
- the cinchona alkaloids (quinine and quinidine)
- the artemisinin derivatives (artesunate, artemether and artemotil)
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CHAPTER 2
MALARIA IN VIET NAM AND THE RESEARCH SITE
2.1 Study site
2.1.1 Geography
Viet Nam is an S-shaped peninsula in South East-Asia, shares borders with Cambodia, 
Laos in the west, China in the north, and faces the East Sea in the east and south (Figure
2.1). The country’s land area is 335,211.6 square km, lies between North latitudes 8°02’ 
and 23°23’, and East longitudes 102°08’ and 109°28’ and is completely within the tropical 
zone. Viet Nam has 4,510 km inland borderline and 3,260 km coastline. Three quarters of 
the land area consist of the mountainous regions (the Truong Son mountain ridge); the 
two major valleys (the Red river delta and the Mekong delta) and the coastal plains.
2.1.1.1 Climate
Viet Nam is located in a tropical and temperate zone. The climate is characterized by 
sunny time, monsoon influence, heavy rainfall and high humidity. The climate of 
mountainous regions is temperate. The annual average temperature is 23°C in the North 
of Viet Nam, 25°C in the Central and 26°-27°C in the South. The Northern provinces have 
4 distinguished seasons; the winter is cold (15°-17°C) but the summer is hot and humid 
(28°-29°C). However the Central and the South have only two seasons: the hot and dry 
season (from November to April) and the rainy season (from May to October). The 
annual average rainfall of Viet Nam is around 1600 mm and may rise up to 200-300 mm 
per month in the rainy season. The two delta areas are usually flooded during the rainy
season. The two main rivers of the country are the Red River in the North and the 
Mekong River in the South. Parts of the Central of Viet Nam have a shorter rainy season 
(April-June) but endure more than 10 tropical storms per year.
Figure 2.1 Viet Nam map
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2.1.1.2 Population
The Vietnamese population was reported to be 84,155,800 in 2006, 49.1% of them males. 
The population density was 252 people per square kilometres, with most (73%) of the 
population living in rural areas. Viet Nam has 54 different ethnic groups. The largest 
groups, Kinh, account for 87% of the total population, and most live in low land regions, 
speak Vietnamese (an alphabet based on the Latin script), and has one close ethnic group 
(Muong). The other two large minority groups are Chinese and the Khmer origins live 
mainly in the South, around the Mekong Delta. The Cham are concentrated in the costal 
area of the Central region. The other 50 ethnic groups traditionally inhabit the highland 
areas, and have been living in endemic regions of malaria for centuries. Population 
growth is very high, nearly one million per year. The total population in 1994 was 
72,509,500, and in 2007 were 85,154,900. Since 1980s, the government decided to 
implement the liberal economic policy and there have been many controlled and 
uncontrolled population movements from plain to highlands.
2.1.1.3 Economy and Environment
Viet Nam is a developing country that has changed from a centrally planned to liberal 
economy. The GDP per capita income was estimated to be US$ 213 in 1994 and 
increased to US$ 722 in 2006. GDP growth was of 4% in 1998 and rose to 8.2% in 2006. 
Although the economy is growing in many parts of the country in the central and northern 
highlands where the incidence of malaria is still high the economic situation remains 
largely unchanged. The ethnic minority population lives in scattered villages with many 
difficulties. Air and water pollution threaten the life of people. Urban industrialization
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and population migration are degrading the environment of big cities. Uncontrolled 
agricultural practices contribute to deforestation and soil degradation.
2.1.2 Health services
Viet Nam is committed to the primary health care approach. A public health system was 
set up to improve the health status in remote rural regions. In 2006 Viet Nam had 954 
hospitals, 847 local medical centres, 10,672 commune health stations, 52,800 doctors, 
5,500 pharmacists, 48,800 medical assistants, 55,400 nurses and 19,000 midwives. On 
average there were 4.4 doctors per 10,000 of population in 1996, and this number 
increased to 6.3 in 2006. The government takes the major responsibility for provision of 
health care although there is a growing private sector. Health services are delivered 
through commune health stations, district hospitals and provincial hospitals. The hospitals 
in three big cities (Ha Noi, Da Nang and Ho Chi Minh City) act as tertiary referral centres 
for severe patients. Commune health stations in malaria areas are the most peripheral unit 
where most of malaria patients can access the health care. Private medical services have 
been improved through out the country but the prescription practices and drug distribution 
have been uncontrolled. Almost all antimalarials are available for sale. The wide use of 
effective antimalarials such as chloroquine, quinine, fansidar, artesunate, mefloquine, 
may contribute to reduction of malaria cases by allowing quick unlimited access, but the 
practice risks encouraging the development of drug resistant malaria parasites.
2.1.3 National Malaria Control Programme (NMCP)
Structure:
The NMCP is directed by a national steering committee chaired by a Vice-Minister of 
Health. The committee manages the malaria control programme with the assistance of
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three Institutes for Malariology, Parasitology and Entomology (IMPE) that are in Ha Noi, 
Quy Nhon and Ho Chi Minh City (HCMC). The three institutes are responsible for 
malaria control activities in their regions. The IMPE in Hanoi is responsible for technical 
advice, training, research, data analysis, and helps the peripheral health communes in case 
of malaria outbreaks in the Red River delta and northern Viet Nam. The IMPE in Quy 
Nhon manages central and southern highlands. The IMPE in HCMC manages the 
Mekong delta and southern provinces. At provincial level, there is a Centre for Malaria 
Control and Malaria Prevention that is responsible for all malaria control activities at 
provincial and district level of the province. This centre attaches to the provincial health 
service. There is a district team of hygiene, epidemiology and malaria at district level. In 
provinces where malaria is not a major problem, the provincial malaria centre is 
integrated with the provincial Centre for Preventive Medicine.
Policies:
The aims of the NMCP are:
1. To improve the capacity of early diagnosis
2. To reduce malaria deaths by early and effective treatment
3. To prevent malaria epidemics or at least detect them early and control them
4. To reduce the incidence of malaria in high-risk population by applying vector 
control and personnel protection programmes.
There are no specific policies for protection of pregnant women and children.
Based on the results of epidemiological and clinical data, the NMCP prepare detailed 
treatment guidelines periodically. In Viet Nam, resistance to anti-malarial drugs has been 
increasing over many years. The first clinical report of chloroquine treatment failure from
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South Viet Nam appeared in 1961. Local studies conducted in 1980s-1990s showed an 
increase in failure rates to 65% for chloroquine, 70% for sulfadoxine-pyrimethamine and 
15% for quinine (Morillon et a l, 1996; Cong, 2000). Quinine was the drug of choice in 
the treatment of falciparum malaria in combination with pyrimethamine-sulfadoxine or 
tetracycline. Chloroquine and primaquine have been recommended for vivax malaria until 
today. P. falciparum resistant rate in vitro to chloroquine was 92% (61/66), to quinine 
was 18% (11/9) and to mefloquine was 6% (4/62) and clinical trials showed that failure 
rates with mono therapy of up to 60% (Hien et al., 1997). Since 1997, the artemisinin 
derivatives have been proved to be rapidly effective and non-toxic anti malarial drugs and 
the NMCP put the new drug in the second-line treatment to be used when uncomplicated 
falciparum malaria did not respond to the first-line recommendation that was quinine. 
Artemisine for 3 days in combination with mefloquine in a single dose of 15mg/kg was 
the best regimen. There was a report of a 34% failure rate with mefloquine monotherapy 
in South Viet Nam (Le et al., 1997). For severe malaria treatment, quinine IV was the 
only choice until artesunate/artemether was produced. In 2003, the drug policy in Viet 
Nam recommended the use of artesunate monotherapy for seven days or the combination 
of dihydroartemisinin, piperaquine, trimethoprim and primaquine (CV8) for the 
confirmed falciparum malaria. The second-line treatment was artesunate 8mg/kg for 
three days plus mefloquine 15mg/kg on day 3. Recent policy changes recommend the 
combination of dihydroartemisinin-piperaquine as the first-line treatment for all cases of 
confirmed falciparum malaria nationwide. Chemoprophylaxis is not recommended in Viet 
Nam. The Viet Nam malaria map is showed in Figure 2.2. The management system of 
the National Malaria Control Program as showed in Figure 2.3. The national guidelines 
for malaria treatment are shown in Table 2.1 (NMCP, 2009).
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Figure 2.2 Viet Nam Malaria Map
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Figure 2.3
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2.1.4 Hospital for Tropical Diseases (HTD)
The Hospital for Tropical Diseases is located in HCMC, and serves the city and the 
southern provinces of Viet Nam (population around 43,000,000). The hospital has 550 
beds, including two (paediatric and adult) intensive care units and 16 wards for non- 
severe infectious diseases. HTD has laboratories for haematology, biochemistry, 
microbiology, parasitology and serology. The hospital acts as a primary, secondary and 
tertiary referral centre for patients with infectious diseases and also involves in the 
control of epidemics or emerging diseases of the south of Viet Nam.
2.1.5 Oxford University Clinical Research Unit (OUCRU)
The Oxford University Clinical Research Unit was opened in January 1991, funded by 
the Wellcome Trust of Great Britain. The unit is located in the Hospital of Tropical 
Diseases and serves as a collaborative centre between the HTD and the University of 
Oxford. The unit started as an 8-bed ward (named as Malaria Research Unit) for the 
treatment of all severe malaria cases. Over 18 years the OUCRU has expanded and 
implemented research on many infectious and emerging diseases such as malaria, dengue, 
tetanus,, typhoid, AIDS, tuberculosis, central nervous system infection, avian and swine 
influenza.
2.2 Aims of this thesis
Malaria in Viet Nam was a major public health problem resulting in serious morbidity 
and mortality from the 1960s onwards. The contributing factors were delayed diagnosis 
and treatment due to lack of trained health care services at the village level, national 
financial difficulties, and the increase of drug resistance in falciparum malaria. The in
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hospital mortality of severe falciparum malaria was between 30-50% in Viet Nam (Hien, 
1994). Since the implementation of National Malaria Control Programme the malaria 
situation in Viet Nam has improved compared with that of the 1980s and the early 1990s. 
However hundreds of thousands of Vietnamese still suffer from this debilitating infection 
every year. In addition, worldwide malaria causes an estimated 2-3 million deaths per 
year, mostly among children. Recently, prolonged parasite clearance time following 
treatment with artemisinin monotherapy and some ACTs has been observed along the 
Thai-Cambodian border (WHO, 2008). These alarming figures explain the continuing 
need for malaria research; particularly that focuses on reducing the morbidity and 
mortality.
Artemisinin and its derivatives have been one of the regimens recommended by the 
National Malaria Control Programme of Viet Nam since 1995. Many of the early studies 
of these drugs were conducted in Viet Nam and showed that these antimalarials are the 
best in terms of clearing malaria parasites (Arnold et al., 1990; Hien and White, 1993; 
Hien et al., 1992 and 1996; Vinh et al., 1997; Phuong et al., 1997) but the recrudescence 
rate was high if these drugs are used as monotherapy for less than 7 days (Hien, 1994). 
The widespread and uncontrolled use of artemisinin and its derivatives in Viet Nam may 
lead to drug resistance and treatment failure. The incidence of cerebral malaria in 
Vietnamese adult patients declined from 90% in 1980 to 50% in 1992-1995 while acute 
renal failure and jaundice have become more common (1980: 6%; 1986-1995: 50-60%) 
(Hien, unpublished data). One of the largest double blind, randomised controlled trials in 
severe falciparum malaria compared to artemether and quinine and was conducted 
between 1991 and 1996 in HTD. This trial indicated that artemether is an effective 
alternative to quinine for the treatment of severe malaria in adults, but failed to show any
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significant difference in mortality (Hien et al., 1996). Why the mortality was not reduced 
in hospitalised patients even though artemether was administered? The explanations 
could be: those patients were admitted too late, they might have developed severe 
complications or they did not have appropriately adjunctive treatment such as renal 
replacement therapy, correct fluid therapy, intensively nursing care or the 
pharmacological properties of this formulation of the artemisinin derivatives was not 
optimal. A comparative study conducted by our group of the pharmacokinetic profile of 
artesunate and artemether showed artesunate to be the preferred choice for the treatment 
of severe malaria (Hien et al., 2004).
Therefore, there were important questions that still required further investigation:
1. Was artesunate a better clinical choice than artemether for the treatment of 
complicated falciparum malaria?
2. Which appropriately ancillary treatments should be introduced to reduce the case 
fatality?
3. Which markers can also be used as predictors of poor outcome?
Research objectives of this thesis:
1. To compare the efficacy of artesunte and artemether in treatment of severe 
falciparum malaria.
2. To compare two available methods of renal replacement therapy (haemofiltration 
and peritoneal dialysis) in acute renal failure associated with severe infection.
3. To assess the fluid therapy in severe malaria.
4. To evaluation the relation of parasite staging in the peripheral blood to prognosis in 
severe falciparum malaria.
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5. To devise a Malaria Severity Score for predicting the outcome of adults with severe 
falciparum malaria that can be applied at remote health settings
6. To assess whether there has been prolongation of parasite clearance time after 
nearly 30 years of implemention of artemisinin treatment in Viet Nam.
2.3 Clinical methods
2.3.1 Scientific and Ethical approval
All study protocols were approved by the Scientific and Ethical Committee of the HTD. 
Informed consent was obtained from each patient or accompanying relative.
2.3.2 Patients, diagnosis and treatment
All patients with a clinical diagnosis and a positive smear for malaria were admitted to a 
dedicated Malaria Research Unit (WHO, 2000). Patients with laboratory confirmed 
malaria were regarded as having severe falciparum malaria if one or more of the 
following: a score on the Glasgow Coma Scale of less than 11 (indicating cerebral 
malaria); anaemia (haematocrit, <20 percent), with a parasite count exceeding 100,000 
per cubic millimetre on a peripheral-blood smear; jaundice (serum bilirubin, >2.5mg per 
decilitre [50pmol per litre]), with a parasite count of more than 100,000 per cubic 
millimetre on a peripheral-blood smear or with serum creatinine, >3mg per decilitre 
[250pmol per litre]; renal impairment (urine out put, <400ml per 24 hours; and serum 
creatinine, >3mg per decilitre [250pmol per litre]); hypoglycaemia (blood glucose, 
<40mg per decilitre [2.2mmol per litre]); hyperparasitaemia(>10 percent parasitaemia) or 
parasite count of more than 500,000 per cubic millimetre; plasma lactate > 4mmol per 
litre; arterial pH < 7.34 with standard base excess < -5mmol per litre (metabolic
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acidosis); and systolic blood pressure below 80 mmHg with cool extremities (indicating 
shock).
On admission patients were examined fully, weighed, and baseline blood samples taken 
for full blood count, clotting studies, biochemistry (BUN, serum creatinine, serum 
bilirubin, AST, ALT, plasma lactate, potassium, sodium etc.), blood culture and malaria 
parasite counts. Arterial pH and blood gases were also measured. Chest X-ray and 
electrocardiography were also performed on admission. Each patient underwent a full 
clinical examination that included a detailed neurological assessment. A full history was 
taken from either the patient or attendant relatives. Hydration status was assessed, and 
patients were hydrated, if necessary with pressure monitoring, via a central venous 
catheter. A urinary catheter was inserted if needed. All antimalarial drugs were free of 
charge and other patient costs were met by the study.
Blood was obtained by a finger-prick for haematocrit measurements and blood smears 
every 4 hours for the first 24 hours and every 6 hours until three consecutive smears were 
negative for asexual stages of P. falciparum. The degree of parasitaemia was determined 
on the basis of the number of parasitized red cells per 1,000 red cells (thin film) or the 
number of parasites per 400 leukocytes (thick film). Parasite counts were derived from 
the percentage thin film parasitaemia and an estimate of the red cell count derived from 
the admission haematocrit (haematocrit x 125,000/pL). Thick film counts were obtained 
assuming a white blood cell count of 8,000/pL.
Hypoglycaemia was corrected with a bolus injection of 50ml of 30 percent dextrose in 
water and a subsequent maintenance infusion of 5 to 10 percent dextrose in water. A 
diagnostic lumbar puncture was performed if the score on the Glasgow Coma Scale was 
below 14. Opening cerebrospinal fluid pressures were measured, the cerebrospinal fluid
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was analyzed microscopically, and levels of protein, glucose, and lactate were 
determined. Renal replacement therapy was performed in patients with acute renal failure. 
Patients with respiratory failure were ventilated. Paracetamol was given for a temperature 
above 39°C. A single dose of intramuscular dose of 5mg/kg Phenobarbital was given if 
Glasgow Coma Scale (GCS) was below 11, and intravenous diazepam, and if necessary, 
intravenous phenytoin were given for convulsions. Antibiotics were prescribed for 
suspected cases of bacterial sepsis. Intensive nursing care was implemented. Detailed 
clinical and nursing observations were recorded a minimum of every 4 hours for the first 
24 hours and every 6 hours thereafter.
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CHAPTER 3
RANDOMIZED CONTROLLED TRIAL OF ARTESUNATE OR 
ARTEM ETHER IN VIET NAMESE ADULTS W ITH SEVERE 
FALCIPARUM MALARIA
INTRODUCTION
Since 1990 the artemisinin derivatives have been increasingly used for the treatment of 
severe malaria. They are the most rapidly acting and potent of all the antimalarial drugs. 
They can be given once daily and are safer and easier to administer compared to quinine. 
Artemisinin derivatives are now part of recommended first line combination treatment for 
uncomplicated falciparum malaria everywhere in the tropical world. Recently the largest 
ever-randomised trial in severe malaria compared intravenous artesunate with intravenous 
quinine. It enrolled 1,461 patients with severe falciparum malaria in South East Asia 
before it was stopped by the data and safety monitoring committee (Newton et al., 2003; 
Dondorp et al., 2005). Artesunate reduced mortality by 34.7% compared to quinine. The 
number need to treat to save one life ranged from 11 to 20 (International Artemisinin 
Study Group, 2004; Jones et al., 2007). As a result the new WHO guidelines (2006) 
recommend parenteral artesunate as the first choice antimalarial treatment of severe 
malaria in low transmission areas. But the recommendation for higher transmission areas 
(i.e. much of Africa) has remained artemether or artesunate or quinine (van Hensbroek at 
al., 1998). The reason for this continued equipoise is that there are important differences in 
the clinical manifestations and evolution of severe malaria and the treatment responses in
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African children compared with adults in Southeast Asia. Notably, in a meta-analysis of 
randomised trials in severe malaria, intramuscular injection of the oil-based artemisinin 
derivative artemether did reduce mortality in Southeast Asian adults compared with 
quinine, but it did not do so in African children (Artemether-Quinine Meta-analysis Study 
Group, 2001). This raised the possibility that artemether was not inferior to artesunate for 
the treatment of severe falciparum malaria in SE Asian adults. The largest study from 
South East Asia in this series was a randomised comparison of artemether and quinine that 
enrolled 560 adults and was conducted in the Hospital for Tropical Diseases of Ho Chi 
Minh City (HTD), Viet Nam (Hien et al., 1996). This study reports a subsequent study 
from this centre in which artemether was compared with artesunate.
METHODS
This was an open label comparison of intramuscular artesunate and intramuscular 
artemether in patients admitted to HTD with severe falciparum malaria. This study was 
approved by the Ethical and Scientific Committee of HTD.
Entry criteria
Patients were included in the study if they (or an accompanying relative) gave informed 
consent, had asexual forms of P. falciparum on a peripheral-blood smear, were older than 
14 years, were not in the first trimester of pregnancy, were not intravenous drug users, 
had received less than 3g of quinine or two doses of artemisinin or a derivative in the 
previous 48 hours, and had one or more of the following: a score on the Glasgow Coma 
Scale of less than 11 (indicating cerebral malaria); anaemia (hematocrit, <20 percent), 
with a parasite count exceeding 100,000 per cubic millimetre on a peripheral-blood
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smear; jaundice (serum bilirubin, >2.5mg per decilitre [50pmol per litre]), with a parasite 
count of more than 100,000 per cubic millimetre on a peripheral-blood smear or with 
serum creatinine, >3mg per decilitre [250pmol per litre]; renal impairment (urine output, 
<400ml per 24 hours; and serum creatinine, >3mg per decilitre [250pmol per litre]); 
hypoglycaemia (blood glucose, <40mg per decilitre [2.2mmol per litre]); 
hyperparasitaemia(>10 percent parasitaemia) or parasite count of more than 500,000 per 
cubic millimetre; plasma lactate > 4mmol per litre; arterial pH < 7.34 with standard base 
excess < -5mmol per litre; and systolic blood pressure below 80 mmHg with cool 
extremities (indicating shock).
Clinical Procedures
On admission patients were examined fully, weighed, and baseline blood samples taken 
for full blood count, clotting studies, biochemistry (BUN, serum creatinine, serum 
bilirubin, AST, ALT, plasma lactate), blood culture and malaria parasite counts. Arterial 
pH and blood gases were also measured. Chest X-ray was also performed on admission. 
Each patient underwent a full clinical examination that included a detailed neurological 
assessment. A full history was taken from either the patient or attendant relatives. 
Hydration status was assessed, and patients were hydrated, if necessary with pressure 
monitoring, via a central venous catheter. A urinary catheter was inserted. Patients were 
not included if there was a convincing history of full treatment with quinine or an 
artemisinin derivative for more than 48 hours before admission. Full treatment with 
quinine over the 24 hours before admission was defined as 40mg salt/kg on the first day 
and 30mg/kg on any subsequent day. Patients were also excluded if there was known 
allergy to one of the artemisinin derivatives or quinine.
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Management, Clinical and Parasitological Monitoring
Patients were cared for according to standard recommendations. All patients were given 
isotonic saline to restore fluid balance, and fluid balance was maintained with saline or 5 
percent dextrose in water. When necessary, a central venous catheter was inserted and the 
central venous pressure maintained at 5cm of water. Blood was transfused if the 
hematocrit fell below 20 percent. Hypoglycaemia was corrected with a bolus injection of 
50ml of 30 percent dextrose in water and a subsequent maintenance infusion of 5 to 10 
percent dextrose in water. Detailed clinical and nursing observations were recorded a 
minimum of every 4 hours for the first 24 hours and every 6 hours thereafter.
A diagnostic lumbar puncture was performed if the Glasgow Coma Scale was below 14. 
Opening cerebrospinal fluid pressures were measured, the cerebrospinal fluid was 
analyzed microscopically, and levels of protein, glucose, and lactate were determined. 
Haemofiltration was started in patients with established renal failure. Patients with 
respiratory failure were ventilated. Paracetamol was given for a temperature above 39°C. 
A single dose of intramuscular Phenobarbital was given if Glasgow Coma Scale was 
below 11, and intravenous diazepam, and if necessary, intravenous phenytoin were given 
for convulsions. Antibiotics were prescribed for suspected cases of bacterial sepsis.
Blood was obtained by a finger-prick for haematocrit measurements and blood smears 
every 4 hours for the first 24 hours and every 6 hours until three consecutive smears were 
negative for asexual stages of P. falciparum. The degree of parasitaemia was determined 
on the basis of the number of parasitized red cells per 1,000 red cells (thin film) or the 
number of parasites per 400 leukocytes (thick film).
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On discharge a detailed neurological examination were performed. A full autopsy was 
performed on patients who died of malaria if permission could be obtained from relatives. 
All information was recorded in the patients' records and then triple-entered in a computer 
database.
Antimalarial treatment and randomization.
Patients were randomized to treatment with either intramuscular artesunate or 
intramuscular artemether.
Artesunate (Guilin No 2 Pharmaceutical Factory, Guangxi, People’s Republic of China) 
(Figure 3.2) was given in a dose of 2.4mg/kg body weight on admission, then 1.2mg/kg 
was given daily until oral medication could be taken reliably. Each 60mg vial contained 
anhydrous artesunic acid that was dissolved initially in 1ml 5% sodium bicarbonate and 
then mixed with 5ml of 5% dextrose before injecting as a bolus into an indwelling 
intravenous cannula.
Artemether (80mgper millilitre; Kunming Pharmaceutical Company, Kunming, People’s 
Republic of China) (Figure 3.3) was given in a dose of 3.2mg/kg body weight on 
admission, followed by 1.6mg/kg daily until oral medication could be taken.
Both drugs were given intramuscularly to the anterior thigh. Randomly selected ampoules 
were checked for sterility and potency. When the patients were able to take tablets, oral 
artesunate was given in a dose of 2mg/kg/day to complete a total course (including 
parenteral treatment) of 7 days, providing a total cumulative dose between 17 and 
18mg/kg over 7 days.
Treatment failure: If parasitaemia did not fall by >75 % of the admission value within 48 
hrs the treatment will be changed to intravenous quinine (20mg/kg followed by lOmg/kg 
8 hourly).
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Randomization and Blinding
The randomization was generated from random number tables. The drugs for each patient 
were placed in a coded sealed envelope, and the envelopes were randomized in blocks of 
20. Once a patient was enrolled in the study the envelope was opened. Subsequent 
analysis of efficacy was on an intention-to-treat basis. To maintain blinding, a separate 
team of nurses, who were not otherwise involved with the care of the study patients, drew 
up and gave the injections. The drugs were kept in an opaque packet in a locked cabinet 
during the study.
Endpoints
The primary endpoint was death during the first 28 days following recruitment to the 
study.
The secondary endpoints were:
1. Time to 50% reduction in parasite count
2. Time to 90% reduction in admission parasite count
3. Time to discharge from hospital
4. Incidence of complication during hospital admission
Statistical Analysis
Results were entered into a database (Microsoft Excel, Microsoft Corp, USA) and 
analysed with a statistical software package (Stata 10, StataCorp, Texas, USA). Chi- 
square or Fisher’s exact test was used to compare proportions as appropriate. Risk 
verification was expressed with odds ratio (OR) and 95% confidence interval (Cl).
Assuming a 20% of mortality in the artemether arm and the study had a power of 70% to
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demonstrate a 50% reduction in absolute mortality. The estimated required sample size 
for each group was 177 patients.
RESULTS
As a result of the fall in incidence of severe malaria in Viet Nam the trial was finished 
early on the recommendation of the Scientific Advisory Committee due to low 
recruitment. The study has recruited enough patients to detect a 50% fall in mortality 
from 20% to 10% with 70% power. We recruited 370 patients into the study at the time 
of completion. The baseline characteristics of patients on admission are shown in table
3.1. Both admission clinical parameter and laboratory investigation were similar in 2 
randomised treatment groups.
Outcome
The overall mortality rate was ten percent (37 of 370 patients). The mortality rate in 
artesunate group (ARTS) was lower than in the artemether group (ARTM) (7 percent vs. 
13 percent, unadjusted relative risk of death for artesunate -0 .54 , 95% Cl: 0.28 -  1.02, p 
= 0.052 (Table 3.2). For cerebral malaria subgroup patients, there was no significant 
difference in this outcome: the unadjusted mortality in the ARTS group was 12.9 percent 
and in the ARTM group was 13.8 percent (RR for artesunate = 0.94, 95% Cl: 0.44 -  2.01, 
p = 0.87). On further exploration of factors associated with fatal outcome using multiple 
logistic regression (Table 3.3), patients who received intramuscular artesunate still had a 
decreased risk of death compared with those treated with artemether (adjusted OR for 
ARTS 0.41, 95% Cl: 0.16 -  1.06, p = 0.06). Other important contributors associated with 
death were admission to hospital after year 2000, an increase in plasma lactate on 
admission, decreased Glasgow Coma score, previous treatment with artemisinin 
derivatives and raised white cell in the peripheral blood. No significant difference was
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found in of the rate of complications between the groups except for the development of 
coma after receiving treatment. The ARTS group was associated with lower risk (7/94, 
6.9%) of developing coma than the ARTM group (15/82, 15.5) RR=0.45 Cl 95%: 0.19 -  
1.05, p = 0.056. This may explain why the mortality in the former subgroup was also 
lower than the latter. (2/99 vs. 12/85, RR = 0.16 Cl 95% 0.04 -  0.70, p = 0.004).
Causes o f Death
The causes of death in severe malaria are often not confined to any specific 
complications, as multiple organ disorder often developed before death. Of the 37 fatal 
cases, we found that 25 of them had acute renal failure (24 of this group underwent 
dialysis); 28 cases had persistent and unrecoverable shock; 20 cases had spontaneous 
bleeding mostly from gastro-intestinal lumen; 12 cases had co-infection of lung and 
urinary tract; and 8 cases had pulmonary oedema.
Recovery
Assessment of most indicators of recovery did not reveal any significant differences 
between the treatment groups (Table 3.4). However, the ARTS group showed a quicker 
initial clearance of parasite from the peripheral blood (median time to 50% parasite 
clearance (IQR) (hrs): 8 (4-12) in ARTS and 8 (4-16) in ARTM). This advantage lasted 
until a decrease of ninety percent of the parasite load (median time to 90% parasite 
clearance (IQR) (hrs): 16 (12-30) in ARTS and 24 (12-36) in ARTM) (Table 3.4; Figure
3.1) and was lost thereafter.
Haematologic Recovery
There was no significant difference between two groups in fall of haematocrit after 
baseline (median percentage reduction of admissive haematocrit in the ARTS group:
23.1, (IQR: 14.3-35.1), range (0-70%) and in the ARTM group: 21.4, (IQR: 12.9-34.7),
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range (0-70), p = 0.25) or in the number of times required blood transfusion (p = 0.19). 
Bleeding sites included of gastro-intestinal, skin, conjunctiva and urinary tract.
Adverse Effects
There was no significant adverse reaction between 2 groups.
DISCUSSION
The treatment of severe malaria has changed in recent years with the introduction of the 
artemisinin derivatives. Until recently artemether was favoured by the WHO and therefore 
most studies had been conducted with it. In an individual patient data meta-analysis of 
randomised trials in severe falciparum malaria artemether was superior to quinine in 
Southeast Asian adults, but not in African children. Unfortunately intramuscular 
artemether was probably not the best artemisinin formulation to choose; it is an oil-based 
formulation that releases the drug slowly and erratically from the injection site (Murphy et 
al., 1997; Hien et al., 2004). In contrast to parenteral artemether, intravenous artesunate is 
obviously instantly bioavailable, and intramuscular artesunate is absorbed reliably and 
rapidly with peak concentrations occurring within one hour (Nealon et al., 2002; Ilett et 
al., 2002: Hien et al., 2004). After i.m. injection, in cases of severe malaria, concentrations 
of artesunate in plasma peaked within 20 minutes of injection, and artesunate was 
hydrolysed rapidly and completely to the biologically active dihydroartemisinin (DHA). 
On the other hand maximum artemether concentrations in plasma occurred at a median of 
10 hours and there was relatively little conversion to DHA (Hien et al., 2004). Moreover, 
artesunate is a more potent antimalarial; artesunate and its main active metabolite 
dihydroartemisinin have relative in vitro potencies, in comparison to artemether, of 2.9
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and 4.0 respectively (Brockman et al., 2000). The pharmacokinetics of artesunate and 
dihydroartemisinin are not influenced by the severity of malaria (Davis et al., 2001). A 
recent large multicentre trial from South East Asia showed that artesunate reduced 
mortality by 34.7% compared with quinine (SEAQUAMAT, 2005). This left the role of 
artemether uncertain -was it as good as artesunate despite the pharmacokinetic drawbacks, 
or was it inferior? This trial set out to answer this question.
The ARTS group was associated with lower risk (7/101, 6.9%) of developing coma after 
initiation of therapy than the ARTM group (15/97, 15.5) RR=0.45 Cl 95%: 0.19 -  1.05, p 
= 0.056. The parasite clearance times were also faster in the ARTS treated patients 
(median 90% reduction PCT (IQR) (hrs): 16 (12-30) in ARTS and 24 (12-36) in ARTM). 
These data may be explained by the pharmacokinetic properties of artesunate compared 
with artemether and the faster bioavailaibilty of the active metabolites with artesunate 
especially in severly ill patients with marked metabolic acidosis. It also suggests that the 
first few hours of effective treatment are very important and the faster the active drug can 
be got to the site of action (the blood) the better. As outlined above after i.m. injection 
concentrations of artesunate peaked within 20 minutes of injection, and artesunate was 
hydrolysed immediately and completely to the biologically active dihydroartemisinin 
(DHA). Maximum artemether concentrations occurred at a median of 10 hours and there 
was much less and slower conversion to DHA. There are also some severely ill patients, 
mostly with severe metabolic acidosis who taken even longer to obtain maximal 
artemether concentrations. This hypothesis would be consistent with the pharmacology 
work done at the Hospital for Tropical Diseases (Hien et al., 2004). Getting active drug 
effective against all stages of the parasites (and thereby reducing or preventing maturation 
and reducing sequestration) into the patient quickly seems crucial. When faced with a 
patient with severe malaria the first few minutes and hours may make a huge difference to
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their subsequent chances of survival. Perhaps it is time to leam the lessons from the 
cardiologists and aim to administer the most effective, fasting acting anti-malarial drug 
into patients as an emergency in the same way as thrombolytic therapy is administered 
urgently in patients with myocardial infarction where delays of minutes can make a huge 
difference to mortality and preservation of myocardium. Getting patients referred through 
the health care systems quickly is crucial, but once in a hospital able to administer 
parenteral drugs speed is of the essence to prevent the further maturation of parasites, 
reduce sequestration and prevent consequent complications.
The trial was overtaken by events. Improved malaria control in Viet Nam led to a dramatic 
decline in the incidence of severe malaria. The Hospital for Tropical Diseases is a referral 
hospital that in the early 1990s was receiving approximately three to five patients each day 
with severe malaria. A decade later this had fallen to approximately one patient per month. 
This was insufficient to sustain this trial and so the trial was terminated before reaching 
the pre-defmed end points. The trial was stopped with the investigators blind to the 
allocations and prior to any analysis of the results. The result after 370 patients had been 
randomised was a borderline difference in favour of artesunate (Unadjusted relative risk of 
death for artesunate = 0.54, 95% Cl: 0.28 -  1.02, p = 0.052). The superiority of artesunate 
over artemether is supported by the larger differences in mortality rates when artesunate 
was compared with quinine (35% reduction in mortality), versus artemether (a 26% 
reduction) (International Artemisinin Study Group, 2004), although these trials were 
conducted in different sites, with different protocols and different drug dosages, so are not 
strictly comparable. There is probably little to choose intrinsically between these two 
derivatives, and so the superiority of artesunate is likely to derive mainly from its more 
rapid and more reliable absorption following intramuscular injection. This may explain 
why the rate of reduction in parasitaemia was more rapid following artesunate.
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Both drugs were very well tolerated with little or no discomfort at the injection site, no 
serious local or systemic reactions, a low rate of hypoglycaemia (presumably disease 
related), and no neurological sequelae (Nontprasert et al, 1998; Hien et al, 2003). 
Although artemether is easier to administer than artesunate, which is an advantage in busy 
epidemic settings, it is probably an inferior drug. Artesunate, administered as an 
emergency should be the treatment of choice for severe falciparum malaria.
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Table 3.1 Baseline Characteristics of Patients, According to Treatment Group
Parameters Number 
in each 
group 
(ARTS/ 
ARTM)
Artesunate 
(ARTS) 
n = 186
Artemether 
(ARTM) 
n = 184
P value
Age (years) 0.33
Median 32 32.5
Range 15-74 15-77
Interquartile range 23-42 25-44
Sex -  Male/Female 133/53 142/42 0.21
Previous treated with quinine for 11(5.9) 15(8.2) 0.4
current malaria contracted: no. of
patients (%)
Previous treated with artemisinin 114(61.3) 105(57.1) 0.41
derivatives for current malaria
contracted: no. of patients (%)
Convulsions: no. of patients (%) 13(7.0) 14(7.6) 0.82
Temperature (°C) 0.75
Median 38.1 38.0
Range 36.5-40.5 36.0-41.0
Interquartile range 37.5-39.0 37.5-39.0
Pulse (rate/min) 0.30
Median 100 100
Range 68-150 60-151
Interquartile range 90-115 90-120
Respiratory rate (rpm) 0.27
Median 28 28
Range 12-60 18-68
Interquartile range 24-32 24-32
Glasgow Coma Score 0.61
Median 11 11
Range 3-15 3-15
Interquartile range 8-15 8-15
Glasgow Coma Score less than 85(45.7) 87(47.3) 0.76
11: no. of patients (%)
Opening CSF pressure (cmP^O) 72/80 0.61
Median 15 16
Range 4-30 2-29
Interquartile range 11-18.5 11-20
Shock: no. of patients (%) 6(3.2) 10(5.4) 0.30
Hypoglycaemia: no. of patients 1(0.5) 0(0) 1.0
(%)
Haematocrit (%) 0.42
Median 32 31
Range 10-50 8-53
Interquartile range 26-38 25-37
Parasite count (xlO /pL) 0.75
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Median 80.7 70.5
Range 0.02-3471 0.02-3534
Interquartile range 10.4-255 7.1-286
White cell count (xl03//jiL) 173/171
Median 7.93 8.40
Range 1.1-47.6 1.7-27.0
Interquartile range 5.5-10.9 5.7-11.2
Serum creatinine (mg %) 179/176
Median 1.8 1.7
Range 0.6-9.5 0.6-17.0
Interquartile range 1.1-3.2 1.1-3.6
Total bilirubin (mg %) 124/120
Median 5.7 5.0
Range 0.6-39.0 0.6-38.8
Interquartile range 2.4-13.6 2.3-12.0
ALT (U/L) 155/161
Median 70 71
Range 10-1900 6-414
Interquartile range 44-129 41-119
Lactate (mmol/L) 168/166
Median 3.2 3.6
Range 0.5-17.7 0.5-16.8
Interquartile range 2-5.6 1.8-5.1
0.45
0.68
0.40
0.45
0.85
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Table 3.2 Primary and secondary outcomes after treatment with intramuscular
Artesunate or Artemether
Outcomes ARTS ARTM Relative Risk 
(95% Cl)
P value
Mortality rate 13/186(7.0) 24/184(13.0) 0.54(0.28-1.02) 0.052
Developing coma* 7/101(6.9) 15/97(15.5) 0.45(0.19-1.05) 0.056
Convulsions 7/186(3.8) . 9/184(4.9) 0.77(0.29-2.02) 0.59
Require blood 69/186(37.1) 69/184(37.5) 0.99(0.76-1.29) 0.94
tranfusion
Renal impairment 111/186(59.7) 105/184(57.1) 1.05(0.88-1.24) 0.61
Renal failure 85/186(45.7) 85/184(46.2) 0.99(0.79-1.23) 0.92
Require dialysis 52/186(28) 54/184(29.3) 0.95(0.69-1.31) 0.77
Hypoglycaemia 7/186(3.8) 9/184(4.9) 0.77(0.29-2.02) 0.59
Spontaneous 26/186(14) 35/184(19) 0.73(0.46-1.17) 0.19
bleeding
Shock 22/186(11.8) 26/184(14.1) 0.84(0.49-1.42) 0.51
Concomitant 66/186(35.5) 75/184(40.8) 0.87(0.67-1.13) 0.30
infection
Jaundice 144/186(77.4) 144/184(78.3) 0.99(0.89-1.1) 0.85
Pulmonary oedema 10/186(5.4) 13/184(7.1) 0.76(0.34-1.69) 0.5
* The number of patients who were not comatose on admission in ARTS group was 101, 
and in ARTM group were 97.
Table 3.3 Multivariate logistic regression analysis of factors associated with death 
in severe falciparum malaria patients
Factors Adjusted Odds Ratio P value Notes
(95% Cl)
IM artesunate treatment 0.41 (0.16 -1.06) 0.066 60 out of 370 were
Year of study (after 2000) 0.14(0.03 -0.71) 0.017 not included (30 in
Each unit higher in 0.82 (0.72 -0.93) 0.002 ARTS and 30 in
Glasgow Coma score ARTM) due to
Unit increase of admissive 1.28(1.15 -1.43) <0.001 missing lactate
plasma lactate and/or WBC count
Each 103 WBC/mm3 rise 1.1 (1.02--1.18) 0.017 values)
Pre-entry treated with 0.29 (0.11 -0.82) 0.019
artemisinin derivatives
Forward stepwise on conditioned of likelihood change logistic regression (p to enter = 
0.075, p to remove = 0.15)________________________________________________ _
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Table 3.4 Assessment of recovery after treatment with intramuscular Artesunate or
Artemether
Parameters ARTS 
n = 186 
hours
ARTM 
n = 184
P value*
Time to parasite clearance 
Decrease to 50% of admission value 
Median 8 8
0.007
Range 4-42 2-60
Interquartile range 4-12 4-18
Decrease to 90% of admission value 
Median 16 24
0.004
Range 4-102 2-152
Interquartile range 12-30 12-36
Total clearance 
Median 72 72
0.97
Range 7-330 2-204
Interquartile range 48-90 54-96
Resolution of fever 
Time first temperature < 37.5°C 
Median 30 20
0.99
Range 0-768 0-648
Interquartile range 4-66 4-60
Time of fever clearance 
Median 108 108
0.27
Range 0-888 0-1088
Interquartile range 54-180 60-204
Time to recovery from coma 
Time to Glasgow Coma score of 8* 
Median 48 54
0.55
Range 4-2136 2-2232
Interquartile range 20-90 20-108
Time to Glasgow Coma score of 11* 
Median 42 42
0.44
Range 4-2136 2-2232
Interquartile range 20-80 24-78
Time to Glasgow Coma score of 15  ^
Median 60 72
0.11
Range 4-2136 2-2232
Interquartile range 36-108 48-126
Time to physical recovery 
Time before patient able to drink 
Median 30 42
0.20
Range 0-2136 0-2232
Interquartile range 8-66 4-84
Time before patient able to eat 
Median 42 46
0.18
Range 0-2136 0-2232
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Interquartile range 12-78 14-96
Time before patient able to sit 0.32
Median 78 90
Range 0-2136 0-2232
Interquartile range 48-156 48-174
Time before patient able to stand 0.66
Median 96 114
Range 0-2136 0-2232
Interquartile range 60-180 60-198
Time before patient able to walk 0.64
Median 102 120
Range 0-2136 0-2232
Interquartile range 72-192 66-216
Time before patient able to leave hospital 0.68
Median 264 288
Range 7-2136 2-2232
Interquartile range___________________192-480_______192-456__________
* Log-rank test
f  Only patients who decreased in Glasgow Coma score below 8 were included (130 pts, 
58 in ARTS group and 72 in ARTM group)
t  Only patients who decreased in Glasgow Coma score below 11 were included (204 pts, 
93 in ARTS group and 111 in ARTM group)
Only patients who decreased in Glasgow Coma score below 15 were included (274 pts, 
134 in ARTS group and 140 in ARTM group)
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Figure 3.2 Artesunate (Guilin No 2 Pharmaceutical Factory, Guangxi, PR China)
(N.H.Phu)
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Figure 3.3 Artemether (Kunming Pharmaceutical Company, Kunming, PR China)
(N.H.Phu)
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CHAPTER 4
A RANDOMIZED COMPARISON OF PUMPED VENOVENOUS 
HAEM OFILTRATION AND PERITONEAL DIALYSIS IN ACUTE 
RENAL FAILURE ASSOCIATED W ITH SEVERE INFECTION
INTRODUCTION
Acute renal failure (ART) is a major contributor to the morbidity and mortality associated 
with severe infections (Lombardi et al., 1998; Kamik et al., 1998). The management of 
ART in severe sepsis is often difficult because the patients are haemodynamically 
unstable and may have multi-organ dysfunction. In the developed world both 
hemodialysis and peritoneal dialysis (PD) have been used in the acute phase of renal 
impairment, although the early use of haemodialysis was dogged by difficulties with 
blood pressure control (Huyghebaert et al., 1985). With the introduction of continuous 
haemofiltration, particularly when pump-assisted to reduce cardiovascular complications 
and ensure constant filtration, many of these difficulties were resolved (Voerman et al., 
1990; Dunham, 2001). In recent years pumped venovenous haemofiltration, and variants 
such as haemodiafiltration, have become standard renal replacement therapy in acutely ill 
patients. However these procedures require the constant presence of highly trained staff, 
anticoagulation to prevent clotting in the extracorporeal circulation, large volumes of 
appropriate fluids, and venous access with sufficient capacity for the relatively high 
extracorporeal flow rates required. With a pump in the circuit there is also an added risk 
of air embolus. These factors and uncertainties over cost and availability cast doubt on
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the practicality, feasibility and safety of haemofiltration in less developed parts of the 
world.
Falciparum malaria is a major cause of acute renal failure in the tropics, and ARP in 
malaria carries a high mortality. There have been a number of reports of successful 
treatment of malaria-associated acute renal failure with acute peritoneal dialysis (Reid et 
al., 1967; Whelton et al., 1967; Reid et al., 1968; Canfield et al., 1968; Lowenthal et al., 
1974; Indraprasit et al., 1988; Trang et al., 1992). PD has the advantage of simplicity, low 
cost, and relatively widespread availability. There are both theoretical advantages and 
disadvantages of using PD in malaria. Severe falciparum malaria is characterised by the 
sequestration of parasitised erythrocytes in the deep microvasculature, which may lead to 
compromise of the blood flow through the peritoneal membrane and reduced dialysis 
efficiency (Canfield et al., 1968). Malaria is particularly severe in pregnant women, and 
an additional limitation of PD is that it cannot be used in late pregnancy. On the other 
hand both malaria itself, and the most widely used treatment of severe malaria, quinine, 
are associated with hypoglycaemia and the use of hypertonic glucose as an osmotic agent 
in peritoneal dialysis fluid may reduce the risk of hypoglycaemia by providing a constant 
glucose infusion. Severe malaria is associated consistently with lactic acidosis, yet most 
haemofiltration replacement fluids use lactate as the alkali generated base. Inability to 
metabolise this additional lactate load could worsen the metabolic acidosis.
There has never been a randomized comparison of acute PD with haemofiltration in the 
treatment of acute renal failure in any context. We conducted this comparison in patients 
with severe infection-related acute renal failure. The setting was an infectious disease 
hospital in Viet Nam, where, before the start of the study, only acute peritoneal dialysis 
was available for the treatment of acute renal failure.
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PATIENTS AND METHODS 
Study Site
The study was carried out in a purpose-built intensive care unit at the Hospital for 
Tropical Diseases, Ho Chi Minh City, an infectious disease hospital which acts as a 
referral centre for much of southern Viet Nam, particularly for the management of acute 
renal failure. Ethical approval was obtained from Ethical and Scientific Committee of the 
institution.
Objectives
This was to assess, using a randomized controlled trial, the relative efficacy, safety, 
practicality and cost of acute peritoneal dialysis and pumped venovenous haemofiltration 
in the setting of a well-equipped hospital in a developing country. The primary end point 
was the rapidity of resolution of metabolic derangements, specifically the rates of change 
and times to normalization of arterial pH and venous creatinine. Mortality, requirement 
for further renal replacement therapy, and incidence of serious complications such as 
bleeding, air embolus, peritonitis, lactic acidosis and hypoglycaemia were documented as 
secondary endpoints.
Patients
Any patient in whom urgent renal replacement therapy (RRT) was indicated to treat acute 
renal failure was considered eligible for the study, with the following exceptions: patients 
were excluded from the study if they were pregnant, under the age of 15 years, or had 
already received renal replacement therapy of any type during the current illness. 
Informed consent was obtained either from the patient, or from their attendant relative if 
the patient was comatose or below the age of 18.
As this was an infectious disease hospital patient either had severe falciparum malaria or 
sepsis-related ARF. A decision to start RRT was based on the presence of one or more of
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the following indications: oliguria (urine output <15mls/hour despite rehydration) or 
anuria; metabolic acidosis (standard base excess < -lOmmol/L with serum creatinine 
>265pmol/L); fluid overload with ARF (serum creatinine >265pmol/L); clinical uremic 
syndrome; and hyperkalaemia (>6mmol/L). Diagnosis and appropriate treatment of the 
underlying condition (malaria or sepsis) was carried out in accordance with normal 
clinical practice, and was not in any way compromised by the study protocol. Patients 
with severe malaria were assessed and managed as described previously (Donadio et al., 
1968; Trang et al., 1992) and patients with sepsis were assessed using Bone’s criteria 
(Bone, 1991), though these were not part of the inclusion criteria for the study.
Study procedure
On admission patients were examined fully, weighed, and baseline blood samples taken 
for full blood count, clotting studies, biochemistry, blood culture and malaria parasite 
counts. Arterial pH and blood gases were also measured. Hydration status was assessed, 
and patients were hydrated, usually with pressure monitoring, via a central venous 
catheter. A urinary catheter was inserted. After the decision was made by the clinician, 
and consent was obtained either from the patients or their relatives, patients were 
randomized to receive either peritoneal dialysis (PD) (Figure 4.4) or pumped venovenous 
haemofiltration (HF) (Figure 4.3). The randomization was generated from random 
number tables, and placed in consecutively numbered sealed, opaque, double-wrapped 
envelopes. A full history was taken from either the patient or attendant relatives. Before 
starting dialysis or filtration the patient was weighed, and body length recorded and, if the 
decision to start renal replacement was taken > 24 hours after admission, the full blood 
sampling was repeated. Once randomized to HF or PD catheters were inserted and 
dialysis or filtration initiated as quickly as possible.
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Peritoneal dialysis
Peritoneal dialysis was carried out as described previously (Trang et al., 1992). Briefly a 
rigid peritoneal dialysis catheter was inserted under local aenesthetic, and an open 
drainage system used. The acetate-based dialysis solution was prepared by the hospital 
pharmacy with the following electrolyte composition (in mmol/L): sodium, 141; chloride, 
101; calcium, 3.5; magnesium, 1.5; and acetate, 45. Two solutions were available: an 
isotonic solution containing dextrose 1.5g/100mL, and a hypertonic solution containing 
dextrose 7g/100mL. The hypertonic solution was used in cases of volume overload and 
pulmonary oedema. Heparine (200 IU) was added to each liter for preventing catheter 
obstruction. The solution was heated in a water bath to 37°C before administration. Two 
litre exchanges were used with a 30 minutes dwell time (a total of up to ~ 70 litres/day).
Haemofiltration
Venous access was obtained through an 8.5Fr Quinton-Mahurkar double lumen catheter 
inserted into the femoral vein. Blood was pumped through a FH-66 haemofilter by a 
BMM 10-1 blood pump (Gambro, Sweden) at a flow rate of 150 mLs/min. Lactate-based 
haemofiltration fluid (Formula No.l, Gambro, Australia) was infused into the 
extracorporeal circuit before the haemofilter (predilution). Haemofiltrate and replacement 
fluid flow rates, and hence overall fluid balance, was controlled using a BS1 Balancing 
System (Gambro, Sweden). Overall haemofiltrate volume was set at ~ 25 litres/day. 
Heparin was infused at an initial rate of 500 IU / hour. The Activated Clotting Time was 
monitored every 5 hours using a Hemochron 801 bedside coagulation testing system 
(International Technidyne Corporation, New Jersey, US).
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Monitoring
Regular clinical assessment (at least 4-hourly), and monitoring of urine output and overall 
fluid balance, was carried out throughout the period of renal replacement therapy. 
Arterial pH, blood gases, SaC>2, potassium, venous plasma lactate, glucose, and creatinine 
were measured 5-hourly. Glucose and lactate were determined using on-line analysers 
(Analox, London, UK), as was plasma creatinine (Boerhinger-Mannheim, Germany). 
Arterial blood gas measurement and haemoximetry were performed using a pre­
calibrated ABL4 blood gas machine (Radiometer, Copenhagen, Denmark). Any 
complications of RRT were assessed and recorded prospectively.
A session of RRT was continued until the physicians caring for the patient considered it 
was no longer indicated clinically. If a complication of therapy occurred there was 
provision for stopping the current treatment session and restarting RRT with the other 
treatment modality. Peritonitis in PD was not considered an indication for stopping 
dialysis unless it persisted despite intraperitoneal (IP) antibiotics. First line treatment for 
peritonitis consisted of IP cefotaxime or ceftriaxone. If the cultures yielded a resistant 
organism or there was no clinical response within 24 hours the combination of IP 
vancomycin and IP gentamicin was substituted. If the patient was systemically septic 
broad-spectrum intravenous antibiotics were started or added.
Only the first RRT session (i.e. until the physician discontinued RRT) was randomized to 
either HF or PD. If a patient required further RRT after initial improvement, then PD was 
used, and was carried out on the same intensive care ward using the same PD protocol. 
Requirement for further RRT was a secondary end-point of the study.
Statistical analysis
An a priori power calculation showed that a sample size of 108 patients would be
r
required to demonstrate a 50% increase in the rate of fall in plasma creatinine on dialysis,
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with 95% confidence and 90% power on the basis of data collected during a previous 
study (Trang et al., 1992). An interim analysis was planned after 50 patients were 
recruited. A significant difference in mortality was not anticipated before the trial with 
these sample sizes.
The statistical packages Stata (College Station, Texas, USA) and StatView (SAS 
Institutes Inc., Cary, North Carolina, USA) were Used for data summary and analysis. 
The distributions of continuous variables were tested for normality using the Shapiro- 
Wilks test. When distributions were skewed log transformations were applied if 
appropriate. Normally distributed continuous variables were compared between groups 
with the unpaired Student’s t test, and untransformed skewed continuous variables with 
the Kruskal Wallis test. Nominal variables were compared between groups using Fisher’s 
exact test. Time to event analyses were carried out using the Kaplan-Meier method and 
logrank test for comparison of treatment groups.
To assess the effects of underlying disease and hepatic dysfunction multivariate analysis 
was carried out using analysis of variance or logistic regression analysis, depending on 
the nature of the outcome variable.
RESULTS
A total of 70 patients were entered into the study. An interim analysis was carried out 
after 42 patients had been recruited, which showed an unexpected trend towards a higher 
mortality in the PD group (p = 0.04). As this was not the originally stated primary end­
point of the trial, it was decided to continue the study and to conduct a second interim 
analysis at 70 patients. The mortality difference persisted so the study was stopped on 
ethical grounds.
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Thirty-six patients had been randomized to PD, 34 to HF. The demographic and baseline 
clinical findings are given in Table 4.1. There was no significant difference in any of the 
baseline variables between groups. Falciparum malaria was the underlying cause of ARF 
in 48 patients (69%). The other 22 patients all had presumed bacterial sepsis: in 8 cases 
serology was positive for leptospirosis, and in 2 an organism was cultured from blood (1 
E.coli and 1 Klebsiella pneumoniae); the remaining 12 cases fulfilled the criteria for 
sepsis syndrome though no organism was cultured (5 had definitely received antibiotics 
before admission, and the antibiotic drug history in the other 7 was unknown). They were 
presumed to have been septicemic.
The indications for dialysis are given in (Table 4.2). One patient with severe malaria had 
a creatinine of 0.9mg/dL on admission, though this rose quickly to 3.1mg/dL. Dialysis in 
this case was carried out for severe metabolic acidosis (pH 7.11, SBD 17.9mmol/L), but 
the patient died of refractory shock (algid malaria) 30 hours after entry. All the other 
patients had abnormally raised plasma creatinine levels (>1.5mg/dL). There was no 
significant difference between the HF and PD groups in the frequency of any of these 
indications, or in the number of indications per patient.
Correction of metabolic abnormalities
Plasma creatinine concentrations in the HF group declined more than twice as rapidly as 
in the PD group (p=0.004, Table 4.3), although there was no difference between the 
treatment groups in the proportion of patients with a normal creatinine at the end of the 
RRT session (Table 4.3)
For technical reasons independent of the conduct of the study, full arterial blood gas 
measurements were available only on 55 of the 70 patients (26 randomised to PD and 29 
to HF, p=0.25). Recruitment continued when the blood gas analyzer was unavailable as 
the other major metabolic measure and primary endpoint of the study (i.e. plasma
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creatinine), was still measurable. In the sub-group with full acidosis measurements, 
which was not selected in any way other than by the serviceability of the blood gas 
analyzer, the rate of resolution of acidosis was considerably faster and normalisation 
more complete in the HF group.
Resolution of acidosis was assessed by
i. the rates of change of pH and base excess, calculated over the duration of the 
RRT session (Table 4.3),
ii. the absolute minimum values of pH and base excess observed (Table 4.3), and
iii. time to normal pH and base excess (Table 4.3 and Figure 4.1).
A significantly higher proportion of patients in the HF group had a normal pH and base 
deficit at the end of the RRT session, even though the duration of the session was 
significantly shorter (Table 4.3 and Figure 4.1).
Mortality
There were 17 deaths in the PD group (47%) compared with 5 (15%) in the HF group 
(relative risk (95% confidence intervals (Cl)) 3.2 (1.3 to 7.7), p=0.005).
The median (95% Cl, range) time to death in the PD group was 29.8 hours (17.5 to 92.5, 
0.5 -  258), compared with 13.8 hours (3.6 to 52, 3.6 to 52) (p=0.17) in the HF group 
(Figure 4.2). Severe acidosis secondary to a combination of severe sepsis / malaria and 
renal failure was a major contributor to death in 16 patients (73%). In 9 patients (41%) 
prolonged hemodynamic shock was present. The ultimate mode of death was 
cardiorespiratory arrest in 18 patients (82%), and respiratory followed by cardiac arrest in 
the remaining 4 (18%). No patient died from hyperkalaemia. A complication of therapy 
contributed either directly or indirectly to death in one patient, who had a major 
gastrointestinal haemorrhage while anticoagulated for HF.
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Except for two patients in the PD group, all fatal cases died during the first RRT session. 
In one severe malaria patient, PD was stopped after a diagnosis of brain stem death was 
made 213 hours into the study; he was taken off life support 38 hours later. PD was 
stopped after 168 hours in a second malaria patient when it was clear major brain damage 
had been sustained secondary to severe malaria. He died at home 5 days later.
Complications
Although cloudy dialysate was seen at some stage in 15 (48%) of the patients treated with 
PD, peritonitis was only confirmed in one patient (dialysate white cell count >250 
cells/mL). No organism was cultured. Intraperitoneal and parenteral cefotaxime was 
given, and the PD fluid became clear within 24 hours.
Serious upper gastrointestinal bleeding was a major complication in 3 patients, 2 in the 
PD group and 1 HF. In these three patients the bleeding was thought to contribute to 
death, though 2 also had intractable acidosis and the other septic shock (before bleeding). 
One patient randomized to haemofiltration was thought to have received an air embolus 
when an alarm on the blood pump was overridden in error, although it was unclear what 
volume of air (if any) entered the circulation. The patient’s systolic blood pressure fell to 
90 mmHg from 115 mmHg, though this recovered after approximately 5 minutes. The 
patient survived and was discharged well from hospital.
There was no difference in the incidence of hypoglycaemia between the two groups 
(Table 4.3).
Duration of RRT and need further dialysis.
The median duration of HF was less than half that of PD (p=0.006) (Table 4.3). Of the 
patients in the PD group who survived the first RRT session 70% (14/20) needed further 
dialysis (with 3 of these patients requiring 2 further dialysis episodes), compared with
133
37% (11/30) of those in the HF group (p=0.04). This reduced requirement for further 
dialysis in the HF group was despite a higher proportion surviving to the end of the first 
RRT session. Three PD patients required two further episodes of dialysis.
Multivariate analysis
Logistic regression analyses were done with death and further dialysis requirement as the 
dependent variables and treatment group, underlying disease (malaria or presumed 
bacterial sepsis) and presence or absence of jaundice as independent variables. PD was 
associated significantly with both death (OR (95% Cl) 5.1 (1.6 to 16), p=0.006) and need 
for further dialysis (4.7 (1.3 to 17), p=0.017), in accordance with the univariate analyses. 
There was no significant effect of underlying disease or jaundice on either outcome 
measure.
Similar logistic regression analyses were carried out on the subgroup of 48 patients in 
whom full serial arterial blood gas data were available and who survived the first RRT 
session. HF was associated significantly with correction to a normal pH (OR 23 (3.9 to 
138), p=0.001) and normal base excess (OR 244 (17 to 3500), p<0.0001) at the end of 
dialysis. The covariates jaundice and underlying disease had no significant effect. To 
explore the possibility of lactate intolerance in jaundiced patients in the HF group (who 
received lactate-base haemofiltration fluid) a term for the interaction of treatment and 
jaundice was added; this had no significant effect on either model.
On multivariate analysis of the variances of i. the rate of change of creatinine and ii. the 
rate of change in pH, treatment group had a significant effect in both cases (p=0.02 & 
p<0.0001 respectively), whereas underlying disease and presence of jaundice did not.
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Impact of lactic acidosis
Although 54 /55 patients in whom admission blood gas measurements were carried out 
had a metabolic acidosis (SBE < -3.3 mmol/L), only 20 (36%) and 40% of all patients 
(28/70) had admission hyperlactataemia (plasma lactate > 4 mmol/L). It is known that 
other acids, primarily renal in origin, contribute to the acidosis in severe malaria patients 
both with and without lactic acidosis. To assess whether lactic acidosis per se was 
refractory to treatment with HF using lactate-based replacement fluid we entered plasma 
lactate and treatment modality into a logistic regression model containning outcome as 
the dependent variable. Plasma lactate, itself is an independent predictor of poor outcome 
(p < o .05), had no significant influence on the relative efficacy of HF compared with PD. 
Admission hyperlactataemia also had no influence independent of admission SBE on the 
rate of normalization of acidosis.
Peak plasma lactate concentrations were significantly higher in the HF group than the PD 
group (p=0.018), reflecting infusion of lactate-based haemofiltration fluid. This was not 
associated with acidosis indeed mean minimum pH and base excess were significantly 
lower in the PD group (p=0.0001 & p=0.002 respectively, Table 4.3).
Economic implications
The mean (95% Cl) cost of hospital stay (from diagnosis of ARF to discharge) for PD 
patients was $1,580 (1,170 to 2,000), compared with $1,150 (960 to 1,330) for HF 
patients. This includes the cost of dialysis, drugs, and bed charges for both the intensive 
care unit and the convalescent ward. The costs per survivor were $3,000 (2,210 to 3,790) 
for PD and $1,340 (1,130 to 1,560) for HF.
The approximate cost per life saved was $6,950 for PD and $2,080 for HF. These figures 
do not include the cost of staff training, though this is unlikely to be very different 
between the two RRT modalities. Nor do they take into account the capital costs of
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equipment. Although these will be higher for HF, with reasonable patient throughput of 
patients these costs are likely to be rapidly defrayed by the per case cost differences 
outlined above, which are all substantially higher for PD. For example, assuming an 
outlay of $10,000 for the haemofiltration system, HF would have become less expensive 
overall in our centre after only 24 patients had received RRT. These calculations are 
based on costs of health care, drugs and consumables in Viet Nam in the late 1990s, but 
can probably be generalized to other developing countries.
DISCUSSION
Acute renal failure associated with severe infections such as malaria and bacterial sepsis 
are a major cause of death in adults in the developing world. Renal replacement therapy 
is one of the most expensive and difficult forms of medical treatment, and is often beyond 
the financial reach or logistic capability of health care systems in the tropics. However 
infection-related ARF carries mortality of over 70% if treated conservatively (Trang et 
al., 1992) and in contrast to the situation in rich countries, ARF in poorer countries often 
affects the young, most economically productive members of society. If temporary renal 
support of some sort can be provided during the acute illness, these previously fit 
individuals will often recover quickly and fully, and very rarely progress to chronic renal 
failure (Trang et al., 1992). Acute peritoneal dialysis has been used extensively in the 
tropics for the treatment of ARF associated with malaria and other infections precisely 
because it is considered relatively inexpensive and practical in a resource-poor context, 
and it is clinically effective. In richer countries acute peritoneal dialysis has been replaced 
almost everywhere (except in paediatric nephrology) by either acute haemodialysis or 
continuous haemofiltration. This is largely because these newer techniques are considered 
more efficient at restoring normal biochemical homeostasis, although there have been no
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randomized comparisons in the management of ARF to determine whether this translates 
into clinical benefit.
As countries develop economically and health budgets increase, the problem arises of 
how to spend most effectively the modest sums available for new initiatives. Expensive 
tertiary care facilities such as dialysis and intensive care units present a particular 
dilemma, particularly as their benefits are difficult to quantify. If haemofiltration or 
haemodialysis is to replace acute peritoneal dialysis as the usual treatment for ARF in 
developing countries, there must be good evidence that it is clinically superior and cost 
beneficial.
The peritoneal dialysis technique used at this referral centre was first introduced in 1989. 
It was associated, at the time, with a halving of the mortality from malaria-associated 
ARF compared with historical controls (Trang et al., 1992). Peritoneal dialysis is 
affordable and practical, and sufficiently simple that, with a moderate degree of training, 
it can be transferred to district hospitals. However this randomized comparison 
demonstrates conclusively that venovenous haemofiltration is superior to acute peritoneal 
dialysis clinically and furthermore in the setting of this regional referral centre in Viet 
Nam it costs less. The large difference in mortality between the two groups was not 
anticipated, but it continued following the initial interim analysis, and it is significant at 
the 1% level even after Bonferroni adjustment to allow for the “double look” at the data. 
This trial is small for a mortality study, and death was not the primary outcome measure 
at the start of the comparison. The mortality difference is readily explained by the 
considerably inferior efficacy of peritoneal dialysis in normalizing the biochemical 
disruption that characterises ARF.
The results from analysis of protocol-specified outcome markers are all greatly in favour 
of HF. Patients randomized to HF were dialysis dependent for a shorter time period, and
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cleared acidosis and azotaemia quicker than those receiving PD. Could this finding have 
resulted from physician bias? It is true that two of the outcome measures were dialysis 
duration and the number of dialysis episodes required, both of which were subjective 
decisions made by physicians who could not be blinded to treatment allocation. However 
despite the longer median dialysis duration in the PD group, the objective measurements 
of metabolic improvement were all strongly in favour of HF, suggesting that the 
physicians’ decisions to prolong dialysis were based on objective clinical concerns rather 
than intrinsic bias.
The majority of patients in this study had severe falciparum malaria as a cause of ARF, 
the central pathophysiological feature of which is sequestration of parasitized 
erythrocytes in the deep microvasculature, including the splanchnic bed. Peritoneal 
dialysis relies on perfusion of the splanchnic bed for apposition across the peritoneal 
membrane of circulation and dialysis fluid. Any obstruction to peritoneal microvascular 
blood flow by sequestration could reduce dialysis efficiency substantially. Previous 
studies have suggested that dialysis efficiency may be reduced in severe malaria (Yorke 
et al., 1911; Canfield et al., 1968; Donadio et al., 1968). A potential benefit from PD in 
severe malaria is the theoretical beneficial effect on malaria and quinine-associated 
hypoglycaemia of the glucose used as an osmotic agent in the dialysis fluid. This is not 
supported by the current trial; of the 6 malaria patients who were hypoglycaemic during 
dialysis, 4 received PD and 2 HF.
Patients receiving HF cleared their acidosis significantly more rapidly than those 
receiving PD. This suggests that hepatic conversion of exogenous lactate anion into alkali 
was possible in the majority of cases despite the high incidence of hepatic dysfunction, 
manifested by jaundice and other biochemical abnormalities in this patient population. In 
severe infections hyperlactataemia usually reflects lactic acidosis, and in severe malaria
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lactic acidosis is a major cause of death (Davenport et al., 1990; Day et al., 2000). Plasma 
lactate increased significantly during HF, but this rise was associated with increases in 
pH and base excess rather than worsening acidosis. Multivariate analysis showed that the 
presence of jaundice had no effect on clearance of acidosis in the HF group, and there 
were no patients in the HF group in who base excess fell after HF started. Other workers 
have described patients with lactate intolerance, but this was not seen in our study 
population (Davenport et al., 1990; English et al., 1997)
There is evidence that HF increases the clearance of molecules of potential pathological 
significance in severe malaria and severe sepsis, though the clinical significance of this 
remains unclear (Hoffmann et al., 2001). Raised levels of pro-inflammatory cytokines are 
associated with poor outcome in both diseases (Casey et al., 1993; Day et al., 1999), and 
molecules of this size are cleared efficiently by HF. Whether this is also true of PD is 
unknown.
The causes of acute renal failure in malaria are not completely understood. The 
presenting features and the clinical evolution suggest ‘acute tubular necrosis.’ 
Rhabdomyolysis with raised creatinine kinase and myoglobin levels is common in severe 
malaria (Miller et al., 1989), and the combination of myoglobinuria, sometimes 
haemoglobinuria, and acidosis may contribute to tubular damage. Haemodialysis and 
haemofiltration have been shown to be of benefit in the early treatment of 
rhabdomyolysis caused by the crush syndrome (Amyot et al., 1999; Splendiani et al., 
2001), raising the possibility that early haemofiltration in severe malaria may actually 
modify the course of the renal pathological process, leading to the observed shortening of 
the period of dialysis dependence.
This study provides evidence that for countries at an intermediate level of development of 
their health care system investment in facilities for venovenous haemofiltration is a more
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cost-effective alternative to the introduction or continuing use of peritoneal dialysis for 
the treatment of acute renal failure, and is associated with a significantly better clinical 
outcome.
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Table 4.1 Clinical and Laboratory Characteristics at Base line*
Characteristic Peritoneal Dialysis (N=36)
Haemofiltration
(N=34)
P
Value
Age -  yr 0.87
Median (95% Cl) 36 (29.6-38.4) 35 (29.5-38.2)
Range 15-74 16-57
Male sex -  no. (%) 27 (75) 30 (88) 0.22
Malaria -  no (%) 23 (64) 25 (74) 0.45
Weight -  kg 0.80
Median (95% Cl) 53.5 (49.7-55) 53.5 (50-55)
Range 36-79 39-71
Body-surface area -  m2 0.99
Mean (95% Cl) 1.56(1.49-1.60) 1.58(1.52-1.60)
Range 1.23-1.89 1.31-1.82
Anuria -  no. (%) 7(19) 5(15) 0.75
Cerebral events -  no. (%) 15 (42) 13 (38) 0.81
Glasgow Coma Scoref 0.58
Median (95% Cl) 12.5 (9-15) 14.5 (9.8-15)
Range 3-15 3-15
Duration of illness -  days 0.06
Median (95% Cl) 7 (6-8) 6 (5-7)
Range 2-35 3-13
Time to parenteral 0.94
antimalarial treatment -  days
Median (95% Cl) 5 (3.1-5.9) 4 (4-5)
Range 1-8 3-8
Hypoglycaemia -  no. (%) 1(3) 3(9) 0.35
Plasma creatinine -  mg/dl§ 0.99
Mean (95% Cl) 6.3 (5.3-7.3) 6.3 (5.5-7.1)
Range 0.9-13.4 2.1-10
Plasma bilirubin -  mg/dl} 0.67
Geometric mean (95% Cl) 6.10(3.9-9.6) 5.4 (3.5-8.2)
Range 0.6-48.5 0.7-75.2
Base deficit -  mmol/litre 0.37
Mean (95% Cl) 11.9 (9.9-14.0) 10.6 (8.2-12.9)
Range 4.6-21.7 0.7-26
Plasma lactate -  mmol/litre 0.51
Geometric mean (95% Cl) 3.7 (2.6-5.1) 3.2 (2.4-4.3)
Range 1.1-12.7 0.6-11
Shock -  no. (%)-f 3(8) 5(15) 0.47
Peripheral-blood parasite 0.36
count in patients with malaria
-/pL
Geometric mean (95% Cl) 16,600 (3,800- 6200(1,200-32,600)
Range 72,000)
20-363,000 20-710,000
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*CI denotes confidence interval
f  Scores on the Glasgow Coma Score range from 3 to 15, with lower scores indicating 
deeper coma.
**Hypoglycaemia was defined as a plasma glucose concentration of less than 40mg per 
decilitre (2.2 mmol per litre).
§To convert values for creatinine to micromoles per liter, multiply by 88.4 
{To convert values for bilirubin to micromoles per liter, multiply by 17.1 
-|-Shock was defined as a systolic blood pressure <90mmHg.
Table 4.2 Indications for dialysis
Characteristic Peritoneal Dialysis (N=36)
Haemofiltration
(N=34) P Value
01iguria=(= 28 (78) 28 (82) 0.77
Hyperkalaemia-||- 4(11) 2(6) 0.67
Severe acidosis+ 18(50) 21 (62) 0.39
Fluid overload with acute 6(17) 1(3) 0.11
renal failure (serum creatinine
> 3 mg/dl)^
Uraemic syndrome 2(6) 1(3) 0.99
No. of indications for dialysis 0.75
per patient
Mean (95% Cl) 1.6 (1.4-1.9) 1.6 (1.3-1.8)
Range 1-3 1-3
^Oliguria was defined as a urine output of less than 15 ml per hour despite adequate fluid 
replacement.
-||-Hyperkalaemia was defined as a potassium concentration of >6 mmol/litre.
+ Severe acidosis was defined as standard base deficit of more than 10 mmol per litre 
with a serum creatinine concentration of more than 3 mg per decilitre
★Fluid overload with acute renal failure was defined by a creatinine concentration of >3 
mg per decilitre.
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Table 4.3 Outcomes According to Treatment*
Variable Peritoneal Dialysis Haemofiltration P
(N=36) (N=34) Value
Plasma creatinine
Normal at the end of 4/26 (15) 6/31 (19) 0.74
dialysis -  no. (%)**
Rate of decrease - 0.004
mg/dl/hr**
Median (95% Cl) 0.018(0.005 to 0.030) 0.039 (0.029 to 0.061)
Range -0.002 to 0.18 0.001 to 0.17
Maximal rise after the <0.001
start of renal-replacement
therapy - mg/dl
Median (95% Cl) 0.2 (0 to 1.2) 0 (0 to 0)
Range 0 to 5.0 0 to 1.8
Arterial blood pH
Normal at the end of 8/21 (38 [18 to 62]) 25/27 (93 [76 to 99]) <0.001
renal-replacement therapy
-n o . (%[95%CI])A
Rate of increase -  XI O' <0.001
5/h r^
Median (95% Cl) -26 (-63 to 10) 218(108 to 304)
Range -2150 to 103 -163 to 1020
Maximal decrease after <0.001
the start of renal-
replacement therapy
Median (95% Cl) 0.125 (0.068 to 0.267) 0(0 to 0.016)
Range 0 to 0.842 0 to 0.207
Base deficit
Normal at the end of 1/21 (5 [0.12 to 24]) 24/27 (89 [71 to 98]) <0.001
renal-replacement therapy
-n o . (% [95% C I]H
Rate base decrease - <0.001
mmol/litre/hr
Median (95% Cl) 0.005 (-0.051 to 0.041) 0.26 (0.20 to 0.32)
Range -0.17 to 0.27 0 to 0.75
Maximal increase after the <0.001
start of renal-replacement
therapy -  mmol/litre
Median (95% Cl) 2.8 (1.7 to 5.3) 0 (0 to 0)
Range 0 to 15.5 0 to 7.1
Secondary outcomes
D eath-no. (% [95% Cl]) 17 (47 [30 to 65]) 5 (15 [5 to 31]) 0.005
Duration of first session of 0.006
renal-replacement therapy
-  hrs
Median (95% Cl) 92 (30 to 128) 43.5 (27.5 to 67)
Range 0.5 to 340 3 to 120
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Further dialysis needed -  14/20 (70 [46 to 88]) 11/30 (37 [20 to 56]) 0.04
no./total no. (% [95%
Cl])**
Hypoglycaemia during 5 (14 (5 to 30]) 2 (6 [0.7 to 18]) 0.43
dialysis -  no. (% [95%
Cl])
Severe bleeding during 2 (6 [0.7 to 18]) 1 (3 [0.7 to 15]) 0.52
dialysis -  no. (% [95%
CI])§
Peritonitis during dialysis 1 (3 [0.07 to 15])
-n o . (% [95% Cl])
Peak plasma lactate 0.05
concentration during 
dialysis -  mmol/litre
Geometric mean (95% Cl) 5.5 (4.3 to 6.0 7.6 (5.9 to 9.9
Range___________________2.1 to 24.2_____________1.6 to 18.9____________________
*CI denotes confidence interval
**This variable excluded patients who died during the first session of renal-replacement 
therapy.
To convert values for creatinine to micromoles per litre per hour, multiply by 88.4. A 
normal creatinine concentration was considered to be <1.5mg per decilitre (133 pmol per 
litre).
^This variable included only patients enrolled in the study when measurements of 
arterial blood gases were available and excluded patients who died during the first session 
of renal-replacement therapy.
A normal pH was considered to be >7.35, and a normal base deficit <3.3 mmol per litre.
§ Severe bleeding was defined by a need for blood transfusion.
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Figure 4.1 Kaplan-Meier Plots of the Time to the Resolution of Acidosis (Panel A) 
and Acidaemia (Panel B). Acidosis was defined as a standard base deficit of >3.3 
mmol per liter, and acidaemia as pH< 7.35. Arrows indicate censoring of data on 
patients who died during the first session of renal replacement therapy or in whom 
acidosis or acidaemia failed to resolve by the end of the first session of renal 
replacement therapy.
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Figure 4.2 Kaplan-Meier Plots of Time to Death (Panel A) and Time to the End of 
the First Session of Renal replacement therapy (Panel B).
In Panel B, arrows indicate censoring of data on patients who died during the first 
session of renal replacement therapy. P values were derived by the log-rank test.
146
Figure 4.3 Haemofiltration in severe falciparum malaria (N.H.Phu)
Figure 4.4 Peritoneal dialysis in severe falciparum malaria (N.H.Phu)
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CHAPTER 5
FLUID MANAGEMENT IN SEVERE MALARIA 
INTRODUCTION
The introduction of artemisinin based combination therapy has revolutionised the care of 
patients with malaria. However, even with the use of intravenous artesunate, between 7- 
25% of adult patients with severe malaria will die; the majority during the first 48 hours 
of their hospital admission (Dondorp et al., 2005). Whilst effective adjunctive 
chemotherapy is being sought, there is surprisingly little clinical data regarding the 
optimal supportive care of these patients in the early stages of their admission. This is 
despite the impressive improvement in mortality that has been demonstrated using early 
goal-directed therapy in patients with sepsis (Rivers et al., 2001) and, in resource poor 
settings, with simple fluid resuscitation protocols in dengue fever (Dung et al., 1999). 
Indeed, even using inferior quinine therapy, patients admitted to a French intensive care 
unit with severe malaria had a mortality rate of 11% (Bruneel et al., 2003), suggesting 
that improved supportive care can lead to better outcomes in malaria as well. Currently, 
there is debate in the paediatric literature about the extent of hypovolaemia in children 
with severe malaria and its contribution to the pathophysiology of the disease (Akech et 
al., 2006; Planche, 2007). However, even those who query its clinical relevance 
acknowledge that moderate dehydration can be demonstrated in this population (Planche 
et al., 2004). In adults, where the duration of coma is relatively prolonged and renal 
failure is more common, hypovolaemia might contribute more significantly to the 
manifestations of the disease. Limited series have confirmed that adult patients with
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severe malaria are hypovolaemic (Davis et al., 1990) or at least have a reduced effective 
circulating volume (Malloy et al., 1967; Sitprija et al., 1996). However, the issue of fluid 
replacement has been relatively ignored, with no good data to guide the selection of 
which fluid should be administered to these patients, nor how quickly it should be given. 
If too little fluid is given, there is the risk of exacerbating the renal failure and acidosis 
associated with severe malaria -  complications associated with a poor outcome (Trang et 
al., 1992; Day et al., 2000). If too much is administered, there is the risk of pulmonary 
oedema, a condition which is the result of increased pulmonary capillary permeability 
with a mortality rate of 80% (WHO, 2000). In most parts of the world where malaria is 
seen precipitating pulmonary oedema is a disaster. Good ventilation is usually not 
possible and the experience of clinicians and nurses to deal with pulmonary oedema is 
limited.
The most recent WHO guidelines emphasise the physical examination of patients and 
offer only very general advice to clinicians: “If there is evidence (on physical 
examination) of dehydration, give only isotonic fluid (0.9% saline) by intravenous 
infusion, but avoid circulatory overload as it may rapidly precipitate fatal pulmonary 
oedema” (WHO, 2006). This is despite the fact that there is little correlation between the 
physical assessment of hypovolaemia and true volume status (McGee et al., 1999) and no 
data to recommend saline over other fluid options. The WHO guidelines also suggest that 
patients with severe malaria should, if possible, have a central line inserted and the 
central venous pressure (CVP) should be used to assist in the assessment of volume status 
(WHO, 2006), despite data that suggest that its role may be limited (Ausudkij et al., 
1998).
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As prolonged fluid therapy will be required in almost all adult patients it makes sense to 
better define the effect of fluid resuscitation on the manifestations of the disease, so that 
recommendations to physicians are based on sound pathophysiological principles. To 
take some early steps down this path, we retrospectively reviewed the clinical, 
haemodynamic and biochemical data of adult patients with severe malaria who were 
enrolled in previous studies (Hien et al., 1996). We aimed to determine whether there was 
any improvement in mortality or prognostic indicators when patients in these studies 
were resuscitated with normal saline or colloid. We also hoped to establish the utility of 
central venous pressure (CVP) and pulmonary artery occlusion pressure (PAoP) as 
measures of volume status in patients with severe malaria.
METHODS
The studies were carried out in a purpose-built intensive care unit at the Hospital for 
Tropical Diseases in Ho Chi Minh City, a hospital that acts as an infectious disease 
referral centre for much of southern Viet Nam. Written informed consent was obtained 
from each patient or, in the case of comatose patients, their attendant relative. All studies 
were approved by the Ethical and Scientific Committee of the Hospital for Tropical 
Diseases. As the fluid resuscitation of patients guided by invasive pressure measurements 
represented standard of care at the time, consent was not specifically sought for the 
collection of data for this retrospective chart review.
Patients were included in this analysis if they had invasive haemodynamic monitoring 
performed as part of the initial study. They were considered to have severe malaria if they 
had asexual forms of P. falciparum on their peripheral blood smear and at least one of the 
following criteria of severity: acute renal failure with oliguria and plasma creatinine of >3 
mg/dL (265 pmol/L); hypoglycaemia (plasma glucose of <40 mg/dL [2.2 mmol/L]);
150
shock with systolic blood pressure of <80 mmHg; metabolic acidosis with a base deficit 
of <10 mmol/L; venous plasma lactate of >4 mmol/L; or pulmonary oedema. These 
criteria are a stricter modification of the widely used World Health Organization criteria 
for severe malaria (WHO, 2000).
Depending on the study in which they were enrolled, patients received either an 
intramuscular quinine-loading dose regimen (20 mg/kg quinine dihydrochloride salt 
followed by 10 mg/kg, eight hourly), intramuscular artemether treatment (4 mg/kg stat 
followed by 2 mg/kg, eight hourly) or artesunate (2.4 mg/kg iv stat) followed by 1.2 
mg/kg at 12 and 24 hrs daily. The requirement for fluids was assessed clinically and 
guided by measures the pulmonary artery occlusion pressure (PAoP). Depending on the 
extent of estimated hypovolaemia and tissue hypoperfusion, patients received normal 
saline, colloid (Gelofundin, B. Braun Medical, Metsungen, Germany) or no fluid loading. 
Patients who received fluid loading were resuscitated to a PAoP of 9-12 mmHg. Oxygen 
was given as necessary, but the patients were not routinely mechanically ventilated.
A full history was taken from either the patient or the attendant relatives and a detailed 
physical examination was performed. The patient was weighed, and body length was 
recorded. Baseline blood samples were taken for full haematology, quantitative parasite 
count, clotting studies, biochemistry (including lactate and glucose), and blood culture.
An arterial catheter was inserted into the femoral artery, and a flow-directed pulmonary 
artery catheter (Abbott Laboratories, North Chicago, IL) was introduced via the internal 
jugular route under fluoroscopy. Continuously monitored intravascular pressures (arterial 
pressure, CVP, PAP), electrocardiogram, and oximetric oxygen saturation were recorded 
on a multifunction monitor (Hewlett-Packard, Palo Alto, CA). PAoP was measured 
intermittently. Cardiac output was determined by thermodilution in triplicate using 10 mL
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boluses of cooled 5% dextrose. Body temperature was recorded as the core temperature 
from the pulmonary artery catheter terminal thermistor. Simultaneous arterial and mixed 
venous plasma lactate and glucose concentrations were determined enzymatically using 
dedicated on-line analyzers (Analox, London, UK). Systemic vascular resistance, oxygen 
delivery (DO2), and oxygen consumption (VO2) were calculated and cardiac index, 
systemic vascular resistance index, DO2 index, and VO2 index derived using standard 
formulae (Edwards et al., 1993). Preparation of the patient and recording of baseline 
hemodynamic and metabolic measurements took 45-120 mins and did not interfere with 
other aspects of clinical management.
Results were entered into a database (Microsoft Excel, Microsoft Corp, USA) and 
analysed with a statistical software package (Stata 9.2, StataCorp, Texas, USA).
RESULTS
Overall there were 43 patients who met criteria for severe malaria and who had data 
available for analysis. Their management is recorded in Figure 5.1.
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Befitting a series set in the ICU, the patients were extremely unwell on admission. Of the 
43 patients, 11 were admitted in shock, 11 had pulmonary oedema and 26 met WHO 
criteria for malaria associated acute renal failure. The median GCS was 8 (95% Cl: 7 to 
10), the median base excess was -10.3 (95% CI:-11.9 to -7.9) and the median arterial 
lactate was 6.1 mmol/L (95% Cl: 5.1 to 7.8). Thirty five percent of the patients would die 
during their admission. Logistic regression using purposeful selection in a model 
incorporating anti-malarial drug used, Glasgow coma scale, Pa02/Fi02 ratio, plasma 
creatinine, total bilirubin, peripheral parasite count, age, haematocrit, cardiac index, 
lactate and arterial pH confirmed that acid base status, as determined by the arterial pH, 
was the only significant predictor of outcome. Acid base status was a strong predictor of 
death: those with a base excess less than -10, had 4 times the risk of death (95%CI 1.01 - 
15.86, p=0.049), and those with a bicarbonate less than 15mmol/L had 6.5 times the risk 
of death (95% Cl 1.4 -  29.7, p=0.02).
Twenty-four (56%) of the patients received a fluid load and nineteen (44%) did not. The 
Pa02/Fi02 ratio and the CVP and PAoP were the only variables that were statistically 
significantly different between these two groups (the PAoP was used to determine 
whether a fluid load would be given, and the CVP was highly correlated with the PAoP 
(p <0.0001, rs=0.75)) (Table 5.1). The median volume of fluid administered was 918mls 
(range 350 -  2000), and it was delivered over a median of 75 minutes (range 30 minutes 
to 3 hours 45 minutes). All the patients who later died were able to complete their fluid 
load.
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Table 5.1 Baseline demographics of the patients (all values are median (95% Cl))
Variable Fluid load n=24 No fluid load n=19 P value*
Age (years) 38 (25.7-48.3) 34 (21 -43.5) 0.39
Male (%) 21/24 (88%) 15/19(79%) 0.68
Parasite count ( x 103 /pi) 94.5 (33 -305.1) 50 (8.7- 107) 0.17
Artemisinin based therapy 15/23 (65%)A 8/17 (47%A 0.34
Glasgow Coma Score 8 (5 -10) 10 (7 -1 3 ) 0.15
Lactate (mmol/L) 6.1 (3.9-7.8) 6.2 (5.3 - 9.7) 0.52
Creatinine (pmol/L) 339 (261 - 526) 247 (203 - 444) 0.39
Total bilirubin (pmol/L) 121 (74- 178) 103 (53 - 158) 0.48
Haematocrit (%) 27 (24 -32 ) 30 (28 -31) 0.45
Sodium (mmol/L) 134 (130- 136) 137 (128 - 143) 0.16
Potassium (mmol/L) 4.1 (3.8-4.5) 4.2 (3.9-4.6) 0.63
Renal failure* 18/24 (75%) 12/19 (63%) 0.51
AnuricA 11/24(46%) 8/19 (42%) 1
Shock 6/24 (25%) 5/19 (26%) 1
Pulmonary oedema 4/24 (18%) 7/19 (37%) 0.17
MABP (mmHg) 78.5 (75.3 - 82) 83 (64.5 - 93.3) 0.59
CVP (mmHg) 2 (0 -3 ) 4 (3 -6 ) 0.005
PAoP (mmHg) 6 (4 - 6.4) 10 (7-13.3) 0.001
Cardiac index (L/min/m) 4.1 (3.3-4.7) 3.9 (3.2-4.7) 0.91
SVR (dyne/s/cm'5m2) 1429 (1313 - 1907) 1375 (1243 - 1962) 0.86
Oxygen saturation (%) 96.5 (95.2-97.2) 95.3 (92.4-97.5) 0.24
Pa02/Fi02 ratio 436 (381 -564) 207 (183 -475) 0.02
Cv02 (%) 60.2 (55.3 - 64.3) 59.3 (49.5 -63.1) 0.57
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pH 7.36 (7.31 -7.39) 7.32 (7.27-7.36) 0.12
Bicarbonate (mmol/L) 13.9 (11.6-16.9) 15 (9.9-16.9) 0.99
Base excess -10.5 (-12.3--7.1) -9.4 (-15.3--7.6) 0.78
D02 (mL/min/m2) 454 (378 - 538) 452 (343 - 533) 0.99
V02 (mL/min/m2) 154.5 (144- 185.4) 168 (151.7- 187.7) 0.52
02ER % 36.5 (32.7-42.7) 37 (32-47.2) 0.83
* P test by Chi squared. A in three patients the antimalarial used was not recorded.
* 1 patient did not have dopamine receipt recorded.
MABP: Mean arterial blood pressure, PAoP: Pulmonary artery occlusion pressure, 
SVR: Systemic vascular resistance, Cv02: Mixed venous oxygen saturation.
D02: Oxygen delivery. V02: Oxygen consumption. 02ER: Oxygen extraction ratio.
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There was a higher mortality rate in the patients who received a fluid load, although with 
the small sample size, this did not reach statistical significance. There was no significant 
difference between the two groups in the development of shock, renal failure, pulmonary 
oedema or neurological deterioration (Table 5.2).
Table 5.2 Outcome by fluid load
Fluid load No fluid load p value
Died 9/24 38% 6/19 32% 0.8
APO developed 1/24 4.2% 1/19 5.3% 1
CM developed 0/24 0% 3/19 16% 0.08
ARF developed 3/24 13% 1/19 5.3% 0.62
Shock developed 5/24 21% 6/19 32% 0.5
P value is determined by Chi-squared.
APO: Acute pulmonary oedema. CM: Cerebral malaria. ARF: Acute renal failure
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With a fluid load there was a significant median increase (95% Cl) in Cardiac Index: 
0.63 L/min/m2 (0.31 - 0.94), PAoP: 5mmHg (3.7-6.7) CVP: 3mmHg (1-5) and mixed 
venous oxygen saturation (Cv02) 3.9% (0.5 - 5.3), and there was a significant median 
decrease (95%CI) in haemoglobin -0.7g/dL (-1.4 to -0.3), systemic vascular resistance 
(SVR) -139dyne/s/cm'5m2 (-334 to -68), oxygen consumption (V02) -8.5 mL/min/m2(-26 
to -0.7) and the oxygen extraction ratio (02ER) -4% (-6 to -0.7). Notably there was no 
significant median change in the acid base status of the patients (Table 5.3)
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Table 5.3 Change in variables with fluid loading n=24
Variable Median A 95% Cl
AMABP (mmHg) 1 -0.3 to 5
ACVP (mmHg) 3 1 to 5
APAoP (mmHg) 5 3.7 to 6.7
A Cardiac index (L/min/m ) 0.63 0.31 to 0.94
A SVR (dyne/s/cm'5m2) -139 -334 to -68
ASa02 (%) 0 -0.2 to 0.6
Ap02/Fi02 0 -18 to 22
APa02 mmHg 0 -3.8 to 4.8
APaC02 mmHg 0 -0.7 to 2.1
A Haemoglobin (g/dL) -0.7 -1.4 to -0.3
A Cv02 (%) 3.9 0.5 to 5.3
A pH -0.01 -0.02 to 0.01
ABicarbonate (mmol/L) -0.1 -0.9 to 0.9
ABase excess -0.55 -1.6 to 0.1
AD02 (mL/min/m2) 18 -16 to 68.4
AV02 (mL/min/m2) -8.5 -26 to -0.7
A02ER (%) -4 -6 to -0.7
ALactate (mmol/L) -0.1 -0.4 to 0.3
MABP: Mean arterial blood pressure, CVP: Central venous pressure, PAoP: Pulmonary 
artery occlusion pressure, SVR: Systemic vascular resistance, Sa02: Oxygen saturation, 
Pa02: Partial pressure of oxygen, PaC02: Partial pressure of carbon dioxide, Cv02: 
Mixed venous oxygen saturation, D02: Oxygen delivery, V02: Oxygen consumption, 
02ER: Oxygen extraction ratio
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Twenty-two patients (92%) had the fluid that was used as the resuscitation agent 
recorded; twelve of these patients received normal saline and ten received gelofundin. 
The group that received gelofundin were sicker with a lower MABP, pH, and base excess 
and a greater arterial lactate. Despite this, patients receiving gelofundin had a similar 
mortality rate to those receiving normal saline. (Tables 5.4 and 5.5)
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Table 5.4 Baseline demographics by resuscitation agent (all values are median (95% 
Cl))
Variable Normal saline Gelofundin p value*
Age 36.5 (22.4-52.8) 34.5 (21 - 46.7) 0.67
Sex (male) 12/12(100%) 7/10 (70%) 0.08
Parasite count ( x 10 /pi) 63.6 (10-285) 113 (26.3 -560) 0.32
Artemisinin based therapy 9/11 (82%) 5/10 (50%) 0.18
Glasgow coma score 8 (3 -1 3 ) 7.5 (3-10) 0.49
Creatinine (pmol/L) 441 (160-675) 309 (203 - 532) 0.4
Total bilirubin (pmol/L) 7.1 (2.6-14.5) 6.9 (2.5 -10) 0.64
Haematocrit 32 (25.5-34) 24.5 (19.3 -36.1) 0.11
Sodium (mmol/L) 134 (127- 139) 133.5 (126.1-138.3) 0.84
Potassium (mmol/L) 4.4 (3.8-4.7) 3.8 (3.2-4.3) 0.07
Renal failure 9/12 (75%) 8/10 (80%) 1
Anuric on admission 6/12 (50%) 4/10(40%) 0.69
Shock on admission 1/12 (9%) 3/10 (30%) 0.29
Cerebral malaria 10/12(85%) 10/10(100%) 0.48
APO on admission 2/12 (17%) 1/10(10%) 1
MABP (mmHg) 84 (78-91.7) 77.5 (69.3 - 79.7) 0.009
CVP (mmHg) 2.5 (0-3.9) 1 (-1-2.7) 0.27
PaoP (mmHg) 5.5 (4 -6 ) 6 (3.3-7.7) 0.64
Cardiac index (L/min/m ) 4.38 (3.24-4.98) 4.06 (2.92 - 4.54) 0.45
SVRdyne/s/cm'5m2) 1570 (1179-2136) 1429 (1120-2142) 1
Pa02/Fi02 ratio 425 (312-575) 477 (389-620) 0.29
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Cv02 (%) 62.4 (58.4 - 67.5) 54.7 (40.9 - 64.4) 0.048
pH 7.39 (7.37-7.41) 7.30 (7.24 - 7.38) 0.004
HC03 (mmol/L) 16.3 (13.7-19.3) 10.8 (8.3 -16.4) 0.009
Base excess -7.4 (-10.5--4.9) -13.4 (-16.7--8.4) 0.006
D02 (mL/min/m2) 518 (385 -610) 377 (291 - 538) 0.09
V02 (mL/min/m2) 178 (135 - 195) 146 (142 - 209) 0.57
0 2 E R (%) 34 (30.1 -40.7) 41.9 (33.5-58.2) 0.06
Lactate (arterial)(mmol/L) 4 (1.6-6.8) 8.3 (2.8 - 12) 0.03
* by Mann Whitney. APO: Acute pulmonary oedema, MABP: Mean arterial blood 
pressure, MPAP: Mean pulmonary artery pressure, CVP: Central venous pressure, PAoP: 
Pulmonary artery occlusion pressure, SVR: Systemic vascular resistance, Sa02: Oxygen 
saturation, Cv02: Mixed venous oxygen saturation, D02: Oxygen delivery, V02: 
Oxygen consumption, 02ER: Oxygen extraction ratio
Table 5.5 Outcomes by resuscitation agent.
Variable Normal saline Gelofundin p value*
Died 5/12 42% 3/10 30% 0.68
APO during admission 0/12 0% 1/10 10% 0.46
ARF during admission 1/12 9% 2/10 20% 0.57
Shock during admission 3/12 25% 2/10 20% 1
* by Mann Whitney. APO: Acute pulmonary oedema, ARF: Acute renal failure
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Patients receiving gelofundin had a significantly greater increase in the cardiac index than 
those patients who received normal saline as the resuscitation fluid. Patients who received 
the colloid had a median increase of 1.07 L/min/m2 (95% Cl 0.66- 2.22) as opposed to a 
median increase of 0.38L/min/m2 (95% Cl 0.01 - 0.66) in the patients who received 
normal saline (p=0.006), this was despite the fact that there was no difference in the 
volume of fluid (median (95% Cl) that the two groups received: normal saline 818ml 
(500 - 1196), Gelofundin 1000ml (500-1000) (p=0.97). However, this did not translate 
into a statistically significant improvement in the D02, Cv02, V02, pH, base excess or 
lactate (Table 5.6).
There was no relationship between the volume of fluid administered and the patient’s 
outcome or their likelihood of developing shock, renal failure or pulmonary oedema. As 
would be expected, there was a significant relationship between the volume of fluid 
infused and the changes in the cardiac index (p=0.04, rs=0.41), haemoglobin (p=0.03, rs 
=-0.44), and the SVR (p <0.001, rs=-0.63). However, there was no relationship between 
the volume of fluid infused and the changes in acid - base status (ABE p=0.23, rs=-0.29, 
Alactate p=0.30, rs=-0.22, AHC03 p=0.24, rs=-0.28, ApH p=0.63, rs= -0.11).
There was no relationship between the CVP and PAoP on admission and cardiac output, 
oxygen delivery or acid/base status. After volume loading there was still no relationship 
between CVP and PAoP and these measures. The increase in CVP and PAoP with 
resuscitation was correlated with the increase in cardiac index, but there was no 
association between the change in CVP and PAoP and the changes in any other markers 
(Table 5.7).
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Table 5.6 Response to resuscitation agents at 24hrs
Variable Normal Saline Gelofundin p *
AMABP (mmHg) 1 (-4.7-4.9) 4.5 (-0.67-13.4) 0.19
ACVP (mmHg) 2.5 (0 -4 ) 5.5 (1 .3 -7 ) 0.07
APAoP (mmHg) 5.5 (2 .2-7 .8) 5 (3 .3 -9 ) 0.43
ACardiac index (L/min/m ) 0.38 (0.01 -0 .66) 1.07 (0.66-2.22) 0.006
ASVRI (dyne/s/cm'5m2) -127 (-281 --8 .4 ) -365(-712 - -30) 0.15
ASa02 (%) 0 (-0.2-1.34) -0.1 ( -0 .5 -1 ) 0.22
AHaemoglobin (g/dL) -0.7 (-1.6- -0.2) -1.1 (-3 -0 ) 0.37
ACv02 (%) 2.8 (-0.3-5.5) 4.7 (-0.9- 11.1) 0.55
ApH -0.02 (-0.04--0.01) 0 (-0.03 - 0 .03) 0.08
AHC03 (mmol/L) -0.2 (-1 .6 -1 ) 0 (-1.3 - 0.7A) 0.78
Abe -1 (-2.3- 0.3) -0.5 (-1.7- 1 A) 0.46
AD02 (mL/min/m2) 8.5 (-21-30) 67.5 (-27.9- 121) 0.11
AV02 (mL/min/m2) -9 (-34-6.3) -6.2 (-45.6-23.3) 0.74
A02ER (%) -2.5 (-5.9-0.9) -5.2 (-11.1-0) 0.32
ALactate (mmol/L) i p i 0
 
L
i 1 p VO -0.1 (-1.5-0.5) 0.7
* by Kruskal Wallis. A upper confidence limit held at maximum of sample. MABP: Mean 
arterial blood pressure, CVP: Central venous pressure, PAoP: Pulmonary artery occlusion 
pressure, SVR: Systemic vascular resistance, Sa02: Oxygen saturation, Cv02: Mixed 
venous oxygen saturation, D02: Oxygen delivery, V02: Oxygen consumption, 02ER: 
Oxygen extraction ratio
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Table 5.7 Correlation between ACVP and APAoP
Variable CVPA Rho* PAoPA Rho*
LactateA 0.56 -0.13 0.71 -0.08
BEA 0.88 0.03 0.62 0.13
HC03A 0.59 -0.14 0.85 -0.05
CIA 0.06 0.39 0.44 0.16
D02A 0.98 0.01 0.74 0.07
V02A 0.8 0.05 0.66 0.1
02ERA 0.69 -0.08 0.66 0.1
Cv02A 0.58 0.12 0.76 -0.07
MABPA 0.13 0.32 0.5 0.14
* Spearman’s rho, p value by Spearman’s.
CVP: Central venous pressure, PAoP: Pulmonary artery occlusion pressure, BE: Base 
excess, HC03: Bicarbonate, Cl: Cardiac index, D02: Oxygen delivery, V02: Oxygen 
consumption, 02ER: Oxygen extraction ratio, Cv02: Central mixed venous oxygen 
saturation, MABP: Mean arterial blood pressure.
165
A PAoP of 9-12 was used as the target for the resuscitation, and the baseline PAoP was 
correlated with the volume of fluid that was required to achieve this endpoint (p=0.001, 
rho=-0.57). However there was a great deal of overlap in these values, for instance in the 
5 patients with a PAoP of 4mmHg anything between 800ml and 2000ml of fluid was 
required to raise the PAoP to the target range. On the other hand, there was no 
relationship between the baseline CVP and the volume of fluid that was required to 
resuscitate the patient (Figure 5.2).
Figure 5.2 Relationship between baseline CVP and volume of fluid required to 
resuscitate patient
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There was no significant difference between the CVP of the patients who did and did not 
have pulmonary oedema on admission. The median CVP (95% Cl) of patients both with 
(n= ll) and without pulmonary oedema (n=32) was 3mmHg 95% (Cl: 0.7-4.2 and 2-4 
respectively, p=0.89 for a difference). Similarly there was no statistical difference in the 
PAoP of the two populations: the median PAoP (95% Cl) was 9mmHg (4-11) in patients 
with pulmonary oedema and 7mmHg (6-8) in those without the complication (p=0.71 for 
a difference). There were only two patients who developed pulmonary oedema during 
their admission, preventing meaningful analysis of this phenomenon, however 
examination of the 56 time points for which there were simultaneous CVP, PAoP and 
Pa02/Fi02 measurements, revealed no relationship between either CVP (p=0.55) or 
PAoP (p=0.77) and gas exchange.
When all of the simultaneous assessments of macrovascular function and acid base status 
were pooled, there were up to 76 time points for which data were available. There was no 
relationship between the oxygen delivery and the prognostic markers of pH, bicarbonate 
or base excess. There was a correlation between the mean arterial blood pressure 
(MABP) and pH (p=0.03, r=0.27), bicarbonate (p=0.01, r=0.34), and base excess 
(p=0.02, r=0.31), although if the 8 datapoints where the MABP was less than 60 were 
removed, there was no longer a correlation: pH (p=0.7, r=0.05), bicarbonate (p=0.31, 
r=0.15), and base excess (p=0.46, r=0.11).
DISCUSSION
Although this is a small series, reviewed retrospectively and not powered to detect 
differences between the treatment groups, it nonetheless raises some interesting issues in
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the fluid management of adults with severe malaria. Apart from the CVP and related 
PAoP (which was used to determine the need for a fluid load), and the Pa02/Fi02 ratio 
(significantly higher in those who were fluid loaded), there were no significant 
differences between the baseline characteristics of patients who received a fluid load and 
those who did not. Whilst it was anticipated that fluid loading would improve outcome 
and renal function in patients who were assessed as being hypovolaemic, the risk of both 
death and renal failure developing were absolutely, if not significantly, higher in the 
patients receiving a fluid load.
It has been suggested that fluid resuscitation can improve the acid base status of patients 
with severe malaria (Maitland, 2006), which is important, as acidosis is repeatedly noted 
to be a factor strongly associated with outcome (Day et al., 2000; WHO, 2000). Indeed, 
in our series, acid base status was the strongest predictor of death: those with a base 
excess less than -10, had 4 times the risk of death (95%CI 1.01 - 15.86, p=0.049), and 
those with a bicarbonate less than 15mmol/L had 6.5 times the risk of death (95% Cl 1.4 
-  29.7, p=0.02). However, in the 21 patients who had a base excess and bicarbonate 
measured before and after their fluid loading, the median values of these variables 
actually fell: -0.6 (95% Cl -1.2 - 0.1) and-0.2mmol/L (95% Cl -0.7-0.7mmol/L) 
respectively.
Patients who received a fluid load did have a rise in their cardiac index, and most had a 
rise in their oxygen delivery, so how do we explain the lack of improvement in their 
acidosis? The mechanical obstruction of the microvasculature is central to the 
pathophysiology of severe malaria (Dondorp et al., 2004), and has been demonstrated to 
link to acid base status (Dondorp et al., 2008). It may be that whilst fluid loading
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improves macrovascular status, it does little to overcome the synchronous microvascular 
sequestration. Indeed, this series supports this hypothesis; when data were pooled there 
was no statistical correlation between cardiac index, oxygen delivery and the markers of 
acidosis.
Could it be that the patients were just given inadequate volumes of fluid to correct any 
hypovolaemia? It would seem unlikely. After fluid loading the cardiac index had 
improved a median of 15% (95% Cl 5.4-21.5) and almost 90% of patients had a normal 
cardiac index. Even if we limit our analysis to the patients who had a low D02 prior to 
resuscitation the median change in BE was 0 (95% Cl -2.5-1), suggesting that fluid 
loading is doing little to change the marker of tissue perfusion most linked to outcome.
Another explanation for the lack of improvement in acid base status is the possibility that 
any improvement in the acidosis resulting from hypoperfusion has been offset by a 
hyperchloraemic metabolic acidosis induced by resuscitation with chloride rich saline and 
Gelofundin. In recent years, use of the physicochemical Stewart approach to acid base 
disturbance (Stewart, 1983) has increased the awareness that resuscitation with fluid of a 
supraphysiological chloride concentration, can lead to a metabolic acidosis through a 
reduction in the strong ion difference of plasma (Brill et al., 2002; Kaplan et al., 2005). 
Although the hyperchloraemic acidosis associated with resuscitation has not been 
conclusively linked to deleterious sequelae (Burdeet et al., 2003), it has been implicated 
in neurological dysfunction, coagulopathy, cardiac dysfunction, renal dysfunction and 
haemolysis (Burdeet et al., 2003). Unfortunately we lack sufficient data to make an 
assessment of the acidosis using the Stewart approach to further elucidate this 
relationship in this series.
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Another concern with fluid loading is that not only might it fail to overcome the 
mechanical obstruction in the microcirculation, but with the increased pulmonary 
capillary permeability present in severe malaria (Charoenpan et al., 1990; Taylor et al., 
2006), it may increase the risk of pulmonary oedema - a complication with a dismal 
prognosis in the resource poor setting. However in this small series only two patients 
developed this complication, one of whom received a fluid challenge and the other not, 
precluding any meaningful analysis.
The decision to fluid load patients, and the volume of fluid that was administered, was on 
the basis of the PAoP, a parameter strongly linked to the CVP. Since this study was 
performed, the weight of clinical opinion has turned against a reliance on pressure-based 
measures of preload to assess the patient’s volume status. Neither CVP nor PaOP are 
good predictors of fluid responsiveness in either healthy volunteers (Kumar et al., 2006) 
or hypovolaemic critically ill patients (Michard et al., 2002), and current opinion in the 
developed world is that neither of these indices should be used to define the state of 
ventricular filling or the potential of patients to respond to a fluid challenge (Pinsky, 
2005). In this series, there was no correlation between point measures of CVP and PAoP 
and cardiac index, oxygen delivery or acid base status, before or after fluid resuscitation. 
In addition to the observations about the potential limitations of CVP and PAoP being 
used as targets for resuscitation, there was no relationship between the CVP and PAoP 
and the presence of pulmonary oedema. There was also no relationship between the 
CVP/PAoP and the Pa02/Fi02 ratio. This accords with previous studies that have 
identified little correlation between pulmonary oedema and CVP (Edwards et al., 1993) 
or PAoP (Kumar et al., 2006), and is consistent with the hypothesis that pulmonary
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oedema in severe malaria is predominantly the result of increased pulmonary capillary 
permeability (Charoenpan et al., 1990). Whilst central lines offer secure access and a 
conduit for the administration of veno-irritant drugs, they are relatively expensive and 
may be associated with serious complications during insertion and maintenance. In view 
of the limited benefit that they appear to provide the clinician in managing the patient 
with severe malaria in this and other series, the WHO recommendation to use them 
appears ill founded.
At baseline the patients who received gelofundin were sicker than the patients who 
received saline. They had a lower pH, MABP, base excess, a higher lactate, and would be 
expected to have a higher mortality rate; but there was no significant difference in 
mortality (Krishna et al., 1994; Day et al., 2000). The patients who received gelofundin 
had a significantly greater increase in their cardiac index and a trend to an increased 
oxygen delivery, although there were no changes in base excess and bicarbonate. A large 
multicenter, randomised trial showed no difference between the 28 day outcomes in a 
heterogeneous group of ICU patients resuscitated with 4% albumin when compared with 
saline (Finfer et al., 2004). However, there are possible reasons why colloid may be 
beneficial in the specific case of severe malaria: by increasing osmotic pressure, colloid 
therapy might reduce the risk of both cerebral and pulmonary oedema (Maitland et al., 
2005). Furthermore, there are promising early results with the use of albumin therapy in 
paediatric series (Akech et al., 2006), although these results need to be replicated in 
prospective trials (Day, 2006; Planche, 2007). Our findings in the Gelofundin group are 
interesting in the light of this, though it must be noted that the possibility of a deleterious 
effect from normal saline loading cannot be dismissed and this has been one of the
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criticisms of the work of proponents of colloid resuscitation in the paediatric malaria 
population (Planche, 2005).
There are several flaws in our study that prevent the generation of strong 
recommendations based on its findings. The first and most obvious is that the small 
sample size limits the power of the study to detect subtle differences between the various 
groups, and the patients were managed according to clinical judgement rather than via a 
defined protocol. Although renal failure is a common complication of severe malaria 
(Trang et al., 1992) the median serum creatinine in this series of 309.4pmol/L (95% Cl 
225.7 - 413.6) is much greater than in other series; indeed 44% of the patients were 
anuric on admission. Patients with renal impairment might be expected to handle a fluid 
load poorly and thus our observation that these patients had little benefit from fluid 
loading may reflect their renal impairment rather than any haemodynamic manifestations 
of their severe malaria. If fluid administration is guided by suboptimal markers of volume 
status -  in this series CVP and PAoP -  it may not be unsurprising that the results are 
poor. The number of patients with severe renal dysfunction also complicates 
interpretation of the acid-base data. Most patients in the series received quinine or 
intramuscular artemether as their anti-malarial agent -  both therapies have now been 
superseded by intravenous artesunate - and thus the mortality rate in the series is higher 
than we might expect if the patients were managed with this newer agent.
Despite these caveats there are several observations worth making. The first is that while 
almost all adults with severe malaria will require intravenous fluids, the results of this 
study do not predict significant improvements in acid base status and outcomes with fluid 
resuscitation. The role of fluid resuscitation remains unclear, and although many will
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have true or at least effective hypovolaemia on admission, a more conservative fluid 
regimen may turn out to be preferable, as has been demonstrated in other patients with 
ARDS and septic shock (Alsous et al., 2000). The results with the colloid resuscitation 
are interesting in light of the results with albumin-based resuscitation published in the 
paediatric literature. However, as in the paediatric population, there would need to be 
prospective randomised clinical trials to conclusively determine if there is any benefit 
with colloid therapy, and importantly to exclude the possibility of a deleterious effect 
from saline resuscitation (Molyneux et al., 2005; Kaplan et al., 2005). On the other hand, 
while concerns have been raised about the cost of colloid solutions, when compared with 
other therapies being instituted in the developing world at present such as anti-retroviral 
therapy for HIV/AIDS (Bradi et al., 2006), and other interventions proposed for severe 
malaria such as haemofiltration (Phu et al., 2002), any clear clinical benefit of colloid 
may be highly cost effective.
Despite malaria claiming the lives of thousands of adults every year, little is known about 
the optimal supportive therapies for these patients. Whilst the search for adjunctive 
therapies continues, much could be gained by optimising the use of the relatively cheap, 
widely available and easy to administer interventions already available -  including 
intravenous fluids. High quality trials are urgently needed to determine the utility and 
safety of fluid resuscitation in severe malaria and the clinical features present in those 
who require fluid resuscitation. Such trials have already been performed in Dengue Shock 
Syndrome and simple, safe resuscitation protocols for this disease are now published 
(Wills et al., 2005). It must be remembered that the vast majority of patients with severe 
malaria will be managed in a resource poor setting, often by relatively inexperienced 
health care providers, with limited intensive care support. Resuscitation protocols would
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need to be tailored to this environment to provide appropriately easy to implement, 
practical guidelines for these practitioners.
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CHAPTER 6
PARASITE STAGING AND PREDICTING 
OUTCOME IN SEVERE FALCIPARUM MALARIA
INTRODUCTION
Severe malaria is a multisystem disease requiring intensive care management. The 
assessment of disease severity is based on the multi-organ dysfunction, the 
haematological and biochemical indices, and the parasitaemia (WHO, 1986, 1990, 2000 
and 2006). Admission peripheral blood smears are an important indicator of prompt 
treatment, and can be performed quickly (White and Silamut, 1989). The relationship 
between parasite counts and mortality in falciparum malaria was first described in 1937 
(Field and Niven, 1937), and since then parasitaemia has been used for outcome 
prediction. The correlation between parasite count and prognosis varies at different levels 
of malaria endemicity. Patients who live in moderate or high transmission likely tolerate 
higher parasitaemia (WHO, 2006). Some patients had died with low parasite density 
(Fitz-Hugh et al., 1944). Pathophysiological and pathological features of severe 
falciparum include sequestration, cytoadherance, rosetting formation and reduced red cell 
deformability (MacPherson et al., 1985; White, 2003), thus the disease severity is related 
more to the number of parasites sequestered than to the number of immature ring forms 
that are seen in the peripheral blood (White and Ho, 1992). The morphology of parasite 
development in peripheral blood films can be used as a reflection of the proportion of 
infected red cells sequestered in the microvasculature of vital organs (White and Krishna, 
1989; White et al., 1992). The stage of parasite development on the admission blood
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slide provides important prognostic information in severe falciparum and previous 
malaria treatment with quinine did not appear to alter the stage distribution of parasites 
(Silamut and White, 1993). However the effects of antimalarial drugs other than quinine 
on the distribution of stage development were as yet unknown. In recent years, 
antimalarial drugs such as quinine, mefloquine, chloroquine, artemisinin and its 
derivatives, have been used widely in Viet Nam for the treatment of falciparum malaria. 
Artemisinin and its derivatives are the most rapidly acting antimalarials known to-date 
and are well tolerated. By acting on ring stages, they clear peripheral parasitaemia more 
quickly than other antimalarial drugs and prevent the development into mature 
sequestering blood stages (White and Olliaro, 1998). I conducted the present study to 
assess the stage distribution of malaria parasite on admission peripheral blood films of 
untreated and treated patients and its relationship with the prognosis in severe malaria.
PATIENTS AND METHODS
The study was conducted in the Malaria Research Unit, Hospital for Tropical Diseases, 
Ho Chi Minh City and was approved by the hospital's Scientific and Ethical Committee. 
Informed consents were obtained from the patients or their accompanying relatives.
Patients were included in had asexual forms of P. falciparum on a peripheral-blood 
smear, were older than 14 years, were not in the first trimester of pregnancy, were not 
intravenous drug users, had received less than 3g of quinine or two doses of artemisinin or 
a derivative in the previous 48 hours, and had one or more of the following: a score on the 
Glasgow Coma Score of less than 11 (indicating cerebral malaria); anaemia (haematocrit, 
<20 percent), with a parasite count exceeding 1 00,000 per microlitre on a peripheral- 
blood smear; jaundice (serum bilirubin, >2.5mg per deciliter [50pmol per litre]), with a
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parasite count of more than 100,000 per microlitre on a peripheral-blood smear; renal 
impairment (urine output, <400ml per 24 hours; and serum creatinine, >3mg per decilitre 
[250pmol per litre]); hypoglycaemia (blood glucose, <40mg per decilitre [2.2mmol per 
litre]); hyperparasitaemia (>10 percent parasitaemia); and systolic blood pressure below 
80mmHg with cool extremities (indicating shock). Patients were also excluded if there 
was known allergy to one of the artemisinin derivatives or quinine. All patients were 
managed with similar intensive care and by the same staff throughout the study.
Parasite counting and staging
Blood was obtained by a finger-prick for hematocrit measurements and blood smears on 
admission, and every 4 hours for the first 24 hours and every 6 hours until three 
consecutive smears were negative for asexual stages of P. falciparum. Thick films were 
stained with Giemsa's stain and thin films with Field's stain. The degree of parasitemia 
was determined on the basis of the number of parasitized red cells per 1,000 red cells (thin 
film) or the number of parasites per 400 white blood cells (thick film). Blood smears were 
examined microscopically under oil immersion at a magnification of x 1,000. Parasite 
counts were derived from the percentage thin film parasitaemia and an estimate of the red 
cell count derived from the admission haematocrit (haematocrit x 125,000/pL). Thick 
film counts were obtained assuming a white blood cell count of 8,000/pL. The slides 
were also divide into groups based on the basis of parasitaemia, whether < 1%, 1-5%, 5- 
10%, or > 10%. Each slide was examined independently by two microscopists, and the 
smears were re-read if there was a disagreement of assessement.
All slides were staged by two experienced microscopists who did not know the severity 
of the patients. One hundred randomly parasites were assessed from the tail of each slides 
for staging. The stage of parasite development is graded into 8 stages, using a
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modification of the method described by Silamut et al., 1999 (Figure 6.1). Thin film was 
used whenever possible, as morphology was easier to categorize. Parasites with bizarre 
forms were not staged. Gametocytes were noticed but excluded in analysis. The 
distribution of parasite stage from slides of survivors was compared to those of fatal 
cases. The comparison between untreated and treated patients was also observed.
Figure 6.1 The stage of malaria parasite development (reproduced from Silamut, 
1999 with permission)
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Tiny ring form (estimated age = 0-6 h): The width of cytoplasm band was less than half 
of the diameter of the nucleus.
Small ring form (estimated age = 6-16 h): The width of cytoplasm band was equal to, or 
greater than, half of the diameter; but less than of the diameter of the nucleus.
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Large ring form (estimated age = 16-26 h): The width of cytoplasm band was equal to, or 
greater than, the diameter of the nucleus.
Early trophozoite (estimated age = 26-30 h): The cytoplasm was a blue mass containing 
little brown pigment first visible pigment.
Middle trophozoite (estimated age = 30-34 h): Nucleus and cytoplasm enlarged. 
Cytoplasm became dark with brown pigment.
Late trophozoite (estimated age = 34-38 h): Cytoplasm became spherical with brown 
pigment. No more than 2 irregular shaped nuclei evident.
Schizont (estimated age = 38-44 h): Dark brown pigment with 3-5 nuclei clearly visible. 
Red cell cytoplasm was paler.
Schizont (estimated age = 44-48 h): Dark brown pigment with more than 5 nuclei clearly 
visible. Red cell cytoplasm was paler.
Statistical analysis
Results were entered into a database (Microsoft Excel, Microsoft Corp, USA) and 
analyzed with a statistical software package (Stata 10, StataCorp, Texas, USA). Stage 
distributions were described by using analysis of raw data, stratified data by admission 
parasitaemia, and by comparison of the distribution of mode value. These distributions 
were compared by Kolmogorov-Smimov equality of distribution test. Because the total 
parasite counts on admission were not normally distributed, we presented the geometric 
mean for log transformation of these variables with 95% Confident interval (Cl). All 
significant tests were set at p< 0.05.
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RESULTS
A total of 370 cases of severe malaria were studied. There were 333 admission slides 
from survivors and 37 slides from fatal cases. The geometric mean admission total 
parasite counts (per pL) were 69,587 (95% Cl 26,155 -  185,139) in the fatal cases, 
26,991 (95% Cl 19,409 -  37,534) in survivors. The different between both groups was 
not significant (p> 0.05). There were 76 slides missing staging information because the 
parasite counts were too low for accurate assessment, or the stage assessment was 
difficult due to inappropriate staining. The total number of slides using for analysis was 
294 (31 from fatal cases (10.5%)).
Parasite age distribution Overall the stage distribution of malaria parasites from 
survivors was shifted towards young ring forms. Tiny rings comprised > 50% of parasites 
in 159/263 survivors compared with 11/31 in fatal cases. Late parasite forms 
(trophozoites and schizonts) carried a poor outcome (Table 6.1).
Table 6.1 Stage distribution and mortality: number of patients in each group.
Died Survived OR (95%CI)
Number 31 263
Proportion in blood
film
>50% tiny rings 11 (35.5) 159 (60.1) 0.36(0.17-0.78)
> 10% trophozoites 16(51.6) 85 (32.3) 2.2 (1.1 -4.7)
>20% trophozoites 14 (45.2) 57(21.7) 3.0 (1.4-6.4)
>1% schizonts 6(19.3) 23 (8.9) 2.5 (0.93 - 6.7)
This shift towards younger forms in survivors was also stated in the distribution of modal 
stages (the most frequent stage), but there was not significant difference between fatal 
cases and survivors (Table 6.2; Figure 6.2 and 6.3).
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Table 6.2 Comparison of synchronicity using means of modal stage.*
Synchronicity N Died 
Mean (SD)
N Survived 
Mean (SD)
p- value
<1% 3 42.3 (22.5) 58 60.3 (20.3) 0.14
1-5% 10 50.9(19.6) 80 59.3 (21.6) 0.26
5-10% 8 63.4 (24.4) 45 64.6(19.0) 0.88
>10% 9 57.3 (23.6) 60 67.7(17.2) 0.11
30 243
* An additional 21 with no RBC parasitaemia information; n for analysis = 273 (30 
(11% died))
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Figure 6.2 Stage distribution of parasites, divided according to admission
parasitaemia.*
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Figure 6.3 Stage distributions of parasites, divided according to admission 
parasitaemia
Variable
Survived
(n=58)
Died
(n=3)
tiny 0.54 0.11
small 0.22 0.27
large 0.06 0.17
early 0.05 0.15
middle 0.04 0.18
late 0.06 0.10
Comparison of distributions by Kolmogorov-Smimov test, p = 0.03
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■ Survived
middle
Variable
Survived
(n=80)
Died
(n=10)
tiny 0.50 0.42
small 0.23 0.22
large 0.10 0.10
early 0.07 0.08
middle 0.04 0.07
late 0.03 0.08
Comparison of distributions by Kolmogorov-Smimov test, p = 0.47
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late 0.003 0.06
Comparison of distributions by Kolmogorov-Smimov test, p = 0.47
* An additional 21 with no RBC parasitaemia information; n for analysis = 273 (30 
(11% died)); category
‘Late’ includes late trophozoites combined with schizonts.
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Effect o f previous treatment on stage distribution: Since 1990 there has been widespread 
use of a wide range of antimalarial drugs in Viet Nam. Artesunate, quinine, chloroquine 
and mefloquine could be administered in any health centres and even in private sectors as 
well. Many patients had antimalarial drugs before admission to HTD. In our study a 
number of 142 (52%) patients had been treated with one or two antimalarials before 
admission, and 17 patients did not know which drug they had taken. I was not able to 
measure the admission plasma level of any antimalarial drug. The stage distribution of 
parasites were compared in each non pretreated and pretreated groups (Figure 6.4)
Figure 6.4 Stage distributions of parasites, divided according to pre-treatment
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(n=99)
Died
(n=15)
tiny 0.54 0.40
small 0.25 0.26
large 0.07 0.15
early 0.04 0.08
middle 0.03 0.03
late 0.04 0.05
Comparison of distributions by Kolmogorov-Smimov test, p = 0.47
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With Pre-treatment
■ Survived
Variable
Survived
(n=132)
Died
(n=10)
tiny 0.56 0.48
small 0.21 0.18
large 0.07 0.07
early 0.05 0.07
middle 0.04 0.08
late 0.03 0.08
Comparison of distributions by Kolmogorov-Smimov test, p = 0.47
NOTE: there were an additional 17 pts with no pretreatment data excluded from this
analysis
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DISCUSSION
In 1894 the Italian researchers noticed the difference between the number and stages of 
malaria parasite development in the peripheral blood and the brain of fatal cases 
(Marchiafava and Bignami, 1894). Only the younger forms of P. falciparum were seen in 
the blood films and the mature stages were noted in the cerebral vessels. Sequestration 
occurs in falciparum infection and is the patholophysiological feature of severe malaria 
(White and Ho, 1992). In contrast all stages of parasite development may be seen in 
peripheral blood smears of P. vivax, P. ovale and P. malar iae infections (Field and Shute, 
1956; Garnham, 1966) and those infections are very rarely fatal. The use of 
hyperparasitaemia as criteria for the diagnosis of severe malaria has been recommended 
by WHO (WHO, 1996, 2000, 2006), but peripheral falciparum parasitaemia alone 
provides limited information about the disease severity and outcome. Thick blood film 
examination was less sensitive and may underestimate the parasite density (Bejon et al., 
2006). Hyperparasitaemia (over 100,000/pL) was correlated with increased mortality 
(Field and Niven, 1937) and the presence of schizonts in the peripheral smears is a poor 
prognosis, particularly if accompanied by hyperparasitaemia (Field, 1949), but a 
predominance of mature trophozoites and schizonts were also seen in peripheral blood of 
mildly ill immune adults (Raper et al., 1945; Schwetz, 1949). High schizont count in 
peripheral blood smear in uncomplicated .pialaria was indicative of potential deteriotation 
(Lwin et al., 2008). Recent study showed that the prognostic significance of 
schizontaemia depended largely on the overall age distribution of parasites. 
Schizontaemia was a specific indicator of poor outcome, but was not sensitive. In this 
study, we did not use the method described by Jiang et al in 1982, in which asexual 
parasites were graded for stage of development into 5 stages (tiny rings, small rings, large 
rings, mature trophozoites and schizonts). I found that using the modified method of
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Silamut et al. was difficult to differentiate between early and middle trophozoites.when 
observing on thick films.
A predominance of older parasites carries a worse prognosis and it may reflect a 
relatively greater sequestration of parasitized red cells (Silamut and White, 1993). The 
effect of parasite age development was examined independently from parasitaemia, and 
the results from our study again suggest that a predominance of tiny ring forms (more 
than 50% tiny rings in blood film) carries a better prognosis in severe falciparum malaria 
than a predominance of older parasites because it reflects a relatively lower sequestration 
(Table 6.1). The difference was not significant at any group of parasitaemia (Table 6.2), 
presumably because the sample size was small.
The sequestered parasite biomass, calculated from parasite derived plasma PFHRP-2 
concentrations, correlates with disease severity (Dondorp, 2008) but laboratory 
measurement equipment is needed. Parasite staging only needs direct microscopic 
observation. Moreover, the dominant clones of parasite sequestered in deep organs are 
ussually the same as those in peripheral circulation (Dembo et al., 2006). There are very 
few studies focusing on the relation of the stage of malaria parasite development in the 
peripheral blood to the prognosis of severe falciparum malaria. Parasite staging has not 
been recognised yet as a predictor of outcome. This might be because it is easier to 
conduct the parasite count, which takes less time to perform than the technique of parasite 
staging, and currently there are not many microscopists interested in this feature.
The effects o f antimalarial drugs on the stage distribution'. The shift to more mature 
forms in fatal groups was evident in both non pretreated and pretreated patients (Figure 
6.3). The result suggests that previous treatment did not alter the stage distribution 
although most of patients had received artemisinin derivatives (39.4% 56/142 treated
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patients) in 48 hours before admission, and there were 8 pretreated patients received 
artemisinin derivarives among 10 fatal cases of treated group. This finding should be 
interpreted with some caution as a high proportion of artesunate in pharmaceutical 
markets in Viet Nam has been found to be counterfeit.
The conclusion of this study was similar to that of the study of Silamut et al. in 1993 that 
there was a relationship of the stage of parasite development in the peripheral blood with 
the severity of malaria disease. A poor outcome should be considered if more mature 
parasites are detected in peripheral smears at any parasitaemia on admission. Further 
prospective studies are needed to determine the applicability of this finding.
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CHAPTER 7
PREDICTIVE SCORE OF OUTCOME IN ADULTS W ITH SEVERE 
FALCIPARUM MALARIA
INTRODUCTION
Severe falciparum malaria remains one of the most important causes of death in the 
tropics. The increasing prevalence of multi-drug resistant falciparum parasite strains is a 
great problem in terms of reducing morbidity and mortality. Severe malaria results in 
serious complications and mortality. Among factors probably contributing factors to this 
high mortality are delayed diagnosis and inappropriate treatment. A reliable malaria 
severity score may help to predict the outcome of severe patients, and facilitate early 
transfer to an appropriate intensity of care. The common definition of severe malaria is 
that recommended by the World Health Organization and based on the presence of 
clinical and laboratory features (WHO, 1996, 2000 and 2006). It has been known that 
some vital organs such as the brain, kidneys, liver and lungs are affected in severe 
malaria. Even with specific antimalarial treatment, vital organ dysfunction will lead to the 
death of patient if these complications are not been immediately treated and resolved. The 
risk of death from severe malaria is very high in the first 2-3 days. In Viet Nam, as in 
other malaria endemic countries, most of severe malaria patients are firstly admitted in 
rural village or district health settings where laboratory facilities and supportive 
treatments are limited. Many outcome predictors have been identified in severe malaria, 
including hyperparasitaemia, schizontaemia, impaired consciousness associated with
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repeated convulsions, respiratory distress, hypoglycaemia, lactic acidosis and acute renal 
failure (Field and Niven, 1937; Molyneux et al., 1989; Trang et al., 1992; Krishna et al., 
1994; Marsh et al., 1995; Dondrop et al., 2004). A predictive score for the development 
of uncomplicated falciparum malaria into severe malaria was published recently 
(Tangpukdee et al., 2007). However there are few studies focusing on the scoring for 
predictive outcome in severe malaria. The objective of this study is to devise a simple 
Malaria Severity Score (MSS) that would help the clinicians to identify the adult malaria 
patients at high risk of death and which might be used as an indicator for referral to 
highest level of health care setting.
PATIENTS AND METHODS
A logistic regression model was built to assess the probability of death using data from 
two studies on severe falciparum malaria in the Hospital for Tropical Diseases (HTD) 
that compared the efficacy of antimalarial drugs. The first study was conducted to 
compare the effects of artemether and quinine (Hien et al., 1996) and the subsequent 
study in which artesunate was compared with artemether (Chapter 3). Severe malaria was 
defined with the same criteria in both studies (WHO, 1990). Because the clinical 
manifestations of severe malaria are different in children and due to the initial protocols 
of both studies, patients below the age of 15 were excluded from our prediction model. 
Both studies were approved by the Scientific and Ethical Committee of HTD. Informed 
consent was obtained from all patients or their accompanying relatives.
Statistical analysis
Results were entered into a database (Microsoft Excel, Microsoft Corp., USA) and 
analysed with a statistical software package (Stata 10, Stata Corp., Texas, USA). Using 
death as the dependant variable, an initial model was set up including all variables used
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by the WHO to define severe malaria (WHO, 1990, 2006) as potential predictors 
(independent variables). A total of 19 admission clinical and laboratory parameters of 
patients were used for analysis. Univariate analysis was performed to examine variables 
associated with death, using the Mann-Whitney U-test for continuous variables. 
Multivariate logistic regression was used to model the probability of death, with the 
results of univariate analysis guiding data selection. Stepwise forward entry logistic 
regression was used to select variables associated with poor outcome and to find 
independent predictors with p-to-enter of < 0.05 and p-to-reject > 0.051. Continuous 
variables were transformed into categorical variables and entered into the model. The 
performance of the new score was assessed, sensitivity, specificity and the area under the 
Receiver Operator Characteristic (ROC) curve was calculated.
The clinical parameters associated with deaths and survivals were compared by using 
Chi-square or Fisher exact test; risk verification was expressed with Odds ratio (OR) and 
95% Confident interval (Cl).
Acidosis (as base excess) was not included because arterial blood gases were not 
routinely measured. Age was included because it was reported to be associated with poor 
outcome (Molyneux et al., 1989; Marsh et al., 1995; Dondorp et al., 2008), although most 
severe malaria cases were seen in Viet Namese adults. Pregnancy was also not included 
due to the protocols of both studies.
RESULTS
A total of the 975 adult patients were enrolled in both studies. Of these patients, 931 
cases subsequently fulfilled the defined WHO criteria for severe malaria. I compared 
characteristics on admission using univariate analysis (Table 7.1). A review of admission
194
criteria confirmed that 42 patients had moderately severe malaria, and 2 patients were 
drug abusers. The differences in mortality rate were not significant between the 
artemether group and the quinine group (13% vs. 17%, p= 0.16 in the first study) (Hien et 
al., 1996), and between the artemether group and the artesunate group (13% vs. 7%, p=
0.52 in the second study) (see Chapter 3), thus the treatment with these artemisinin 
derivatives was not excluded. I compared characteristics on admission using univariate 
analysis. Among continuous data, age, temperature, Glasgow Coma Scale, respiratory 
rate, parasitaemia, serum creatinine, serum bilirubine, white blood cell count, platelet 
count and blood lactate were significantly different between who died and those who 
survived (Table 7.1). All categorical data such as pre-treatment with antimalarial drugs, 
previous malaria infection, convulsions, pulmonary oedema, spontaneous bleeding, 
except sex were also significantly different between the two groups (Table 7.2). Because 
of the widespread use of antimalarial drugs and the relationship between pre-treatment 
and outcome, the dataset was divided into two groups (pretreated or non pretreated) and 
the number of patients was reduced because there were 24 with missing data. The final 
logistic model with independent predictors of the two groups was described in Tables 7.3 
and 7.4. To create the severity score of each group all significantly continuous variables 
were transformed to categorical variables. The final severity score of each group is 
calculated from the total of individual section score. For the non pretreated group, MSS 1 
was from 0 to 6, with Glasgow Coma Scale have a maximum score of 2 (Tables 7.5), and 
a cut point of 4 was selected to divide “predicted survival” from “predicted death” (with 
> 4 indicating predicted death), with the sensitivity was 70.7% (95% Cl: 54.4-83.8), the 
specificity was 90.5% (95% Cl: 85.9-94.0) and AUC = 0.84. For pre-treated group, MSS 
2 was from 0 to 4 (Table 7.6), a cut point of 2 was selected with > 2 indicating predicted 
death, in order to optimize sensitivity (77.7%, 95% Cl: 64.4-87.9), specificity (69.0%,
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95% Cl: 64.5-73.2) and AUC = 0.80. Each MSS had different cut-off points to optimize 
sensitivity and specificity.
Table 7.1 Results of univariate analysis of continuous data for symptoms present on 
or before admission to hospital. Values are median (interquartile range)
n Survived Died p-value
Age (years) 931 30 (22-41) 35 (26-45) <0.0016
Temperature (°C) 925 38.5 (37.5-39) 38 (37-39) <0.023
Systolic BP (mmHg) 929 110(100-120) 110(100-120) <0.80
Glasgow Coma Scale 931 11 (8-15) 9(7-13) <0.0000
Respiratory Rate(/min) 931 28 (24-32) 32 (28-40) <0.0000
Parasitaemia (/pi) 930 72094 114045 <0.0097
(12057-300435) (35168-384959)
Haematocrit (%) 931 31 (25-37) 30 (27-37) <0.33
Blood glucose (mg/dL) 928 94.5 (74-122) 90 (60-134.5) <0.31
Serum creatinine (mg/dL) 915 1.85 (1.3-3.09) 3.15(1.87-5.4) <0.0000
Serum bilirubine (mg/dL) 791 3.6(1.8-8.6) 8.5 (3.2-14.8) <0.0000
White blood cell count (/pi) 893 8000 11850 <0.0000
(5800-11000) (9200-16000)
Platelet count (/pi) 864 60000 40000 <0.0000
(38000-90000) (26000-78000)
Blood lactate (mmol/L) 878 3.1 (1.9-4.6) 5.9 (3.4-10.2) <0.0000
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Table 7.2 Results of univariate analysis of categorical data for symptoms present on 
or before admission to hospital.
Proportion dying
(n=931)
n % p-value
Sex 0.27
Male 96/701 13.69
Female 25/230 10.87
Previously infected malaria 0.009
No 52/320 16.25
Yes 39/400 9.75
Pre-treated 0.021
No 49/298 16.44
Yes 67/609 11.00
Convulsion 0.019
No 102/840 12.14
Yes 19/91 20.88
Pulmonary oedema 0.000
No 108/898 12.03
Yes 13/33 39.39
Spontaneous bleeding 0.000
No 62/751 8.26
Yes 59/180 32.78
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Table 7.3 Multivariate logistic regression analysis of admission data (non 
pretreated patients)
OR (95% Cl) p-value
Glasgow Coma Scale 2.503 (1.356-4.620) 0.003
High white blood cell count 2.863 (1.264-6.480) 0.012
Spontaneous bleeding 2.944 (1.279-6.773) 0.011
Renal failure 3.473 (1.385-8.706) 0.008
Hyperlactataemia 2.847 (1.273-6.370) 0.011
Table 7.4 Multivariate logistic regression analysis of admission data (pretreated 
patients)
OR (95% Cl) p-value
Jaundice 3.910 (1.456-10.495) 0.007
Spontaneous bleeding 4.724 (2.515-8.871) 0.000
Renal failure 2.605 (1.356-5.003) 0.004
Pulmonary oedema 3.014 (0.963-9.425) 0.058
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Table 7.5 Malaria Severity Score 1 (MSS 1) for non pretreated patients
Score
Glasgow Coma Scale 
= 15 0
11-14 1
<10  2
High white blood cell count (> 10,000/pL)
No 0
Yes 1
Spontaneous bleeding 
No 0
Yes 1
Renal failure (serum creatinine > 3 mg/dL)
No 0
Yes 1
Hyperlactataemia (plasma lactate > 4 mmol/L) 
No 0
Yes 1
Total MSS 1 < 4 = predicted survival 
Total MSS 1 > 4 = predicted death
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Table 7.6 Malaria Severity Score 2 (MSS 2) for pretreated patients
Score
Jaundice (total bilirubinaemia > 2.5 mg/dL)
No 0
Yes 1
Spontaneous bleeding
No 0
Yes 1
Renal failure (serum creatinine > 3 mg/dL)
No 0
Yes 1
Pulmonary oedema
No 0
Yes 1
Total MSS 2 < 2 = predicted survival 
Total MSS 2 > 2 = predicted death
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DISCUSSION
Rapid diagnosis and prompt treatment are crucial to prevent the development of 
complications in malaria infection. An accurate and inexpensive way of assessing levels 
of severity of severe malaria is also very important to reduce the mortality because it can 
help the physician at resource-poor settings to decide whether further supportive 
treatment is needed or whether the patient needs referring to the next level of health care. 
A Malaria Prediction Score was introduced in 2007 by using 5 variables such as age, 
serum creatinine, haemoglobinaemia, presence of cerebral malaria or pregnancy or 
ventilatory support (Mishra et al., 2007). In Viet Nam, jaundice and acute renal failure 
have been more often seen most of complicated malaria cases were in adults, and health 
care facilities at district level are limited. The mortality rate of severe falciparum malaria 
admitted to the Hospital for Tropical Diseases has declined markedly since early 2000, 
which was from 50-70% as reported in the decade of 1990 dropping to below 10%. In 
2005, there were only 22 hospitalized severe malaria cases, and none of them was fatal. 
However, the mortality rate increased from that year to 2008. It was 2.9% in 2006, 6.6% 
in 2007, and 7.1% in 2008 (HTD, unpublished data). Most of the fatal cases were referred 
from remote health centres and had severe complications such as deep jaundice, acute 
renal failure and lactic acidosis which might represent some explanation for this outcome. 
To take some examples, the patients had arrived to the first health station for seeking 
antimalarial drugs too late, the junior doctors seldom thought that their patients had 
malaria, which resulted from the fact that malaria incidence had decreased dramatically in 
Viet Nam. Another reason was that the doctors delayed referring their severe patients to 
the higher level hospitals due to their failure to predict the severity of with an absence of
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ventilators, blood gas measurement machines and dialysis capability. This tendency for 
the mortality rate of severe malaria tends to increase again in the recent years has made it 
is necessary to develop the Malaria Severity Score (MSS). The assessment indicators 
should be developed for the health care system where resources are limited, but the health 
officers can apply them in making their decisions on whether to retain their patients for 
further treatment at their sites or to transfer the patients to a well-equipped hospital.
I used data from two clinical studies which included detailed clinical and laboratory 
assessments and derived severity scores based on clinical signs and simple laboratory 
features. The univariate analyses showed that 15 variables were significantly associated 
with outcome, but only 7 independent predictors were selected due on multivariate 
analysis (Tables 7.5 and 7.6). The MSS 1 or MSS 2 can be easily applied in any district 
health settings. The new two MSS can be used in routine clinical practice to identify 
high-risk malaria patients to be transferred to higher levels of intensive care available, 
although further validation is needed in different settings.
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CHAPTER 8
ASSESSMENT OF THE EFFICACY OF THE ARTEMISININ 
DERIVATIVES IN THE TREATMENT OF SEVERE FALCIPARUM 
MALARIA IN VIET NAM 1991-2008
INTRODUCTION
Since 1995 Viet Nam has been one of the first countries to decide to use artemisinin and 
its derivatives for the treatment of falciparum malaria, although the effect of these 
antimalarials had not been widely studied. Remarkably China was the only manufacturer 
of these drugs at that time. The reason for Viet Namese authorities making that decision 
was the high morbidity and mortality of malaria in the population. Although antimalarials 
such as quinine and mefloquine were available at all levels of the health care system, 
clinical trials had shown artemisinin and its derivatives to be the useful alternative to 
quinine; which was why artemisinin and its derivatives became the national first-line 
treatment of falciparum malaria since 2000. After 15 years of using these antimalarials, 
there was a need to know whether artemisinin resistance has emerged in Viet Nam. 
Recent clinical and molecular studies suggested the emergence of ACT-resistant P. 
falciparum infections along the Cambodia-Thailand border (Wongscrichalanai et al., 
2006; Lim et al., 2009). Widespread and uncontrolled use of artemisinin could result in 
improper dose schedules and poor compliance, which in turn, might cause primary 
treatment failure, recrudescences and unexpected resistance to the drug. Such problems 
can be avoided or managed by regulating and monitoring its use. In 1989, the first 
preparation of artemisinin used in the Hospital for Tropical Diseases of Ho Chi Minh
City (HTD) was a suppository (Figure 8.2). Since 1995, artemisinin and its derivatives 
have been used as the main treatment for both uncomplicated and severe falciparum 
malaria, and the use of quinine has reduced. Hence, we conducted this preliminary study 
to investigate the parasite clearance time (PCT) from all severe malaria cases admitted to 
the Hospital for Tropical Disesases, Ho Chi Minh City between 1991 and 2008, and to 
monitor the efficacy of artemisinin derivatives over the years.
PATIENTS AND METHODS
Four therapeutic studies on severe malaria were conducted in the Hospital for Tropical 
Diseases, Ho Chi Minh City between 1991 and 2008: intramuscular (i.m.) artemether vs
i.m. quinine (AQ study -  Hien et al., 1996), i.m. artemether vs i.m. artesunate (pilot 
study) in 1996 (SMD -  Unpublished data), i.m. artemether vs i.m. artesunate (AAV -  
Manuscript in preparation), intravenous artesunate between 2005 and 2008 (FK -  
Manuscript in preparation). All these studies took place on the same clinical ward, with 
essentially the same staff and followed identical procedures and so I believe the results 
are comparable. Patients were included in the studies if they (or an accompanying 
relative) gave informed consent, had asexual forms of P. falciparum on a peripheral- 
blood smear, were older than 14 years, were not in the first trimester of pregnancy, were 
not intravenous drug users, had received less than 3g of quinine or two doses of 
artemisinin or a derivative in the previous 48 hours, and had one or more of the 
following: a score on the Glasgow Coma Scale of less than 11 (indicating cerebral 
malaria); anaemia (hematocrit, <20 percent), with a parasite count exceeding 100,000 per 
cubic millimetre on a peripheral-blood smear; jaundice (serum bilirubin, >2.5mg per 
decilitre [50pmol per litre]), with a parasite count of more than 100,000 per cubic
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millimetre on a peripheral-blood smear or with serum creatinine, >3mg per decilitre 
[250pmol per litre]; renal impairment (urine out put, <400ml per 24 hours; and serum 
creatinine, >3mg per decilitre [250pmol per litre]); hypoglycaemia (blood glucose, 
<40mg per decilitre [2.2mmol per litre]); hyperparasitaemia(>10 percent parasitaemia) or 
parasite count of more than 500,000 per cubic millimetre; plasma lactate > 4mmol per 
litre; arterial pH < 7.34 with standard base excess < -5mmol per litre; and systolic blood 
pressure below 80 mmHg with cool extremities (indicating shock).
These studies were approved by the Ethical and Scientific Committee of HTD.
Blood was obtained by a finger-prick for haematocrit measurements and blood smears 
every 4 hours for the first 24 hours and every 6 hours until three consecutive smears were 
negative for asexual stages of P. falciparum. The degree of parasitaemia was determined 
on the basis of the number of parasitized red cells per 1,000 red cells (thin film) or the 
number of parasites per 400 leukocytes (thick film).
Artesunate was given in a dose of 2.4mg/kg body weight on admission, and then 
1.2mg/kg was given daily until oral medication could be taken reliably. Each 60mg vial 
contained anhydrous artesunic acid that was dissolved initially in 1ml 5% sodium 
bicarbonate and then mixed with 5ml of 5% dextrose before injecting.
Artemether (50mg per millilitre; Kunming Pharmaceutical Company, Kunming, P 
People’s Republic of China) was given in a dose of 3.2mg/kg body weight on admission, 
followed by 1.6mg/kg daily until oral medication could be taken.
Both drugs were given intramuscularly to the anterior thigh in AQ, AAV and SMD 
studies. Artesunate was given intravenously in the FK study.
The blood level of any antimalarial drugs before admission was not measured.
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Statistical analysis
Data were entered into a database (Microsoft Excel, Microsoft Corp., USA) and analysed 
with a statistical software package (Stata 10, Stata Corp., Texas, US). Chi-square or 
Fisher's exact test was used to compare proportions as appropriate.
RESULTS
A total of 807 patients were studied: 371 in AAV study, 271 in AQ, 43 in SMD and 122 
in FK. Only patients who received artemether in the AQ study were included. There were 
37 deaths in AAV, 33 in AQ, 11 in FK and none in SMD. Thirteen cases were missing an 
admission parasite count and were excluded, so the total number of cases using for 
analysis was 794 (Table 8.1).
Table 8.1 Number of patients included by study
Study Freq. Percent
AAV 369 46.47
AQ 266 33.50
SMD 38 4.79
FK 121 15.24
Total 794 100.00
The patients were classified into 3 groups by year (1991-1995; 1996-2000 and 2001 - 
2008) (Table 8.2) for final analysis because the artemisinin derivatives have been 
deployed widely since 1996, and there has been a remarkable reduction of malaria 
morbidity and mortality since 2001. Because of the widespread and uncontrolled use of
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antimalarial drugs in Viet Nam since 1991, the history of previous antimalarial treatment 
before admission was also recorded (Table 8.2).
Table 8.2 Number (%) of patients pretreated or not pretreated before admission *
Group Years Not pretreated Pretreated Total
0 1991-1995 223 (81%) 52 (19%) 275
1 1996-2000 103 (39%) 159 (61%) 262
2 2001-2008 61 (30%) 143 (70%) 204
Total 387 (52%) 354 (48%) 741*
* 53/794 patients were missing data on pretreatment; n for analysis = 741
The results of our study showed that between 1991 and 2008, 82.9% of severe malaria 
cases were still parasitaemic after 48 hours in those patients who were not pretreated and 
in 67.8% in patients who had been treated with any antimalarials before admission. At 72 
hours, 59.1% of cases are still parasitaemic in the non pretreated group, and 41.2% in the 
pretreated group (Table 8.3 and 8.4) (p= 0.15 and 0.26). In pretreated patients, the 
proportions of patients in each group of year who did not cleared their parasitaemia after 
48 hours were also not significantly different (Table 8.3) (p= 0.35), but there was a 
significant decline in the proportion clearing after 72 hours between groups of years, 
group 0: 53.8% and group 2: 32.9% (Table 8.4) (p= 0.01) throughout this period.
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Table 8.3 Proportion of patients still parasitaemic on day 2
Group Not pretreated Pretreated Total
N % (95% Cl) N . (%) (95%CI) (N)
0 178/223 79.8 (74.0-84.5) 34/52 65.3 (51.8-76.8) 212/275
1 91/103 88.3 (80.7-93.2) 114/159 71.7 (64.2-78.1) 205/262
2 52/61 85.2 (74.3-92.0) 92/143 64.3 (56.2-71.7) 144/204
Total 321/387 82.9 (78.8-86.3) 240/354 67.8 (62.7-72.4) 561/741
Table 8.4 Proportion of patients still parasitaemic on day 3
Group Not pretreated Pretreated Total
N % (95%CI) (N) (%) (95%CI) (N)
0 124/223 55.6 (49.0-62.0) 28/52 53.8 (40.5-66.7) 152/275
1 66/103 64.1 (54.5-72.7) 71/159 44.7 (37.1-52.4) 137/262
2 39/61 63.9(51.4-74.8) 47/143 32.9 (25.7-40.9) 86/204
Total 229/387 59.1 (54.2-63.9) 146/354 41.2 (36.2-46.4) 375/741
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DISCUSSION
I assessed the efficacy in terms of parasite clearance of the artemisinin derivatives in the 
treatment of severe malaria in patients admitted to the Hospital for Tropical Diseases 
between 1991 and 2008.
From 1991 to 1996, artemisinin derivatives were not yet available in Viet Nam; most of 
pretreated patients received other antimalarials such as chloroquine, quinine or 
sulfadoxine-pyrimethamine. With the introduction of artemisinin derivatives in 1995, the 
use of chloroquine, sulfadoxine-pyrimethamine and quinine was reduced. Since 2000 
quinine and other antimalarials have become unavailable for sale, therefore all of 
pretreated patients are likely to have taken artesunate before admission to hospital, and 
the continued treatment with parenteral artemisinin derivatives has affected the parasite 
clearance time (Table 8.4). Overall, the number of patients who had received antimalarial 
drugs as pretreatment increased through the years (Table 8.2), and approximately 40-60% 
of severe patients became aparasitaemic on day 3.
Through this parasitological observational study we could find no clear evidence of a 
change in the number of patients failing to clear their parasites after 72 hours. However 
there may be a small number of patients in the later years of this period who failed to 
clear their parasites (Table 8.3 and 8.4; Figure 8.1), leading to wider confidence intervals 
around the medians.
There are some reasonable criticisms of this study. Inevitably the study was retrospective, 
although the fact that all patients were seen on a single ward with a single study team 
following identical protocols I hope mitigates some of the retrospective nature of the
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study. Despite studying 800 patients this may still not be a sufficient number of patients 
to see significant difference in the parasite clearance times, particularly if the number of 
patients with a resistant parasite was low. Obviously the time to parasite clearance is a 
variable controlled by many factors including age, sex, pregnancy, prior immune status, 
malnutrition, and the pharmacokinetic: pharmacodynamic relationship of the drugs. 
However in this low transmission setting most patients were non-immune, we only 
assessed adults (>15 years of age), very few suffered from other medical conditions 
including malnutrition and I believe these factors were less relevant in this relatively 
homogenous population anyway. Also I was unable to assess recrudescence by following 
up the patients for 28 days. It is recommended that the minimum duration of patient 
follow-up is 28 days in a study of uncomplicated malaria assessing antimalarial drugs 
with elimination half-lives of less than 7 days such as the artemisinin derivatives (WHO, 
2003 and 2009). If there were ‘resistant’ parasites we might have expected to see more 
relapses in that group.
Southeast Asia is home to drug-resistant P. falciparum malaria. Both chloroquine- 
resistant and mefloquine-resistant falciparum parasites were firstly found in this region 
(Moore and Lanier, 1961; Harinasuta et al., 1965, Wongsrichanalai et al, 2004). The first 
clinical report of chloroquine treatment failure from South Viet Nam appeared in 1961. A 
standard in vivo test to assess the response of P. falciparum to chloroquine was developed 
in 1965 (WHO, 1965). This WHO classification of in vivo antimalarial drug sensitivity 
was used to assess the antimalarial drug efficacy, and was revised twice, in 1967 and 
1972 (WHO, 1967 and 1973). In 2003, another classification for assessment of the 
efficacy of antimalarial drugs was introduced (WHO, 2003).
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Recently, a significant increase in the proportion of patients failing to clear their 
parasitaemia by day 2 was noticed at the Thailand-Myanmar border (WHO Meeting 
report, Cambodia, 2008). Prolonged parasite clearance time following treatment with 
artemisinin mono or combination therapy has been observed along the Thai-Cambodian 
border from 2001 to 2007 (WHO Meeting report, Cambodia, 2008). In 2000, the 
artesunate and mefloquine combination was introduced as the first-line treatment for 
falciparum malaria in Cambodia, Thailand and Viet Nam. Recent clinical trials at the 
Thai-Cambodian border have pointed to the declining efficacy of both artesunate- 
mefloquine and artemether-lumefantrine combinations (Wongscrichalanai et al., 2006; 
Denis et al., 2006), and high dose of artesunate montherapy (Noedl et al., 2008).
Since the 1990s, artemisinin or artesunate monotherapy have been used as the main 
treatment for falciparum malaria in Viet Nam. It is regarded as one of the important 
factors leading to the reduction of malaria mortality and morbidity since then. While 
there were no clear documented reports of artemisinin derivative resistance in vitro, in 
vivo studies indicated emerging resistance with 17% failures in Dak Lak province, 18% 
in Binh Thuan and 8-50% in Binh Phuoc (NMCP, 2003). In the period 1991-1995 an in 
vitro drug resistance study was carried out in Yunnan, China in sites close to the border 
with Viet Nam. The result showed that there was no resistance to quinine or mefloquine, 
but there was resistance to chloroquine, amodiaquine and pyronaridine, and some 
unexpected resistance to artesunate, arteether and dihydroartemisinin (Yang et al., 1995). 
Molecular studies documented an increase in the level of mefloquine resistance in 
secondary isolates after artemisinin treatment and amplification of the wild-type Pfmdrl 
gene, which is linked to antimalarial drug resistance, so that the monitoring for 
artemisinin resistance is needed (Ngo et al., 2003; Phuc et al., 2008).
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Artesunate plus mefloquine is a mutually protective combination and remains highly 
effective in Viet Nam, but because of the lack of mefloquine supply the NMCP has 
switched to the combination of dihydroartemisinin and piperaquine for the treatment of 
uncomplicated falciparum malaria since 2007. In vitro study noticed that some isolates 
showed a diminished susceptibility to dihydroartemisinin (Cojean et al., 2006). For the 
moment, there is no replacement for parenteral artesunate in treatment of severe 
falciparum malaria. It is however required to monitor the efficacy of artemisinin 
derivatives routinely and precisely for early detection of artemisinin resistance, especially 
at the malarious regions near the Viet Nam-Cambodia border. The in vivo therapeutic 
efficacy and in vitro sensitive tests; molecular and genetic studies should be conducted to 
observe the decline of any antimalarial drug efficacy. The sale of all antimalarial drugs 
must be banned and their distribution should be strictly controlled by the NMCP. And all 
malaria patients should be treated with ACT regimen. Despite the official malaria drug 
policy, the injudicious use of artemisinin monotherapy and inappropriate dose used by the 
public health settings and private sectors may contribute to the development of resistance 
because of the increased drug pressure for selection of artemisinin tolerant malaria 
parasites. In this 18 year study we could find no clear evidence of a poorer response to 
artemisinin therapy. But the containment of artemisinin tolerant malaria should be 
considered. Otherwise, it will be very difficult to manage malaria disease, and as a result, 
malaria will probably re-emerge and spread in Viet Nam. Artemisinin resistance is truly a 
global threat! The emergence of malaria parasites that are resistant to the artemisinin 
derivatives will seriously undermine global malaria control.
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Figure 8.2 Qinghaosu suppository, the first artemisinin used in HTD in 1989 (N.H. 
Phu)
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CHAPTER 9
DISCUSSION
In the last twenty years, the most important change in the management of malaria is the 
introduction of artemisinin based combination therapy as first line treatment. The effect 
of Qinghaosu (artemisinin and its derivatives) in the treatment of malaria has been 
studied in China since 1979 (Li et al., 1994) and as a direct result of meeting between 
Cho En Lai and Ho Chi Minh. Research in China showed good results after the treatment 
of uncomplicated and severe malaria with artemisinin and its derivatives. The first 
randomised controlled comparative study, to assess the efficacy of artemisinin was 
conducted outside of China, was done at HTD, Viet Nam in 1989 (Arnold et al., 1990). 
Following these initial results, many comparative trials throughout the world have 
confirmed the high efficacy of these antimalarial drugs that was claimed (but initially 
dismissed by the rest of the world) by Chinese and Vietnamese scientists. During the 
1980s the mortality of severe falciparum malaria was approximately 40 per cent in HTD 
(almost 100% if accompanied by renal failure) (Hien, 1994), but decreased to 14.9 per 
cent in the period 1991-1995 (Hien, unpublished data). In 2009 the mortality rate at HTD 
was <5% for the same severity of disease. We would like to reach zero tolerance for 
malaria deaths at HTD. However as the incidence of a disease falls the mortality often 
rises and young clinicians in Viet Nam have much less personal experience of managing 
patients with severe malaria. In Viet Nam, artemisinin and its derivatives were 
recommended by the NMCP in 1995 and the use of artemisinin derivatives has been 
central to successful malaria control efforts in the country. The most important question
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is whether artemisinin and its derivatives can reduce the mortality rate of severe malaria. 
Unexpectedly, a largest double-blind, controlled trial of artemether or quinine in adults 
with severe falciparum conducted in HTD between 1991 and 1996 did not show any 
significant difference in mortality (Hien et a l, 1996). For the parenteral treatment of 
severe falciparum malaria artesunate and artemether are commonly recommended. 
Artemether is formulated in an oil base and can only be injected by the intramuscular 
route. Artesunate is more widely used because it is water-soluble and can be administered 
by either intravenous or intramuscular injection. A comparative pharmacokinetic (PK) 
study was performed at HTD and suggested that parenteral artesunate had considerable 
pharmacokinetic advantages over artemether in the treatment of severe malaria (Hien et 
al., 2004). In my work reported in this thesis the unadjusted relative risk of death for 
artesunate = 0.54, 95% Cl: 0.28 -  1.02, p = 0.052 compared with treatment with 
artemether (Chapter 3). This data and the data from the PK studies strongly suggests that 
artesunate with its better pharmacological profile should be the treatment of choice 
among the Qinghaosu and its derivatives. The SEAQUAMAT trial provides powerful 
evidence that Artesunate is better than Quinine in adults in Asia and we wait for the 
results of the AQUAMAT trials with great interest.
In general, the number of deaths from severe malaria in Viet Nam has declined 
dramatically since the deployment of artemisinin derivatives. The explanation could be 
the contribution of artemisinin derivatives in reducing the number of severe malaria cases 
because artemisinins rapidly clear all stages of parasite in the peripheral blood, thus 
reducing the development of complications. The improvement of facilities for diagnosis 
and treatment may also play a role in reducing the mortality rate of severe falciparum 
malaria.
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Severe malaria is a multisystem disease requiring intensive care management but 
optimum treatment is usually not available in most of the health settings where severe 
malaria occurs. Severe falciparum malaria results from sequestration of parasitized red 
blood cells in the vital organs. The evidence that immunological processes contribute to 
pathology is unconvincing. In Viet Nam the incidence of cerebral malaria and 
convulsions have declined from 90% in 1980s to 10 % in the early years of 2000 while 
jaundice, acute renal failure and lactic acidosis are now more common (1980: 6%, 1986- 
2006: 50-80%) (Hien, unpublished data). The clinician should not feel restricted by any 
strict definition of severe malaria. A simpler bedside assessment based on any 
impairment of consciousness or prostration, respiratory distress, oliguria or anuria, visible 
jaundice, hypoglycaemia, anaemia, high parasitaemia or shock identifies those patients in 
need of intensive care. A rapid clinical appraisal should be made. This includes 
assessment of level of central nervous system dysfunction, measurement of vital signs, 
paricularly respiratory pattern and rate, measurement of urine output, questioning of the 
patient or relatives concerning convulsions, duration of complications and earlier 
antimalrial treatment. A malaria parasite count, blood glucose, haematocrit, venous 
lactate and arterial blood gases should be measured immediately. Blood glucose should 
be regularly monitored in children and pregnant patients. Prompt chest X-ray on 
admission is helpful to exclude pulmonary oedema or pneumonia. A lumbar pucture 
should be done in cerebral malaria. The quantity of malaria pigmented neutrophils and 
parasite staging may be the measures of disease severity. Antimalarial drugs should be 
given on a miligram per kilogram basis. Artesunate (i.v., i.m., or rectal preparations) is 
the only drug of choice for the treatment of severe falciparum malaria. Therapeutic 
responses are assessed in terms of clinical and laboratory measures. Artemisinin based
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combination therapy must be given when the patient can take oral medicine. Oral Artekin 
(dihydroartemisinin-piperaquine combination) now is available on prescription and free 
of charge in Viet Nam. If the parasitaemia has not cleared by 72 hours with the 
administration of artemisinin derivatives, the parasite count should be regularly 
monitored in order to detect any case of drug resistance. Fluid resuscitation should be 
carefully considered and if there is any doubt about fluid overload, a central venous line 
could be inserted for central venous pressure monitoring. Dialysis should be started early 
in severe patients with acute renal failure or lactic acidosis. Haemofiltration has been 
shown to be superior to peritoneal dialysis. Blood transfusion is needed if the haematocrit 
falls below 20%. Broad-spectrum antibiotics should be given in malaria patients with 
shock or in suspectedly bacterial coinfection. There is no evidence that adjunctive 
therapies are beneficial. Special nursing care is very important in the management of 
severe malaria, but is usually forgotten.
Conclusion
In summary the specific objectives set out in this thesis have been met. I hope my work 
(some of it included in this thesis) and that of my many colleagues at the Hospital for 
Tropical Diseases has made a contribution to improving the care of patients with severe 
malaria in my country and by extension globally.
The artesunate has become the first line treatment of severe falciparum malaria in Viet 
Nam. Our study on comparison of haemofiltration and peritoneal dialysis in patients with 
infection-associated acute renal failure, mostly severe falciparum malaria, have made an 
impact on the recommendation for the clinical management of severe malaria by the 
NCMP, Viet Nam and by the WHO (WHO, 2006). The measurement of arterial blood
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gases requires expensive equipment and lactic acidosis or hyperlactataemia is an indicator 
of poor prognosis in severe malaria, therefore an inexpensive lactate measurement such 
as dipstick should be supplied for remote health stations. The technicians’ skill for 
performing malaria parasite count, parasite staging and pigmented neutrophil count 
should be improved. Fluid resuscitation has not been routinely indicated, and intravenous 
fluid regimens are now carefully considered by clinicians. The Malaria Severity Score 
can be evaluated in larger clinical trials and in different places, especially at remote 
settings but is now in routine use at my hospital. Resistance to artemisinin drivatives has 
not yet been reported in Viet Nam but antimalarial drug efficacy monitoring should be 
urgently established. My data suggests that between 1991 and 2008 there has not been a 
dramatic prolongation in the parasite clearance times in patients with severe malaria 
treated with the artemisinin. Artemisinin based combination therapy must be restrictly 
prescribed in order to prevent the development of drug resistance. Most of the fatal 
malaria cases in the recent years were misdiagnosed therefore the regular update of the 
management of malaria for the health officers at the endemic areas will be helpful, 
aiming to remind them to guarantee an objective attitude to malaria as receiving a febrile 
patient in Viet Nam, a tropical country. Because of the widespread and uncontrolled use 
of artemisinin derivatives a negative blood smear should not excluded malaria diagnosis 
or delay malaria treatment, particularly in endemic or formerly endemic malaria areas.
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